
<html lang="en"     class="pb-page"  data-request-id="5fbe52f4-0910-4f20-9401-0ff92ad9ef51"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2017.60.issue-20;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.7b00678"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat" /></meta><meta name="dc.Creator" content="Lianbin  Yao" /></meta><meta name="dc.Creator" content="Nurulhuda  Mustafa" /></meta><meta name="dc.Creator" content="Eng Chong  Tan" /></meta><meta name="dc.Creator" content="Anders  Poulsen" /></meta><meta name="dc.Creator" content="Prachi  Singh" /></meta><meta name="dc.Creator" content="Minh-Dao  Duong-Thi" /></meta><meta name="dc.Creator" content="Jeannie X. T.  Lee" /></meta><meta name="dc.Creator" content="Pondy Murugappan  Ramanujulu" /></meta><meta name="dc.Creator" content="Wee Joo  Chng" /></meta><meta name="dc.Creator" content="Jeffrey J. Y.  Yen" /></meta><meta name="dc.Creator" content="Sten  Ohlson" /></meta><meta name="dc.Creator" content="Brian W.  Dymock" /></meta><meta name="dc.Description" content="Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy. To achieve such an outcome with a single molecule would simplify treatment regimes. Herein the core feat..." /></meta><meta name="Description" content="Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy. To achieve such an outcome with a single molecule would simplify treatment regimes. Herein the core feat..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 10, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00678" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00678" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00678" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00678" /></link>
        
    
    

<title>Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00678" /></meta><meta property="og:title" content="Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0016.jpeg" /></meta><meta property="og:description" content="Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy. To achieve such an outcome with a single molecule would simplify treatment regimes. Herein the core features of ruxolitinib (1), a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat (2), leading to new molecules that are bispecific targeted JAK/HDAC inhibitors. A preferred pyrazole substituted pyrrolopyrimidine, 24, inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is &lt;100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases. Broad cellular antiproliferative potency of 24 is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematological cell lines. Methyl analogue 45 has an even more selective profile. This study provides new leads for assessment of JAK and HDAC pathway dual inhibiton achieved with a single molecule." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00678"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00678">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00678&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00678&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00678&amp;href=/doi/10.1021/acs.jmedchem.7b00678" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 8336-8357</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00576" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00743" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lianbin++Yao">Lianbin Yao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nurulhuda++Mustafa">Nurulhuda Mustafa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>∞</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eng+Chong++Tan">Eng Chong Tan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol "><sup>∞</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anders++Poulsen">Anders Poulsen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-2790-9340" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Prachi++Singh">Prachi Singh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Minh-Dao++Duong-Thi">Minh-Dao Duong-Thi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeannie+X.+T.++Lee">Jeannie X. T. Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pondy+Murugappan++Ramanujulu">Pondy Murugappan Ramanujulu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wee+Joo++Chng">Wee Joo Chng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>◆</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>¶</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+J.+Y.++Yen">Jeffrey J. Y. Yen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sten++Ohlson">Sten Ohlson</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+W.++Dymock">Brian W. Dymock</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-2374-5756" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Pharmacy, National University of Singapore, 18 Science Drive 4, 117543, Singapore</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 10, 117549, Singapore</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Taiwan International Graduate Program in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, 115, Taiwan</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Experimental Therapeutics Centre, 31 Biopolis Way, 03-01 Nanos, 138669, Singapore</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">#</span> <span class="aff-text">Department of Chemistry, National University of Singapore, 3 Science Drive 3, 117543, Singapore</span></div><div class="aff-info" id="aff7"><span class="aff-symbol">∇</span> <span class="aff-text">School of Biological Sciences, Nanyang Technological University (NTU), 637551, Singapore</span></div><div class="aff-info" id="aff8"><span class="aff-symbol">○</span> <span class="aff-text">Centre for Life Sciences Level 5, Life Sciences Institute, National University of Singapore, 28 Medical Drive, 117456, Singapore</span></div><div class="aff-info" id="aff9"><span class="aff-symbol">◆</span> <span class="aff-text">Cancer Science Institute, National University of Singapore, 117599, Singapore</span></div><div class="aff-info" id="aff10"><span class="aff-symbol">¶</span> <span class="aff-text">National University Cancer Institute of Singapore, National University Health System, 119074, Singapore</span></div><div class="corresp-info"><strong>*</strong>S.O.: e-mail, <a href="/cdn-cgi/l/email-protection#8ddec2e5e1fee2e3cde3f9f8a3e8e9f8a3feea"><span class="__cf_email__" data-cfemail="73203c1b1f001c1d331d07065d1617065d0014">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>B.W.D.: e-mail, <a href="/cdn-cgi/l/email-protection#84e6f3e0eaf1f7c4e3e9e5ede8aae7ebe9"><span class="__cf_email__" data-cfemail="bbd9ccdfd5cec8fbdcd6dad2d795d8d4d6">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00678&amp;href=/doi/10.1021%2Facs.jmedchem.7b00678" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 8336–8357</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 27, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 May 2017</li><li><span class="item_label"><b>Published</b> online</span>10 October 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 October 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00678" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00678</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8336%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLianbin%2BYao%252C%2BNurulhuda%2BMustafa%252C%2BEng%2BChong%2BTan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D20%26contentID%3Dacs.jmedchem.7b00678%26title%3DDesign%2Band%2BSynthesis%2Bof%2BLigand%2BEfficient%2BDual%2BInhibitors%2Bof%2BJanus%2BKinase%2B%2528JAK%2529%2Band%2BHistone%2BDeacetylase%2B%2528HDAC%2529%2BBased%2Bon%2BRuxolitinib%2Band%2BVorinostat%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8357%26publicationDate%3DOctober%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00678"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3842</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">50</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00678" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Lianbin&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Nurulhuda&quot;,&quot;last_name&quot;:&quot;Mustafa&quot;},{&quot;first_name&quot;:&quot;Eng&quot;,&quot;last_name&quot;:&quot;Chong Tan&quot;},{&quot;first_name&quot;:&quot;Anders&quot;,&quot;last_name&quot;:&quot;Poulsen&quot;},{&quot;first_name&quot;:&quot;Prachi&quot;,&quot;last_name&quot;:&quot;Singh&quot;},{&quot;first_name&quot;:&quot;Minh-Dao&quot;,&quot;last_name&quot;:&quot;Duong-Thi&quot;},{&quot;first_name&quot;:&quot;Jeannie&quot;,&quot;last_name&quot;:&quot;X. T. Lee&quot;},{&quot;first_name&quot;:&quot;Pondy&quot;,&quot;last_name&quot;:&quot;Murugappan Ramanujulu&quot;},{&quot;first_name&quot;:&quot;Wee&quot;,&quot;last_name&quot;:&quot;Joo Chng&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;J. Y. Yen&quot;},{&quot;first_name&quot;:&quot;Sten&quot;,&quot;last_name&quot;:&quot;Ohlson&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;W. Dymock&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;8336-8357&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00678&quot;},&quot;abstract&quot;:&quot;Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy. To achieve such an outcome with a single molecule would simplify treatment regimes. Herein the core features of ruxolitinib (1), a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat (2), leading to new molecules that are bispecific targeted JAK/HDAC inhibitors. A preferred pyrazole substituted pyrrolopyrimidine, 24, inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is &lt;100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases. Broad cellular antiproliferative potency of 24 is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematological cell lines. Methyl analogue 45 has an even more selective profile. This study provides new leads for assessment of JAK and HDAC pathway dual inhibiton achieved with a single molecule.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00678&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00678" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00678&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00678" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00678&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00678" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00678&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00678&amp;href=/doi/10.1021/acs.jmedchem.7b00678" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00678" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00678" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26pmid%3D28953386%26genre%3Darticle%26aulast%3DYao%26date%3D2017%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BLigand%2BEfficient%2BDual%2BInhibitors%2Bof%2BJanus%2BKinase%2B%2528JAK%2529%2Band%2BHistone%2BDeacetylase%2B%2528HDAC%2529%2BBased%2Bon%2BRuxolitinib%2Band%2BVorinostat%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D20%26spage%3D8336%26epage%3D8357%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (12)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291763" title="Noncovalent interactions">Noncovalent interactions</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/jmcmar.2017.60.issue-20/20171026/jmcmar.2017.60.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy. To achieve such an outcome with a single molecule would simplify treatment regimes. Herein the core features of ruxolitinib (<b>1</b>), a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat (<b>2</b>), leading to new molecules that are bispecific targeted JAK/HDAC inhibitors. A preferred pyrazole substituted pyrrolopyrimidine, <b>24</b>, inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC<sub>50</sub> values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases. Broad cellular antiproliferative potency of <b>24</b> is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematological cell lines. Methyl analogue <b>45</b> has an even more selective profile. This study provides new leads for assessment of JAK and HDAC pathway dual inhibiton achieved with a single molecule.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87053" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87053" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Combination drug treatment targeting two or more pathways is the mainstay of modern cancer therapy.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Simultaneous inhibition of two oncogenic pathways is typically achieved with a combination of two or more separate therapies.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Each therapy–target couple is usually demonstrated to be independently important in the development of a tumor cell through single agent studies. It must then be shown that the combination of multitarget inhibition is complementary. Optimization of the best combinations can be expensive and time-consuming in clinical development. In efforts to simplify combination dosing regimens, we have been focused on studies toward development of molecules that have dual, or multiple, inhibition capabilities against two different classes of enzyme target, the Janus kinase (JAK) family and histone deacetylases (HDACs). JAK kinases include JAK1, JAK2, JAK3, and TYK2 which are activated by different cytokines leading to phosphorylation and dimerization of the STAT (signal transducers and activators of transcription) family of proteins.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> STAT dimers translocate to the nucleus where they stimulate gene expression. Blocking of JAK kinases has antiproliferative and anti-inflammatory effects as demonstrated by <b>1</b>, a marketed JAK1/2 inhibitor for the treatment of myelofibrosis and polycythemia vera (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>),<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and the pan-JAK inhibitor tofacitinib, approved for treatment of rheumatoid arthritis (RA).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Selective JAK kinase inhibitors, such as JAK1 selective agents for the treatment of RA,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> are now in late stage clinical trials.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Inhibition of JAKs directly leads to reduction of intracellular levels of STATs. Inhibition of HDACs has also been reported to reduce STAT levels with the HDAC inhibitor pracinostat demonstrating modest activity in a myelofibrosis clinical trial.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> Catalyzing the removal of acetyl groups from histones and other nuclear proteins such as tubulin, HDACs have become a popular target for combination cancer therapy.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of pan-HDAC inhibitor <b>2</b> (vorinostat, SAHA),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> the JAK1/2 selective inhibitor <b>1</b> (ruxolitinib, INCB018424),<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and the JAK2-HDAC dual inhibitor <b>3</b> (EY3238).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">There are now four HDAC inhibitors approved by the U.S. FDA, the first being <b>2</b>, with a multitude of others in clinical development.<a onclick="showRef(event, 'ref11 ref12 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref14">(11, 12, 14)</a> However, finding optimal clinical applications for HDAC inhibitors has been hampered by poor single agent efficacy often related to dose limiting toxicity.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Investigators are increasingly focusing on using HDAC inhibitors as partners in a combination or trying to develop isoform selective HDAC inhibitors.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> Combining two different inhibitory activities into a single molecule is a relatively underexplored approach to achieve combination therapy. Given that both JAK and HDAC inhibitors have demonstrated clinical activity in similar diseases, dual inhibition of both JAKs and HDACs in a single molecule could be a compelling new strategy for the treatment of myelofibrosis and potentially a wider range of oncology diseases, such as leukemia or lymphoma, and for immune-inflammatory diseases such as RA. Comprehensive reviews are available describing efforts toward new epigenetic agents and their combinations into multiligand designs.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Achieving the right balance of JAK and HDAC family inhibition could lead to improved efficacy and lower toxicity. Isoform selective inhibitors of JAKs and HDACs have been reported with varying degrees of success.<a onclick="showRef(event, 'ref8 ref18'); return false;" href="javascript:void(0);" class="ref ref8 ref18">(8, 18)</a> It has been particularly challenging to develop selective inhibitors of HDACs.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Ideally we are aiming to achieve JAK1/2 selectivity with class I/IIA HDAC inhibition for optimial antiproliferative activity. Avoiding JAK3 is desirable due to its role in immune suppression.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> We recently reported a dual JAK-HDAC inhibitor, <b>3</b>, with low nanomolar activity against JAK2 and HDAC6 while also inhibiting HDACs 2 and 10 with IC<sub>50</sub> values below 100 nM.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> This early work demonstrates that it is possible to achieve very specific selectivity profiles with dual JAK-HDAC inhibitors. Exploring new selectivity profiles while improving drug-like properties of selective JAK-HDAC dual inhibitors is a key goal of our research. In this report we extend our work using <b>1</b> as a template for a low molecular weight dual inhibitor, which has potency against a wider range of family members of the JAKs and HDACs, with a focus on JAK1/2 and class I, II, and IV HDAC isozymes.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Design of Dual Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51800" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51800" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Critical donor–acceptor hydrogen bonding interactions between <b>1</b> and the hinge of JAK1/2 kinases are mediated by the pyrrolpyrimidine via the NH and the 7-N heteroatoms.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Hence this motif was not altered in our dual inhibitor design. HDAC inhibition can be achieved with a simple zinc-binding head group, the most potent and ligand efficient being the hydroxamic acid, attached to a linker and a cap group.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Linkers can be alkyl, alkenyl, or aryl with a wide range of cap groups tolerated. Illustrated by the simple structure of <b>2</b>, a chain of five to seven carbons is typically optimal in dual inhibitor designs.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Attaching an HDAC inhibiting alkyl hydroxamate to small aryl groups can therefore be expected to lead to at least low micromolar HDAC activity. This potency is derived from binding to the HDAC substrate pocket Zn as well as hydrophobic interactions in the channel. Selectivity can be achieved by varying interactions at the edge of the pocket, such as against HDACs 6 and 8.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> When considering design of a dual JAK-HDAC inhibitor based on <b>1</b>, HDAC inhibition can, in theory, be most easily achieved by attachment of a hydroxamate-bearing chain at the pyrazole of <b>1</b> leading to a simple dual inhibitor design (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). It is critically important to maintain the pyrrolopyrimidine nitrogens which provide a donor–acceptor interaction with the hinge of the JAK2 kinase.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> For optimal JAK potency in this series it is likely that alkyl or cycloalkyl groups will be required appended adjacent to the pyrazole. An alkyl chain appended to the pyrazole is flexible and able to adopt a conformation that will allow the polar hydroxamic acid to occupy a tolerated postion near solvent. Various designs meeting this pharmacophore and assessment of their dual target potency are described herein.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic showing design of a merged JAK-HDAC pharmacophore taking advantage of the solvent binding channel in JAK1/2 and the probable interactions to be gained by a merged inhibitor at the entrance to the HDAC substrate binding pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We set out to explore dual inhibitor designs based on <b>1</b> by preparing suitable protected pyrrolopyrimidine intermediates to enable later stage attachment of the desired hydroxamates. We found that 2-(trimethylsilyl)ethoxymethyl (SEM) and tosyl (Ts) were the most robust protecting groups (PGs) and possible to remove with acceptable yields later in the synthesis. Starting from SEM- or Ts-protected intermediate <b>4</b> or <b>5</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), substitution with different carbon length bromoesters gave esters <b>6</b>–<b>11</b> (yield, 81–97%).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Compounds <b>4</b>–<b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, rt, overnight, 81–97% (note: <b>8</b> is isolated as an ethyl ester from ethyl 6-bromohexanoate); (b) LiBF<sub>4</sub>, MeCN, reflux, 24 h, 50%; (c) (i) LiOH, THF/H<sub>2</sub>O, rt, overnight; (ii) <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, HOBT, EDC, Et<sub>3</sub>N, DMSO, rt, overnight, 21–74%; (d) TBAF, MeCN, reflux, 48 h, 64–73%; (e) HCl/dioxane, THF, rt, overnight, 55–93%.</p></p></figure><div class="NLM_p">In one case, compound <b>6</b> was deprotected with lithium tetrafluoroborate under reflux in acetonitrile to give <b>12</b>, which was then directly coupled with <i>O</i>-tetrahydropyranyl (<i>O</i>-THP) protected hydroxylamine using 1-hydroxybenzotriazole (HOBT) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) to give <b>15</b> but in low yield. Alternatively, esters <b>7</b> and <b>10</b> were saponified using lithium hydroxide at room temperature in good yield. The acids were successfully coupled with <i>O</i>-THP protected hydroxylamine to furnish THP-protected hydroxamic acids <b>13</b> and <b>14</b>. Deprotection of the SEM group with tetrabutylammonium fluoride (TBAF) under reflux conditions in acetonitrile gave <b>16</b> and <b>19</b>. Saponification and coupling of <i>O</i>-THP protected hydroxylamine with <b>8</b>, <b>9</b>, and <b>11</b> directly resulted in tosyl deprotection but with successful installation of the THP to give <b>17</b>, <b>18</b>, and <b>20</b>. Deprotection of the THP using anhydrous hydrogen chloride in 1,4-dioxane released the free hydroxamic acids (compounds <b>21</b>–<b>26</b>, yields from 55 to 93%).</div><div class="NLM_p">Substitution of tosyl protected intermediate <b>5</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) with <i>tert</i>-butyl (4-(3-iodopropyl)phenyl)carbamate (<b>A</b>) gave Boc-protected <b>27</b> (yield, 75%). Aldehyde <b>29</b> was prepared from <b>5</b> by N-alkylation using 2-(2-bromoethyl)-1,3-dioxolane (<b>B</b>) in DMF followed by deprotection of the acetal with dilute HCl in acetone. Boc deprotection of <b>27</b> was achieved in ethyl acetate using sulfuric acid, and the resulting amine was coupled with acid <b>C</b> using (1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate) (HATU) in DMF to give ester <b>30</b>. Saponificaiton of <b>12</b> was accomplished in THF using lithium hydroxide followed by coupling of aniline <b>D</b> to give ester <b>31</b>. Aldehyde <b>29</b> was reductively aminated with <b>D</b> in the presence of sodium cyanoborohydride in methanol, giving ester <b>32</b> in good yield. Saponification of esters <b>30</b>–<b>32</b> was achieved with lithium hydroxide at room temperature. The acids were then coupled with <i>O</i>-THP protected hydroxylamine to give the THP-protected hydroxamic acids <b>33</b>–<b>35</b>. As before, deprotection of the THP using anhydrous hydrogen chloride in 1,4-dioxane released the free hydroxamic acids <b>36</b> (yield, 38%), <b>37</b> (yield, 61%), and <b>38</b> (yield, 23%).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>27</b>–<b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>A</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 16 h, 75%; (b) (i) <b>B</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 18 h, 89%; (ii) 1 M HCl, acetone, 55 °C, used crude; (c) (i) H<sub>2</sub>SO<sub>4</sub>, EtOAc, DCM, rt, overnight, 98%; (ii) <b>C</b>, HATU, Et<sub>3</sub>N, DMF, 60 °C, 24 h, 82%; (d) (i) LiOH, THF/H<sub>2</sub>O, rt, 16 h; (ii) <b>D</b>, HATU, DIPEA, DMF, 60 °C, 24 h, 57% (2 steps); (e) <b>D</b>, NaBH<sub>3</sub>CN, MeOH, rt, 16 h, 76%; (f) (i) LiOH, THF/H<sub>2</sub>O, rt, 16 h; (ii) <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, HATU, Et<sub>3</sub>N, DMF, rt, 16 h, 23–48% (2 steps); (g) HCl/dioxane, THF, rt, 16 h, 23–61%.</p></p></figure><div class="NLM_p">Cinnamoyl is an important linking moiety in belinostat and panobinostat, both marketed HDAC inhibitors. Synthesis of the cinnamoyl hydroxamic acid dual inhibitor <b>40</b> was therefore a desirable goal (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Reductive amination of aldehyde <b>29</b> with methyl 3-(4-aminophenyl)acrylate (<b>E</b>) using sodium cyanoborohydride in methanol furnished <b>39</b> in a good yield (71%). Treating ester <b>39</b> with lithium hydroxide gave the acid which was coupled with <i>O</i>-THP protected hydroxylamine using HATU to give <b>40</b> in 57% yield over two steps. Deprotection of the THP in <b>40</b> using anhydrous hydrogen chloride in dioxane released the free hydroxamic acid compound <b>41</b> which was isolated with good purity in 90% yield.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compounds <b>39</b>–<b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>E</b>, NaBH<sub>3</sub>CN, MeOH, rt, 16 h, 71%; (b) (i) LiOH, THF/H<sub>2</sub>O, rt, 16 h; (ii) <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, HATU, Et<sub>3</sub>N, DMF, rt, 16 h, 57% (2 steps); (c) HCl/dioxane, 1,4-dioxane, rt, 16 h, 90%.</p></p></figure><div class="NLM_p">Building a small lipophilic group adjacent to the pyrazole ring appeared to be tolerated from modeling studies of <b>24</b> bound to HDAC1/6 (<a class="ref internalNav" href="#fig3" aria-label="Figures 3">Figures 3</a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) and JAK1/2 (<a class="ref internalNav" href="#fig5" aria-label="Figures 5">Figures 5</a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). Adding an alkyl group at this positon would enable access to the cyclopentyl binding pocket which is important for the potency of <b>2</b>. Hence we synthesized methyl analogue <b>45</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0013.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Compound <b>45</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>42</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, overnight; (b) (i) LiOH, THF/H<sub>2</sub>O, 50 °C, 24 h; (ii) <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, HATU, Et<sub>3</sub>N, DMF, rt, overnight; (c) HCl/dioxane, dioxane, rt, overnight.</p></p></figure><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>24</b> docked into a homology model of the second catalytic domain of HDAC6. Compound <b>24</b> is shown in stick with green carbon and the catalytic zinc in magenta CPK representation. HDAC6 is shown as a turquoise cartoon with selected residues in thin stick with gray carbon (left) and with an electrostatic surface (right). The hydroxamic acid coordinates to the catalytic zinc and forms three additional hydrogen bonds to the side chains of Tyr782, His610, and His611. The pyrrolopyrimidine and pyrazole have hydrophobic interactions with the surface residues His500, Pro501, and Phe620.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>24</b> docked into HDAC1. Compound <b>24</b> is shown in stick with green carbon and the catalytic zinc in magenta CPK representation. HDAC1 is shown as a turquoise cartoon with selected residues in thin stick with gray carbon (left) and with an electrostatic surface (right). The hydroxamic acid coordinates to the catalytic zinc and forms two additional hydrogen bonds to the side chains of Tyr303 and His141.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>24</b> docked into JAK1. Compound <b>24</b> is shown with green carbon in stick representation. JAK1 is shown as a turquoise cartoon with selected residues in thin stick with gray carbon (left) and with an electrostatic surface (right). The pyrrolopyrimidine forms hydrogen bonds to the backbone of the kinase hinge residues Glu957 and Leu959. The methylene chain extends under the glycine-rich loop with the hydroxamic acid extending out of the binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>24</b> docked into JAK2. Compound <b>24</b> is shown with green carbon in stick representation. JAK2 is shown as a turquoise cartoon with selected residues in thin stick with gray carbon (left) and with an electrostatic surface (right). The pyrrolopyrimidine forms hydrogen bonds to the backbone of the kinase hinge residues Glu930 and Leu932. The methylene chain extends under the glycine-rich loop with the hydroxamic acid extending out of the binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Intermediate <b>5</b> was alkylated with secondary iodide <b>42</b> under mild conditions. Saponification of the ester was followed by coupling with THP protected hydroxylamine to give <b>44</b>. The final deprotection was accomplished with HCl in dioxane at room temperature to give <b>45</b> as a racemate (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Enzyme Inhibitory Activity</h3><div class="NLM_p">In previous work<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> we had observed high levels of potency against HDAC6 when larger cap groups were added to <b>2</b>. Hence our initial testing strategy included HDAC6 as well as HDAC1 and JAK2. We used both compounds <b>1</b> and <b>2</b> and HDAC6 selective tubastatin A<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> as reference compounds. Ligand efficiency<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and lipophilic efficiency<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> were monitored for all compounds which gave full dose–response curves with top concentration of 10 μM. Shorter linkers, as in propyl <b>21</b>, bring the cap group and hydroxamate too close together and lead to significant decreases in HDAC activity (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Furthermore, with this design the hydroxamate enters too deeply into the JAK2 ATP pocket, leading to drastic loss of potency of over 4 orders of magnitude compared to the highly potent <b>1</b>. The sensitivity of the linker length is clearly demonstrated with butyl <b>22</b>, which has 100-fold greater HDAC6 potency (IC<sub>50</sub> = 6 nM) compared to <b>21</b> and over 10-fold improved potency against JAK2. Also, <b>22</b> is now significantly active against HDAC1 with an IC<sub>50</sub> of 854 nM. Further extension of the linker to 5 carbons (<b>23</b>) improves HDAC1 activity significantly with minimal changes against either HDAC6 (2-fold) or JAK2. An optimal length of six carbons, as in compound <b>24</b>, provides a compound with single digit nanomolar potency against both HDAC targets and an IC<sub>50</sub> of 75 nM against JAK2. Increasing the chain length further to seven carbons (<b>25</b>) maintained HDAC but reduced JAK activity. Interestingly, the very long 10-carbon linker (<b>26</b>) retained JAK2 potency but lost nearly an order of magnitude against HDAC6 and 2 orders of magnitude against HDAC1. This reflects the well documented sensitive nature of the linker especially for HDAC1 activity.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Enzyme Inhibition for Hydroxamic Acids <b>21</b>–<b>26</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0014.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (% inhibition at 10 μM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center"><i>n</i></th><th class="colsep0 rowsep0" align="center">HDAC1</th><th class="colsep0 rowsep0" align="center">HDAC6</th><th class="colsep0 rowsep0" align="center">JAK2</th><th class="colsep0 rowsep0" align="center">LE (kcal/mol)<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char=".">cLogP<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">LipE<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.000056<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">0.63</td><td class="colsep0 rowsep0" align="char" char=".">1.83</td><td class="colsep0 rowsep0" align="left">8.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.306<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.020<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.58–0.49</td><td class="colsep0 rowsep0" align="char" char=".">2.47</td><td class="colsep0 rowsep0" align="left">5.23–4.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tubastatin A</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(37%)</td><td class="colsep0 rowsep0" align="left">0.0035<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">2.25</td><td class="colsep0 rowsep0" align="left">6.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">(0%)</td><td class="colsep0 rowsep0" align="left">0.604<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">3.56<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.42–0.37</td><td class="colsep0 rowsep0" align="char" char=".">–0.07</td><td class="colsep0 rowsep0" align="left">6.63–5.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.854 ± 0.025</td><td class="colsep0 rowsep0" align="left">0.006 ± 0.001</td><td class="colsep0 rowsep0" align="left">0.219 ± 0.016</td><td class="colsep0 rowsep0" align="left">0.53–0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td><td class="colsep0 rowsep0" align="left">8.73–6.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">0.138 ± 0.021</td><td class="colsep0 rowsep0" align="left">0.0029 ± 0.0002</td><td class="colsep0 rowsep0" align="left">0.200 ± 0.027</td><td class="colsep0 rowsep0" align="left">0.53–0.41</td><td class="colsep0 rowsep0" align="char" char=".">0.94</td><td class="colsep0 rowsep0" align="left">8.53–6.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">0.0069 ± 0.0004</td><td class="colsep0 rowsep0" align="left">0.0014 ± 0.00001</td><td class="colsep0 rowsep0" align="left">0.075 ± 0.008</td><td class="colsep0 rowsep0" align="left">0.52–0.42</td><td class="colsep0 rowsep0" align="char" char=".">1.45</td><td class="colsep0 rowsep0" align="left">8.31–6.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">0.036 ± 0.001</td><td class="colsep0 rowsep0" align="left">0.0018 ± 0.0006</td><td class="colsep0 rowsep0" align="left">0.481<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.50–0.36</td><td class="colsep0 rowsep0" align="char" char=".">1.95</td><td class="colsep0 rowsep0" align="left">7.68–5.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">3.54 ± 0.035</td><td class="colsep0 rowsep0" align="left">0.088 ± 0.012</td><td class="colsep0 rowsep0" align="left">0.043 ± 0.006</td><td class="colsep0 rowsep0" align="left">0.37–0.28</td><td class="colsep0 rowsep0" align="char" char=".">2.46</td><td class="colsep0 rowsep0" align="left">4.71–2.79</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Average of two duplicate 10-dose IC<sub>50</sub> determinations ± SD unless otherwise noted.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Reported values (<a href="http://www.reactionbiology.com" class="extLink">http://www.reactionbiology.com</a>).</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">10-dose IC<sub>50</sub>.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">56 pM (10-dose IC<sub>50</sub>).</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">Ligand efficiency, given as a range for the three targets, defined as <i>RT</i> ln(IC<sub>50</sub>)/<i>N</i>, where <i>N</i> = number of heavy atoms.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></p></div><div class="footnote" id="t1fn6"><sup>f</sup><p class="last">Calculated as miLogP using Molinspiration property engine version 2014.11 (<a href="http://www.molinspiration.com" class="extLink">http://www.molinspiration.com</a>).</p></div><div class="footnote" id="t1fn7"><sup>g</sup><p class="last">Lipophilic efficiency, defined as pIC<sub>50</sub> – cLogP given as a range for the three targets.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></div></div><div class="NLM_p">To achieve compounds with a wider HDAC profile compared to pacritinib based dual inhibitors,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> the optimal number of carbons for dual activity is 6 (<b>24</b>). A compelling feature of these dual compounds is their excellent ligand efficiency (LE).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> shows the range of LE for <b>21</b>–<b>26</b>, calculated based on the measured IC<sub>50</sub> values. LE values up to 0.53 demonstrate that these dual compounds achieve their potency with the minimum of molecular weight. This compares favorably to the highly potent <b>1</b> which has a very high LE of 0.63. Likewise, for lipophilic efficiency (LipE), these compounds have some very high values up to 8.81 (values above 5 are generally regarded as desirable for orally available small molecules).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">After confirmation of a basic design able to yield efficient JAK-HDAC inhibiting compounds, functionalized linkers were next explored (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Simply adding the pyrazole substituted pyrrolopyrimidine to the phenyl cap group of <b>2</b> might be expected to produce a potent dual inhibitor. Compound <b>36</b>, although very potent for HDAC6 (IC<sub>50</sub> = 0.9 nM), was less potent for HDAC1 and JAK2. These data indicate that to prepare compounds with a dual inhibition profile is not just a simple matter of joining two pharmacophores together with an alkyl linker. The challenge is more subtle, requiring deep understanding of dual design SAR in order to arrive at a well balanced merged structure. This fact is further confirmed with the amide connected compound <b>37</b> which has reduced potency even for HDAC6. However, potency is regained in <b>38</b>, bearing an aniline linker. This compound has very high potency for HDAC6 (IC<sub>50</sub> = 140 pM) and moderate potency for HDAC1 (IC<sub>50</sub> = 110 nM) and JAK2 (IC<sub>50</sub> = 265 nM). The very high HDAC6 activity is responsible for its high LipE (8.81), even higher than <b>1</b>, but LE is lower than the simpler series described in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> due to its higher molecular weight. Cinnamoyl <b>41</b> lost activity against all targets; hence this class was not pursued further. Addition of a single methyl significantly increased the lipophilicity of <b>45</b> (cLogP = 1.81) compared with <b>24</b> (cLogP = 1.45). HDAC6 ligand efficiency of <b>45</b> was high (0.51) with a high LipE (7.19).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Enzyme Inhibition for Hydroxamic Acids <b>36</b>-<b>38</b> and <b>40</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0015.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (% inhibition at 10 μM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">HDAC1</th><th class="colsep0 rowsep0" align="center">HDAC6</th><th class="colsep0 rowsep0" align="center">JAK2</th><th class="colsep0 rowsep0" align="center">LE<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">cLogP<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">LipE<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.000056<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">0.63</td><td class="colsep0 rowsep0" align="left">1.83</td><td class="colsep0 rowsep0" align="left">8.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.306<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.020<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.58–0.49</td><td class="colsep0 rowsep0" align="left">2.47</td><td class="colsep0 rowsep0" align="left">5.23–4.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tubastatin A</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(37%)</td><td class="colsep0 rowsep0" align="left">0.0035<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.48</td><td class="colsep0 rowsep0" align="left">2.25</td><td class="colsep0 rowsep0" align="left">6.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">bond</td><td class="colsep0 rowsep0" align="left">0.265 ± 0.068</td><td class="colsep0 rowsep0" align="left">0.0009 ± 0.0001</td><td class="colsep0 rowsep0" align="left">0.865 ± 0.058</td><td class="colsep0 rowsep0" align="left">0.36–0.24</td><td class="colsep0 rowsep0" align="left">3.45</td><td class="colsep0 rowsep0" align="left">7.01–4.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">CONH</td><td class="colsep0 rowsep0" align="left">(10.84%)</td><td class="colsep0 rowsep0" align="left">0.55 ± 0.066</td><td class="colsep0 rowsep0" align="left">1.20 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.24–0.23</td><td class="colsep0 rowsep0" align="left">2.48</td><td class="colsep0 rowsep0" align="left">4.82–4.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.011</td><td class="colsep0 rowsep0" align="left">0.00014 ± 0.00003</td><td class="colsep0 rowsep0" align="left">0.265 ± 0.024</td><td class="colsep0 rowsep0" align="left">0.36–0.24</td><td class="colsep0 rowsep0" align="left">2.88</td><td class="colsep0 rowsep0" align="left">8.81–5.54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(74.30%) 2.65</td><td class="colsep0 rowsep0" align="left">0.148 ± 0.073</td><td class="colsep0 rowsep0" align="left">0.502 ± 0.062</td><td class="colsep0 rowsep0" align="left">0.32–0.30</td><td class="colsep0 rowsep0" align="left">1.87</td><td class="colsep0 rowsep0" align="left">5.64–5.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.006 ± 0.002</td><td class="colsep0 rowsep0" align="left">0.001 ± 0.0001</td><td class="colsep0 rowsep0" align="left">0.065 ± 0.002</td><td class="colsep0 rowsep0" align="left">0.51–0.41</td><td class="colsep0 rowsep0" align="left">1.81</td><td class="colsep0 rowsep0" align="left">7.19–5.38</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Average of two duplicate 10-dose IC<sub>50</sub> determinations ± SD unless otherwise noted.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Reported values (<a href="http://www.reactionbiology.com" class="extLink">http://www.reactionbiology.com</a>).</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">10-dose IC<sub>50</sub>.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">56 pM (10-dose IC<sub>50</sub>).</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">Ligand efficiency, given as a range for the three targets, defined as −<i>RT</i> ln(IC<sub>50</sub>)/<i>N</i>, where <i>N</i> = number of heavy atoms.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last">Calculated as miLogP using Molinspiration property engine version 2014.11 (<a href="http://www.molinspiration.com" class="extLink">http://www.molinspiration.com</a>).</p></div><div class="footnote" id="t2fn7"><sup>g</sup><p class="last">Lipophilic efficiency, defined as pIC<sub>50</sub> – cLogP, given as a range for the three targets.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Compound Screening by Affinity-LC/MS on JAK2 Capillary Column</h3><div class="NLM_p">Biophysical confirmation that the compounds were binding to JAK2 was achieved by the use of weak affinity chromatography (WAC).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> This affinity-LC/MS based method has recently been reviewed, and it can be applied to confirm binding through simple estimation of retardation of compounds toward a target.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> A <i>K</i><sub>D</sub> can be estimated directly by the retention of the compound versus a control column with no target. The HPLC columns with immobilized JAK2 were prepared on a small scale (capillary columns) using only small amounts of protein (<1 mg and as low as 100 μg in some cases). These columns are typically stable for months and can be monitored using known reference compounds. Affinities in the 0.1 μM to high mM range are quantifiable. It should be noted that this method is not suitable for generating accurate IC<sub>50</sub> values of potent compounds but can be used to provide evidence of binding to target. In the case of JAK2, the effective loading of protein onto the column was estimated to be about 50% (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_001.pdf" class="ext-link">Supporting Information</a>). Compound affinity (<i>K</i><sub>D</sub>) was determined in the range of 0.2–10 μM (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). It is essential to note that the affinity reported is an <i>apparent K</i><sub>D</sub> value because of the lack of an accurate experimental loading (<i>B</i><sub>tot</sub> value). Although the affinity LC/MS apparent <i>K</i><sub>D</sub> values were not correlated with the kinase biochemical IC<sub>50</sub> values, mainly due to different experimental protocols and principles, the data were useful for confirming the affinity binding of the compounds to JAK2. Interestingly, the tightest binder as measured with WAC (<b>26</b>) coincided with the strongest inhibitor as measured with the kinase assay. Performance of the positive control (compound <b>S13</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_001.pdf" class="ext-link">Supporting Information</a>) was found to be consistent throughout the experiment with a <i>K</i><sub>D</sub> of approximately 55 μM (IC<sub>50</sub> of 45 μM in the biochemical assay) indicating that the affinity column was stable throughout the studies.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Affinity Constants (<i>K</i><sub>D</sub>) for Compounds towards JAK2 Protein</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">JAK2-WAC,<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> apparent <i>K</i><sub>D</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">biochemical assay,<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">3.56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.219</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">0.200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0.075</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.481</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="char" char="."><1</td><td class="colsep0 rowsep0" align="char" char=".">0.043</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.865</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">1.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.265</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.502</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Weak affinity chromatography tandem mass spectrometry, JAK2 protein immobilized on a silica based HPLC column and compounds eluted; net retention time is proportional to apparent <i>K</i><sub>D</sub>.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Kinase assay, see <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.</p></div></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Isoform Selectivity</h3><div class="NLM_p">Assessing potency of synthesized compounds against HDAC1, HDAC6, and JAK2 as a primary screening approach enabled the selection of compounds with broad inhibitory profiles. To fully understand a preferred JAK-HDAC dual inhibitor, HDAC and JAK family profiles must be assessed by determining potency against family members of each target. Compounds <b>24</b> and <b>45</b> were selected for further profiling in functional kinase enzyme assays (same format as primary screens) since these compounds met our goals of good potency against the three primary enzyme targets (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Isoform Selectivity of <b>24</b> and <b>45</b> against the JAK Family Kinases and FLT3 Kinase<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">isoform</th><th class="colsep0 rowsep0" align="center"><b>24</b></th><th class="colsep0 rowsep0" align="center"><b>45</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="left">0.017 ± 0.0001</td><td class="colsep0 rowsep0" align="left">0.011 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="left">0.075 ± 0.008</td><td class="colsep0 rowsep0" align="left">0.065 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="left">0.569 ± 0.057</td><td class="colsep0 rowsep0" align="left">0.436 ± 0.016</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TYK2</td><td class="colsep0 rowsep0" align="left">0.188 ± 0.022</td><td class="colsep0 rowsep0" align="left">0.144 ± 0.028</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="left">27% at 1 μM</td><td class="colsep0 rowsep0" align="left">NT</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Kinase IC<sub>50</sub> values are average of at least two duplicate 10-dose IC<sub>50</sub> determinations ± SD. NT = not tested.</p></div></div></div><div class="NLM_p">Considering that <b>24</b> and <b>45</b> are based on the pyrazole substituted pyrrolopyrimidine of <b>1</b>, it was not surprising to learn that they were also similarly active for JAK1; however it was surprising to find that they were 4.4- and 5.9-fold more active for JAK1 compared to JAK2, respectively. Selectivity against JAK3 and TYK2 was approximately 10-fold and 30–40-fold.</div><div class="NLM_p">Compound <b>24</b> was also tested against FLT3, which is inhibited by <b>3</b>, where it was observed that <b>24</b> is less active with only 27% inhibition of kinase function at a concentration of 1 μM. Overall, the JAK profile of <b>24</b> and <b>45</b> is broader that than of pacritinib-based <b>3</b>, clearly differentiating this series.</div><div class="NLM_p">Having established selectivity within the JAK family of kinases, we selected <b>24</b> for testing in a kinase panel composed of 90 different parent kinases (97 kinases including mutants) from across the kinome. These data depict binding to the ATP sites of the tested kinases, as opposed to functional biochemical inhibition, in the well-known TREE<i>spot</i> interaction map<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>). At the test concentration of 1000 nM (1 μM) there were no new kinases inhibited in the 0.1–1.0% control range or 1–5% range, giving a low “<i>S</i>” score of <0.1 (except for JAK family members JAK2, JAK3, and TYK2) indicating a high degree of kinase selectivity for this compound. Four other nonmutant kinases were bound by <b>24</b> at lower levels including SNARK, SRPK3, ROCK2, and IKKβ, with weak binding values ranging from 7.5% to 30% of control (see <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a> for full list of kinases).</div><figure id="cht1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0001.jpeg" id="GRAPHIC-d129e2426-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Kinase Panel Screening Data of Compound <b>24</b> against 97 Kinases (DiscoveRx) Tested at a Concentraiton of 1 μM<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Chart a</span>The TREE<i>spot</i> map indicates the very high selectivity of compound <b>24</b>. From 90 nonmutated kinases only 7 were hit with <35% of control binding remaining (approximately equates to an IC<sub>50</sub> of around 10 μM). “<i>S</i>” scores are all less than 0.1, indicating a high degree of kinase selectivity.</p></p></figure><div class="NLM_p">HDAC panel testing was carried out for both <b>24</b> and <b>45</b>. Selectivity of <b>24</b> against class I HDACs was only seen for HDAC8 (335-fold selective versus HDAC6), with single digit nanomolar potency against HDACs 1, 2, and 3. As observed for <b>3</b>, compound <b>24</b> is about 1 order of magnitude selective for HDAC10. However, <b>24</b> is quite potent for HDAC11, exhibiting an IC<sub>50</sub> of 31 nM. Inhibition of class IIA HDACs is only seen at concentrations above 10 μM (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Isoform Selectivity of <b>24</b> and <b>45</b> against the Class I, II, and IV HDAC Enzymes<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">isoform</th><th class="colsep0 rowsep0" align="center">class</th><th class="colsep0 rowsep0" align="center"><b>24</b></th><th class="colsep0 rowsep0" align="center"><b>45</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC1</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">0.0069</td><td class="colsep0 rowsep0" align="left">0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC2</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">0.0058</td><td class="colsep0 rowsep0" align="left">0.047</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC3</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">0.0039</td><td class="colsep0 rowsep0" align="left">0.024</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC4</td><td class="colsep0 rowsep0" align="left">IIA</td><td class="colsep0 rowsep0" align="left">23% at 10 μM</td><td class="colsep0 rowsep0" align="left">8% at 10 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC5</td><td class="colsep0 rowsep0" align="left">IIA</td><td class="colsep0 rowsep0" align="left">10.5</td><td class="colsep0 rowsep0" align="left">7.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC6</td><td class="colsep0 rowsep0" align="left">IIB</td><td class="colsep0 rowsep0" align="left">0.0014</td><td class="colsep0 rowsep0" align="left">0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC7</td><td class="colsep0 rowsep0" align="left">IIA</td><td class="colsep0 rowsep0" align="left">17.2</td><td class="colsep0 rowsep0" align="left">33% at 10 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC8</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">0.469</td><td class="colsep0 rowsep0" align="left">0.310</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC9</td><td class="colsep0 rowsep0" align="left">IIA</td><td class="colsep0 rowsep0" align="left">30% at 10 μM</td><td class="colsep0 rowsep0" align="left">8.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC10</td><td class="colsep0 rowsep0" align="left">IIB</td><td class="colsep0 rowsep0" align="left">0.019</td><td class="colsep0 rowsep0" align="left">0.031</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC11</td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="left">0.031</td><td class="colsep0 rowsep0" align="left">40% at 10 μM</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">HDAC enzymes were tested in a 10-dose IC<sub>50</sub>.</p></div></div></div><div class="NLM_p last">The data indicate that methyl derivative <b>45</b> is more selective than <b>24</b> with IC<sub>50</sub> values below 10 nM for HDACs 1 and 6 only (6 and 1 nM, respectively). IC<sub>50</sub> values for HDACs 2, 3, and 10 were less than 50 nM with much weaker inhibitory activity against other HDACs.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Modeling Studies</h3><div class="NLM_p last">Our previous studies of <b>3</b> indicated a high degree of selectivity between HDACs 6 and 1 which was understood from modeling to be likely due to differences in interactions between the ligand and the residues at the entrance to the catalytic site.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> For <b>24</b> we carried out similar docking studies in order to explain its broader profile with only 5-fold selectivity for HDAC6 compared to HDAC1. As expected, the hydroxamic acid of <b>24</b> coordinates to the catalytic zinc of HDAC6 and forms three additional hydrogen bonds to the side chains of Tyr782, His610, and His611 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Hydrophobic interactions are formed between the pyrrolopyrimidine and pyrazole with the surface residues His500, Pro501, and Phe620. Similarly, <b>24</b> hydrogen-bonds to the side chains of Tyr303 and His141 in HDAC1 and may form a hydrogen bonding interaction with Glu98 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). These binding modes do not indicate any clear differences, which agrees with the observed low selectivity between HDACs 1 and 6. In JAK1, the pyrrolopyrimidine of <b>24</b> forms hydrogen bonds to the backbone of the kinase hinge residues Glu957 and Leu959. The methylene chain extends under the glycine-rich loop with the hydroxamic acid extending out of the binding site (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Compound <b>24</b> binds in a very similar manner to JAK2 where the pyrrolopyrimidine forms hydrogen bonds to the backbone of the kinase hinge residues Glu930 and Leu932 (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). These binding modes explain how <b>24</b> is able to bind potently to two different classes of enzyme.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Cellular Assays</h3><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Solid Tumor Cell Lines</h4><div class="NLM_p">All synthesized final compounds were tested against four solid tumor cell lines for their antiproliferative potency: breast cancer cell lines MDA-MB231 and MCF7, colorectal cancer cell line HCT-116, and prostate cancer cell line PC-3 (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Antiproliferative activity approximately tracked enzyme potency. Less enzyme active <b>21</b> was found to be unable to slow the proliferation of all cell lines at the highest concentration tested of 100 μM. As JAK2/HDAC potency increased through <b>22</b> and <b>23</b>, cellular activity gradually increased to single digit micromolar. The most potent JAK2/HDAC inhibitor, <b>24</b>, was also the most potent against these cell lines with the breast cancer cell lines being the most sensitive with IC<sub>50</sub> values of 790 and 840 nM, respectively. All other tested compounds were less active than <b>24</b> by a considerable margin having IC<sub>50</sub> values above 10 μM.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. IC<sub>50</sub> (μM) for Cell Proliferation Inhibition of Compounds in Different Cancer Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">MDA-MB-231</th><th class="colsep0 rowsep0" align="center">MCF7</th><th class="colsep0 rowsep0" align="center">HCT-116</th><th class="colsep0 rowsep0" align="center">PC3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tubastatin<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">10.4</td><td class="colsep0 rowsep0" align="left">3.7</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">8.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.19 ± 0.18</td><td class="colsep0 rowsep0" align="left">0.65 ± 0.08</td><td class="colsep0 rowsep0" align="left">1.85 ± 0.52</td><td class="colsep0 rowsep0" align="left">0.85 ± 0.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">17.3 ± 4.7</td><td class="colsep0 rowsep0" align="left">12.8 ± 4.8</td><td class="colsep0 rowsep0" align="left">46.2 ± 11.3</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">5.78 ± 0.45</td><td class="colsep0 rowsep0" align="left">8.16 ± 0.87</td><td class="colsep0 rowsep0" align="left">8.99 ± 1.23</td><td class="colsep0 rowsep0" align="left">18.8 ± 4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">0.79 ± 0.18</td><td class="colsep0 rowsep0" align="left">0.84 ± 0.07</td><td class="colsep0 rowsep0" align="left">2.32 ± 1.03</td><td class="colsep0 rowsep0" align="left">2.41 ± 0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">12.9 ± 0.2</td><td class="colsep0 rowsep0" align="left">12.4 ± 0.3</td><td class="colsep0 rowsep0" align="left">11.8 ± 1.4</td><td class="colsep0 rowsep0" align="left">12.9 ± 6.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">12.9 ± 0.2</td><td class="colsep0 rowsep0" align="left">13.3 ± 2.9</td><td class="colsep0 rowsep0" align="left">41.1 ± 16.8</td><td class="colsep0 rowsep0" align="left">54.3 ± 5.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">70.0 ± 11.3</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">23.0 ± 3.3</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">25.5 ± 9.9</td><td class="colsep0 rowsep0" align="left">15.2 ± 0.3</td><td class="colsep0 rowsep0" align="left">19.4 ± 8.2</td><td class="colsep0 rowsep0" align="left">23.9 ± 8.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">13.3 ± 5.8</td><td class="colsep0 rowsep0" align="left">14.4 ± 7.9</td><td class="colsep0 rowsep0" align="left">25.3 ± 6.6</td><td class="colsep0 rowsep0" align="left">17.0 ± 3.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Values are the mean ± SD of at least three determinations. Compound <b>1</b> is >10 μM in all assays.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">HDAC6 selective inhibitor.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Pan-HDAC inhibitor.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></p></div></div></div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Hematological Cancer Cell Lines</h4><div class="NLM_p">Selected compounds with the highest potency against JAK1/2 and either or both HDAC1/6 were then tested in three hematological cell lines: the acute myeloid leukemia (AML) cell line HL-60, the erythroleumekia cell line HEL92.1.7, and the acute T-cell leukemia cell line Jurkat (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). These cell lines are sensitive to pan-HDAC and FLT3 inhibition evidenced from the low IC<sub>50</sub> values observed with <b>2</b> and pacritinib. However, selective HDAC6 and JAK1/2 inhibiting compounds tubastatin and <b>1</b> were not potent in these cell lines. Compound <b>3</b>, which combines JAK2 with HDACs 2, 6, and 10 inhibition, is broadly potent in these cell lines. Compound <b>24</b>, the best performing example found from solid tumor testing, was also the most active against hematological cells. Compound <b>24</b> is also the most potent of all the test compounds against the Jurkat cell line and similar to <b>3</b> against the other cell lines. Hence <b>24</b> was selected for further study in a wider range of hematological cell lines (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Cell Proliferation Inhibition Assay Data of Selected Compounds in Three Leukemia Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">HL-60<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">HEL92.1.7<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">Jurkat<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pacritinib<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">1.78 ± 0.62</td><td class="colsep0 rowsep0" align="left">1.17 ± 0.03</td><td class="colsep0 rowsep0" align="left">1.09 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tubastatin<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">>4<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">>4<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">>4<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a class="ref internalNav" href="#t7fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">>4<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">>4<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">>4<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">2.28 ± 1.28</td><td class="colsep0 rowsep0" align="left">0.49 ± 0.10</td><td class="colsep0 rowsep0" align="left">0.59 ± 0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b><a class="ref internalNav" href="#t7fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left">c.4<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a><sup>,</sup><a class="ref internalNav" href="#t7fn11" aria-label="k">k</a></td><td class="colsep0 rowsep0" align="left">0.94 ± 0.22</td><td class="colsep0 rowsep0" align="left">1.19 ± 0.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">7.36 ± 1.78</td><td class="colsep0 rowsep0" align="left">1.33 ± 0.14</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">>10<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">>4<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">c.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">>10<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">>4<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">>4<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Antiproliferative inhibitory activities are the average of at least three determinations.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Acute myeloid leumekia.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">Erythroleukemia (JAK2<sup>V617F</sup>).</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last">Acute T-cell leukemia.</p></div><div class="footnote" id="t7fn5"><sup>e</sup><p class="last">JAK2/FLT3 inhibitor.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></p></div><div class="footnote" id="t7fn6"><sup>f</sup><p class="last">HDAC6 selective inhibitor.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></p></div><div class="footnote" id="t7fn7"><sup>g</sup><p class="last">Top concentration tested.</p></div><div class="footnote" id="t7fn8"><sup>h</sup><p class="last">JAK1/JAK2 inhibitor.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></p></div><div class="footnote" id="t7fn9"><sup>i</sup><p class="last">Pan-HDAC inhibitor.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></p></div><div class="footnote" id="t7fn10"><sup>j</sup><p class="last">JAK2/HDAC inhibitor.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></p></div><div class="footnote" id="t7fn11"><sup>k</sup><p class="last">47% inhibition at 4 μM.</p></div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Cell Proliferation Inhibition Assay Data of <b>24</b> and Reference Standards in a Range of Hematological Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="8" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">KMS-12-BM<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">OPM-2<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">XG-6<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">KG-1<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">MOLM-14<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">MV4-11<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">NKYS<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">KHYG<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>10<a class="ref internalNav" href="#t8fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">>10<a class="ref internalNav" href="#t8fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>10<a class="ref internalNav" href="#t8fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">>10<a class="ref internalNav" href="#t8fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a class="ref internalNav" href="#t8fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left">0.94 ± 0.24</td><td class="colsep0 rowsep0" align="left">2.91 ± 0.87</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pacritinib<a class="ref internalNav" href="#t8fn11" aria-label="k">k</a></td><td class="colsep0 rowsep0" align="left">0.75 ± 0.24</td><td class="colsep0 rowsep0" align="left">1.21 ± 0.65</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.48<a class="ref internalNav" href="#t8fn12" aria-label="l">l</a></td><td class="colsep0 rowsep0" align="left">0.079<a class="ref internalNav" href="#t8fn12" aria-label="l">l</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.60<a class="ref internalNav" href="#t8fn12" aria-label="l">l</a></td><td class="colsep0 rowsep0" align="left">1.24<a class="ref internalNav" href="#t8fn12" aria-label="l">l</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b><a class="ref internalNav" href="#t8fn13" aria-label="m">m</a></td><td class="colsep0 rowsep0" align="left">2.11 ± 0.91</td><td class="colsep0 rowsep0" align="left">2.05 ± 0.89</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.63 ± 0.53</td><td class="colsep0 rowsep0" align="left">1.14 ± 0.39</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.08 ± 0.22</td><td class="colsep0 rowsep0" align="left">1.09 ± 0.45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">2.02 ± 1.07</td><td class="colsep0 rowsep0" align="left">2.16 ± 0.57</td><td class="colsep0 rowsep0" align="left">2.01 ± 0.99</td><td class="colsep0 rowsep0" align="left">0.15 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.74 ± 0.21</td><td class="colsep0 rowsep0" align="left">0.46 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.45 ± 0.16</td><td class="colsep0 rowsep0" align="left">0.57 ± 0.22</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Antiproliferative inhibitory activities are the average of at least three determinations.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Multiple myeloma.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Acute myeloid leukemia.</p></div><div class="footnote" id="t8fn4"><sup>d</sup><p class="last">Natural killer T-cell lymphoma.</p></div><div class="footnote" id="t8fn5"><sup>e</sup><p class="last">JAK1/2 inhibitor.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></p></div><div class="footnote" id="t8fn6"><sup>f</sup><p class="last">59% viability at 10 μM.</p></div><div class="footnote" id="t8fn7"><sup>g</sup><p class="last">74% viability at 10 μM. Blank cells = not tested.</p></div><div class="footnote" id="t8fn8"><sup>h</sup><p class="last">73% viability at 10 μM.</p></div><div class="footnote" id="t8fn9"><sup>i</sup><p class="last">52% viability at 10 μM.</p></div><div class="footnote" id="t8fn10"><sup>j</sup><p class="last">Pan-HDAC inhibitor.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></p></div><div class="footnote" id="t8fn11"><sup>k</sup><p class="last">JAK2/FLT3 inhibitor.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></p></div><div class="footnote" id="t8fn12"><sup>l</sup><p class="last">Single determination of an 8-dose response in triplicate.</p></div><div class="footnote" id="t8fn13"><sup>m</sup><p class="last">JAK2/HDAC dual inhibitor.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Blank cells = not tested.</p></div></div></div><div class="NLM_p last">Three multiple myeloma cell lines (KMS-12-BM, OPM-2, XG-6), three AML cell lines (KG-1, MOLM-14, MV4-11), and two natural killer T-cell lymphoma cell lines (NKYS, KHYG) were tested against <b>24</b> as well as four reference compounds against selected cell lines: the JAK1/2 inhibitor <b>1</b>, pan-HDAC inhibitor <b>2</b>, JAK2/HDAC inhibitor <b>3</b>, and JAK2-FLT3 inhibitor pacritinib. Potency ranged from 0.15 to 2.16 μM for <b>24</b>, which compares very favorably with the reference compounds. Compound <b>24</b> was either more potent or similarly potent (within 2- to 3-fold) to each reference compound for all cell lines with the exception of MOLM-14 where <b>24</b> (IC<sub>50</sub> = 0.74 μM) is nearly 10-fold less active than the very potent pacritinib (IC<sub>50</sub> = 0.079 μM).</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Normal Cells</h4><div class="NLM_p">Having shown that <b>24</b> is a broad antiproliferative agent in a range of cancer cells, it was then determined if these effects also applied to two normal cell lines, transforming growth factor α mouse hepatocytes (TAMH)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and the cardiomyocyte AC10<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>). Compound <b>24</b> stopped the growth of TAMH cells at a concentration higher than its average anticancer potency (IC<sub>50</sub> = 4.63 μM), whereas for AC10 cells <b>24</b> was considerably less potent (56% at 100 μM). These data suggest that dual inhibitors such as <b>24</b> may have a therapeutic window.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Cell Proliferation Assay Data of Compounds in Two Normal Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">TAMH IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">AC10 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a class="ref internalNav" href="#t9fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">7.86 ± 2.2</td><td class="colsep0 rowsep0" align="left">79.2 ± 43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pacritinib<a class="ref internalNav" href="#t9fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">3.68 ± 0.88</td><td class="colsep0 rowsep0" align="left">2.02 ± 0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b><a class="ref internalNav" href="#t9fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">9.57 ± 1.00</td><td class="colsep0 rowsep0" align="left">2.07 ± 0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">4.63 ± 0.91</td><td class="colsep0 rowsep0" align="left">>100 (56% viable)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">Average ± SD of four determinations.</p></div><div class="footnote" id="t9fn2"><sup>b</sup><p class="last">Mouse hepatocyte.</p></div><div class="footnote" id="t9fn3"><sup>c</sup><p class="last">Cardiomyocyte.</p></div><div class="footnote" id="t9fn4"><sup>d</sup><p class="last">Pan-HDAC inhibitor.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></p></div><div class="footnote" id="t9fn5"><sup>e</sup><p class="last">JAK2/FLT3 inhibitor.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></p></div><div class="footnote" id="t9fn6"><sup>f</sup><p class="last">JAK2/HDAC dual inhibitor.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></p></div></div></div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Intracellular Target Engagement</h3><div class="NLM_p">Having shown that compound <b>24</b> had a desirable antiproliferative profile, it was next determined whether or not the compound was inhibiting both the JAK-STAT and HDAC pathways in two different cell lines (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Cell lines from multiple myeloma (KMS-12-BM) and acute myeloid leukemia (MOLM-14) were used to demonstrate target engagement of <b>24</b> (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Compounds were compared using acetylated histone 3 (Ac-H3) as a marker for HDAC 1, 2, or 3 inhibition<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and using acetylated tubulin (Ac-Tub) as a marker for HDAC6 inhibition.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Compound <b>2</b> was used as an HDAC1–3 positive control and tubastatin as a selective HDAC6 control.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Effects on HDAC1–3 were observed at concentrations just above the antiproliferative IC<sub>50</sub> in both cell lines (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A,B). Inhibition of HDAC6 appeared to be more sensitive in these cell lines with increases in Ac-Tub seen at concentrations lower than that required for Ac-H3 induction. JAK pathway inhibition (contributions from both JAK1 and JAK2<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a>) were clearly apparent with p-STAT3 levels being reduced at submicromolar concentrations (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>C,D). Taken together, these data support the engagement of JAK1/2 and HDACs 1–3, 6 in these two cell lines. It is important to note that the effects of the compound are dependent on the cell line and the pathways that are active in that cell line (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_001.pdf" class="ext-link">Figure S2</a> for effects of <b>24</b> and reference compounds on HEL92.1.7 cells and HeLa cells).</div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>24</b> effectively blocks dual signaling pathways in MM and AML cell lines. (A) KMS-12-BM and (B) MOLM-14 were treated with <b>24</b> at the respective concentrations for 16 h. After lysis, acetylated tubulin (Ac-tubulin) and acetylated histone 3 (Ac-H3) were detected by immunoblotting. Subsequently, as a loading control the same membranes were reprobed with tubulin and H3, respectively. Compound <b>2</b> was used as a postive control for the inhibtion of HDACs. (C) KMS-12-BM and (D) MOLM-14 were pretreated with <b>24</b> for 3 h and then were treated with 10 ng/mL of IL-6 for 15 min. Compound <b>1</b> was used as a positive control for the inhibition of the JAK2 pathway at 3 μM (sub-IC<sub>50</sub> concentration). After lysis, p-STAT3 was detected by immunoblotting. The same membranes were reprobed with STAT3 to detect total protein levels. (E) KMS-12-BM and (F) MOLM-14 cells were treated with <b>24</b> at the respective concentrations for 24 h and then lysed. Tubastatin and <b>1</b> were utilized as negative and positive controls, respectively. Cleaved PARP was detected by immunoblotting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Poly(ADP-ribose) polymerase (PARP) has been implicated in cell death pathways via apoptosis where it is cleaved by caspases to give a N-terminal DNA binding domain. Increase in cleaved PARP following treatment of cells by a therpaeutic agent indicates cell death via apoptosis.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a> Treatment of KMS12BM and MOLM-14 cells with <b>24</b> led to dose related increases in cleaved PARP at concentrtinos from 1 to 6 μM (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>E,F).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> ADME Properties</h3><div class="NLM_p">Compound <b>24</b> was selected for further profiling (<a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>). With a low molecular weight and hydrogen bond donors (three) and acceptors (eight), <b>24</b> has potential to be an oral drug. Calculated log <i>P</i> was 1.45 with polar surface area of 108.7 Å<sup>2</sup>. Unfortunately, the PAMPA assay was unable to detect any compound, a result that could be due to low solubility. Hence solubilty in pH 7.4 PBS buffer was quantified using a UV assay at 3 and 24 h. This indicated a moderate solubilty of 66 μg/mL which increased to over 73 μg/mL after stirring for 24 h. Metabolic stability in rat liver microsomes (RLMs) was excellent with half-lives in either male or female RLM of over 200 min (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Physicochemical Properties and in Vitro ADME Data for <b>24</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">property</th><th class="colsep0 rowsep0" align="center">value</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">molecular weight</td><td class="colsep0 rowsep0" align="left">328.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of HBD<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of HBA<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP<a class="ref internalNav" href="#t10fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TPSA (Å<sup>2</sup>)<a class="ref internalNav" href="#t10fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">108.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PAMPA <i>P</i><sub>e</sub> (×10<sup>–6</sup> cm/s)<a class="ref internalNav" href="#t10fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"><LOD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aq solubility (μg/mL, pH 7.4, 3 h)<a class="ref internalNav" href="#t10fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">66.2 ± 3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aq solubility (μg/mL, pH 7.4, 24 h)<a class="ref internalNav" href="#t10fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">>73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RLM (<i>t</i><sub>1/2</sub>, min)<a class="ref internalNav" href="#t10fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">>200</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup>a</sup><p class="last">Hydrogen bond donors.</p></div><div class="footnote" id="t10fn2"><sup>b</sup><p class="last">Hydrogen bond acceptors.</p></div><div class="footnote" id="t10fn3"><sup>c</sup><p class="last">Calculated as miLogP using Molinspiration property engine version 2014.11 (<a href="http://www.molinspiration.com" class="extLink">http://www.molinspiration.com</a>).</p></div><div class="footnote" id="t10fn4"><sup>d</sup><p class="last">Topological polar surface area (<a href="http://www.molinspiration.com" class="extLink">http://www.molinspiration.com</a>).</p></div><div class="footnote" id="t10fn5"><sup>e</sup><p class="last">Parallel artificial membrane permeability assay; LOD = 1 nM.</p></div><div class="footnote" id="t10fn6"><sup>f</sup><p class="last">Thermodynamic aqueous solubility.</p></div><div class="footnote" id="t10fn7"><sup>g</sup><p class="last">Rat liver microsomes.</p></div></div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Pharmacokinetics</h3><div class="NLM_p">Given the encouraging aqueous solubility and microsomal stability of <b>24</b>, pharmacokinetics (PK) in rats was determined for <b>24</b>. The compound was dosed at 5 mg/kg orally (po) and 1 mg/kg intravenously (iv). Concentrations of <b>24</b> were quantifiable up to 2 h postdose but were below the limit of quantitation between 4 and 24 h postdose (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). The compound was rapidly cleared (CL = 95 mL min<sup>–1</sup> kg<sup>–1</sup>), with a moderate volume of distribution at steady state (<i>V</i><sub>ss</sub>= 1.5 L/kg) and a short terminal half-life of ∼0.4 h. The high systemic clearance was unexpected given the slow turnover in rat liver micosomes. This suggests that <b>24</b> is cleared by other routes, such as biliary or renal clearance. Oral bioavailability was measurable but poor at 1.4% possibly indicative of low permeability.</div><figure id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Pharmacokinetics of <b>24</b> in Wistar rats. (A) Semilogarithmic plot of mean plasma concentration versus time following a single iv dose of 1 mg/kg and oral dose of 5 mg/kg. Error bars are ± SEM. (B) Intravenous PK parameters. (C) Oral PK parameters.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an oral/iv pharmacokinetic study in rats, increased bioavailability was observed for <b>45</b>; however clearance was high indicating further optimization of these templates is required prior to oral efficacy studies (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p last">In conclusion, by use of the core scaffold of the marketed <b>1</b> as a base template, HDAC activity was added by linking a hydroxamate to the pyrazole nitrogen. Optimization of the linker between the pyrazole and hydroxamate led to the identification of <b>24</b> (7-(4-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide, YLB243B), a highly lipophilic efficient compound selectively inhibiting JAK1 and HDACs 1, 2, 3, 6, and 10 with IC<sub>50</sub> values of less than 20 nM. JAK1/JAK2 selectivity was about 5-fold with >10-fold selectivity against TYK2 and JAK3. Proposed binding modes in the hinge of JAK1/2 and the substrate site of HDACs1/6 support the observed activity profile. Compound <b>24</b> was shown to inhibit JAK2 and HDACs 1–3 in a range of cancer cell types supporting its broad antiproliferative mechanism of action. Low dose pharmacokinetics in rats indicated oral exposures detectable for several hours postdose. Given the low molecular weight and high ligand and lipophilic efficiency, <b>24</b> represents a promising lead candidate suitable for optimization. Addition of a methyl group led to <b>45</b> (7-(4-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyoctanamide, YLB343B), with a more selective enzyme profile than <b>24</b> but with increased cLogP and increased bioavailability. The highly efficient template shared by <b>24</b> and <b>45</b> represents an opportunity for dual pathway control with a single molecule. Further optimization could lead to selective suppression of a number of oncogenic targets in a single clinical candidate for the treatment of a range of proliferative disorders.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22086" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22086" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Experimental</h3><div class="NLM_p last">Unless stated otherwise, all nonaqueous reactions were performed in oven-dried round-bottom flasks under an inert nitrogen atmosphere. Commercially available AR grade solvents or anhydrous solvents packed in resealable bottles were used as received. All reaction temperatures stated in the procedures are external bath temperatures unless otherwise stated. Commercial reagents were purchased from Sigma-Aldrich, Alfa Aesar, TCI Chemicals, Combi-Blocks, or Strem Chemicals and used as received without further purification unless otherwise stated. Compound <b>1</b> and tubastatin were purchased from Selleckchem (<a href="http://www.selleckchem.com" class="extLink">www.selleckchem.com</a>). Compound <b>3</b> was prepared previously in our laboratory.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Compound <b>2</b> was prepared in-house. Yields refer to chromatographically and spectroscopically homogeneous materials unless otherwise stated. Reaction progress was monitored by analytical thin layer chromatography (TLC) with 0.25 mm Merck precoated silica gel plates (60F-254) using UV light (254 nm) as visualizing agent and ceric ammonium molybdate or potassium permanganate solutions as developing stains. Flash chromatography was performed on silica gel 60 (0.040–0.063 mm) purchased from SiliCycle or Merck. Melting points were determined using an OMEGA (MPA100) automated melting point system. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AMX400 (400 MHz) NMR spectrometer at ambient atmosphere. The deuterated solvent used was CDCl<sub>3</sub> unless otherwise stated. Chemical shifts are reported in parts per million (ppm), and residual undeuterated solvent peaks were used as internal reference: proton (7.26 ppm for CDCl<sub>3</sub>, 2.50 ppm for DMSO-<i>d</i><sub>6</sub>), carbon (77.0 ppm for CDCl<sub>3</sub>, 39.52 ppm for DMSO-<i>d</i><sub>6</sub>). <sup>1</sup>H NMR coupling constants (<i>J</i>) are reported in hertz (Hz), and multiplicities are presented as follows: s (singlet), d (doublet), t (triplet), m (multiplet), and br (broad). Low resolution mass spectra were obtained on an Agilent 6130B quadrupole LC/MS in ESI mode with an Agilent 1260 Infinity LC system using a ThermoScientific Hypersil 150 mm × 2.1 mm, 5 μm column. High resolution electrospray ionization (ESI) mass spectra were obtained on a Shimadzu MS-IT-TOF spectrometer. Shimadzu formula predictor software was used to process the data. MS and HRMS were reported in units of mass to charge ratio (<i>m</i>/<i>z</i>). Mass samples were dissolved in CH<sub>3</sub>CN/DMSO mixture (HPLC grade, 90% CH<sub>3</sub>CN) unless otherwise stated. The purity of new compounds that underwent biological testing was determined by HPLC using an Agilent 1200 SL instrument. All tested compounds had purity of >95%. The analysis was performed with a flow rate of 0.5 mL/min, an Agilent C-18 column of dimensions 250 mm × 4.6 mm, a particle size of 5 μm, and a loop volume of 20 μL. The detector was set at 254 nm. The mobile phase consisted of phase A (Milli-Q H<sub>2</sub>O, 18.0 MΩ, TFA 0.05%) and phase B (95% CH<sub>3</sub>CN, 5% phase A). The gradient elution was performed as reported: 0 min, %B = 5; 0–10 min, %B = 95; 10–12 min, %B = 95; 12–13 min, %B = 5; 13–15 min, %B = 5.</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Methyl 4-(4-(7-((2-(Trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)butanoate (<b>6</b>)</h3><div class="NLM_p last">A mixture of compound <b>4</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_001.pdf" class="ext-link">Supporting Information</a>) (100 mg, 0.317 mmol), potassium carbonate (132 mg, 0.951 mmol, 3.0 equiv), and methyl 4-bromobutanoate (115 mg, 0.634 mmol, 2.0 equiv) in DMF (15 mL) was stirred at room temperature overnight. The reaction mixture was suspended in ethyl acetate (30 mL) and washed with H<sub>2</sub>O (3 × 30 mL). Drying of the organic phase over Na<sub>2</sub>SO<sub>4</sub> followed by removal of the solvent in vacuo afforded the crude product. The crude was purified by column chromatography (DCM/MeOH, 40:1) to yield <b>6</b> (120 mg, 0.289 mmol, 91%) as a colorless oil. LRMS (ESI) <i>m</i>/<i>z</i> 416.4 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.81 (s, 1H), 8.23 (s, 1H), 8.19 (s, 1H), 7.36 (d, <i>J</i> = 3.7 Hz, 1H), 6.77 (d, <i>J</i> = 3.7 Hz, 1H), 5.64 (s, 2H), 4.28 (t, <i>J</i> = 6.7 Hz, 2H), 3.66 (s, 3H), 3.53 (t, <i>J</i> = 8 Hz, 2H), 2.36 (dd, <i>J</i> = 10.7, 3.8 Hz, 2H), 2.27–2.24 (m, 2H), 0.90 (t, <i>J</i> = 8 Hz, 2H), −0.08 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.7, 152.8, 152.5, 151.8, 140.1, 130.8, 128.8, 122.2, 114.7, 101.5, 73.4, 67.2, 52.4, 52.1, 31.2, 26.1, 18.4, −0.8.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Methyl 5-(4-(7-((2-(Trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)pentanoate (<b>7</b>)</h3><div class="NLM_p last">A mixture of <b>4</b> (110 mg, 0.501 mmol), potassium carbonate (208 mg, 1.503 mmol, 3.0 equiv), and methyl 5-bromopentanoate (195 mg, 1.002 mmol, 2.0 equiv) in DMF (15 mL) was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 40:1) to yield <b>7</b> (202 mg, 0.470 mmol, 94%) as a colorless oil. LRMS (ESI) <i>m</i>/<i>z</i> 430.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.83 (s, 1H), 8.23 (d, <i>J</i> = 5.3 Hz, 2H), 7.38 (d, <i>J</i> = 3.7 Hz, 1H), 6.80 (d, <i>J</i> = 3.7 Hz, 1H), 5.67 (s, 2H), 4.24 (t, <i>J</i> = 7.0 Hz, 2H), 3.66 (s, 3H), 3.55 (t, <i>J</i> = 8.0 Hz, 2H), 2.37 (t, <i>J</i> = 7.3 Hz, 2H), 2.00–1.96 (m, 2H), 1.71–1.65 (m, 4H), 0.92 (t, <i>J</i> = 8.4 Hz, 2H), −0.06 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.2, 152.9, 152.5, 151.9, 140.0, 130.6, 128.9, 122.2, 114.8, 101.7, 73.5, 67.2, 52.9, 52.3, 34.1, 30.3, 22.6, 18.4, −0.8.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Ethyl 6-(4-(7-Tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>8</b>)</h3><div class="NLM_p last">A mixture of <b>5</b> (100 mg, 0.295 mmol), potassium carbonate (82 mg, 0.589 mmol, 2.0 equiv), and ethyl 6-bromohexanoate (132 mg, 0.589 mmol, 2.0 equiv) in DMF (15 mL) was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 40:1) to yield <b>8</b> (115 mg, 0.239 mmol, 81%) as a pale-yellow oil. LRMS (ESI) <i>m</i>/<i>z</i> 482.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.89 (s, 1H), 8.13 (d, <i>J</i> = 1.6 Hz, 2H), 8.09 (d, <i>J</i> = 8.4 Hz, 2H), 7.74 (d, <i>J</i> = 4.1 Hz, 1H), 7.30 (d, <i>J</i> = 8 Hz, 2H), 6.84 (d, <i>J</i> = 4.1 Hz, 1H), 4.19 (t, <i>J</i> = 7.0 Hz, 2H), 4.09 (q, <i>J</i> = 7.1 Hz, 2H), 2.38 (s, 3H), 2.28 (t, <i>J</i> = 7.4 Hz, 2H), 2.00–1.85 (m, 2H), 1.75–1.65 (m, 2H), 1.40–1.30 (m, 2H), 1.21 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.1, 153.9, 153.0, 152.5, 146.5, 139.8, 135.6, 130.8, 130.5, 128.9, 127.0, 121.4, 116.5, 104.5, 61.0, 53.1, 34.7, 30.5, 26.7, 25.0, 22.3, 14.9.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Methyl 7-(4-(7-Tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>9</b>)</h3><div class="NLM_p last">A mixture of <b>5</b> (68 mg, 0.2 mmol), potassium carbonate (83 mg, 0.6 mmol, 3.0 equiv), and methyl 7-bromoheptanoate (134 mg, 0.4 mmol, 2.0 equiv) in DMF (10 mL) was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 45:1) to yield <b>9</b> (94 mg, 0.195 mmol, 97%) as a pale-yellow oil. LRMS (ESI) <i>m</i>/<i>z</i> 482.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.89 (s, 1H), 8.13 (s, 2H), 8.09 (d, <i>J</i> = 8.4 Hz, 2H), 7.74 (d, <i>J</i> = 4.1 Hz, 1H), 7.30 (d, <i>J</i> = 8 Hz, 2H), 6.84 (d, <i>J</i> = 4.1 Hz, 1H), 4.18 (t, <i>J</i> = 7.2 Hz, 2H), 3.64 (s, 3H), 2.38 (s, 3H), 2.28 (t, <i>J</i> = 7.2 Hz, 2H), 2.00–1.85 (m, 2H), 1.65–1.55 (m, 2H), 1.40–1.30 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.7, 153.9, 153.0, 152.5, 146.5, 139.8, 135.6, 130.8, 130.5, 128.9, 127.0, 121.4, 116.5, 104.5, 53.3, 52.1, 34.5, 30.6, 29.2, 26.9, 25.3, 22.3.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Methyl 8-(4-(7-((2-(Trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)octanoate (<b>10</b>)</h3><div class="NLM_p last">A mixture of <b>4</b> (180 mg, 0.571 mmol), potassium carbonate (158 mg, 1.141 mmol, 2.0 equiv), and methyl 8-bromooctanoate (271 mg, 1.141 mmol, 2.0 equiv) in DMF (20 mL) was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 35:1) to yield <b>10</b> (220 mg, 0.466 mmol, 82%) as a pale-yellow oil. LRMS (ESI) <i>m</i>/<i>z</i> 472.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.83 (s, 1H), 8.23 (s, 1H), 8.19 (s, 1H), 7.37 (d, <i>J</i> = 3.7 Hz, 1H), 6.80 (d, <i>J</i> = 3.7 Hz, 1H), 5.66 (s, 2H), 4.20 (t, <i>J</i> = 7.1 Hz, 2H), 3.65 (s, 3H), 3.54 (t, <i>J</i> = 8 Hz, 2H), 2.30–2.27 (m, 2H), 1.95–1.85 (m, 2H), 1.65–1.50 (m, 2H), 1.40–1.25 (m, 6H), 0.91 (t, <i>J</i> = 8 Hz, 2H), −0.06 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.8, 152.9, 152.6, 152.0, 139.8, 130.5, 128.8, 122.1, 114.7, 101.6, 73.5, 67.2, 53.4, 52.1, 34.7, 30.8, 29.6, 29.4, 27.1, 25.5, 18.4, −0.8.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Methyl 11-(4-(7-Tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)undecanoate (<b>11</b>)</h3><div class="NLM_p last">A mixture of <b>5</b> (57 mg, 0.168 mmol), potassium carbonate (47 mg, 0.336 mmol, 2.0 equiv), and methyl 11-bromoundecanoate (94 mg, 0.336 mmol, 2.0 equiv) in DMF (15 mL) was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 50:1) to yield <b>11</b> (77 mg, 0.143 mmol, 85%) as a yellow oil. LRMS (ESI) <i>m</i>/<i>z</i> 538.6 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.88 (s, 1H), 8.12 (d, <i>J</i> = 0.7 Hz, 2H), 8.08 (d, <i>J</i> = 8.4 Hz, 2H), 7.73 (d, <i>J</i> = 4.1 Hz, 1H), 7.29 (d, <i>J</i> = 8.1 Hz, 2H), 6.83 (d, <i>J</i> = 4.1 Hz, 1H), 4.17 (t, <i>J</i> = 7.1 Hz, 2H), 3.64 (s, 3H), 2.36 (s, 3H), 2.26 (t, <i>J</i> = 7.5 Hz, 2H), 1.95–1.80 (m, 2H), 1.65–1.55 (m, 2H), 1.29–1.24 (m, 12H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.9, 153.9, 153.0, 152.5, 146.5, 139.7, 135.5, 130.7, 130.5, 128.9, 126.9, 121.3, 116.4, 104.5, 53.4, 52.1, 34.7, 30.8, 29.9, 29.9, 29.8, 29.7, 29.7, 27.2, 25.5, 22.3.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Methyl 4-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)butanoate (<b>12</b>)</h3><div class="NLM_p last">To a RBF was added <b>6</b> (120 mg, 0.289 mmol), acetonitrile (20 mL) and H<sub>2</sub>O (2 mL), and the mixture was degassed three times backfilling with nitrogen each time before being treated with LiBF<sub>4</sub> (271 mg, 2.89 mmol, 10.0 equiv) at room temperature. The resulting reaction mixture was heated to gentle reflux for 24 h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH, 60:1) to yield <b>12</b> (41 mg, 0.144 mmol, 50%) as a colorless oil. LRMS (ESI) <i>m</i>/<i>z</i> 286.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.44 (s, 1H, NH), 8.83 (s, 1H), 8.26 (d, <i>J</i> = 4.3 Hz, 2H), 7.41 (d, <i>J</i> = 3.6 Hz, 1H), 6.78 (d, <i>J</i> = 3.4 Hz, 1H), 4.30 (t, <i>J</i> = 6.7 Hz, 2H), 3.67 (s, 3H, CH3), 2.38 (dd, <i>J</i> = 10.8, 3.8 Hz, 2H), 2.27 (t, <i>J</i> = 6.9 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.7, 153.0, 151.6, 151.5, 140.2, 131.0, 126.5, 122.1, 114.7, 101.1, 52.4, 46.9, 31.3, 23.4.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-((Tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-5-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)pentanamide (<b>13</b>)</h3><div class="NLM_p last">To a solution of <b>7</b> (141 mg, 0.328 mmol) in THF (20 mL) and H<sub>2</sub>O (5 mL) was added LiOH (79 mg, 3.282 mmol, 10.0 equiv). The mixture was stirred overnight at room temperature. When the reaction was deemed complete, as determined by TLC, the mixture was neutralized with 1 M aqueous HCl and concentrated under reduced pressure. To the residue was added DMSO (20 mL), triethylamine (332 mg, 3.282 mmol, 10.0 equiv), HOBT (67 mg, 0.429 mmol, 1.5 equiv), <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (77 mg, 0.656 mmol, 2.0 equiv), and EDC (126 mg, 0.656 mmol, 2.0 equiv), and the mixture was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 40:1) to yield <b>13</b> (110 mg, 0.214 mmol, 65%) as a colorless oil. LRMS (ESI) <i>m</i>/<i>z</i> 515.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.01 (s, 1H), 8.81 (s, 1H), 8.22 (s, 2H), 7.37 (d, <i>J</i> = 3.7 Hz, 1H), 6.79 (d, <i>J</i> = 3.7 Hz, 1H), 5.65 (s, 2H), 4.94 (s, 1H), 4.22 (t, <i>J</i> = 6.8 Hz, 2H), 3.92 (s, 1H), 3.59 (s, 1H), 3.54 (t, <i>J</i> = 8 Hz, 2H), 2.13 (s, 2H), 2.05–1.90 (m, 2H), 1.77–1.54 (m, 8H), 0.90 (t, <i>J</i> = 8.4 Hz, 2H), −0.07 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ170.5, 152.8, 152.4, 151.8, 140.0, 130.8, 128.9, 122.1, 114.7, 103.1, 101.6, 73.4, 67.2, 63.2, 52.8, 33.1, 30.1, 28.7, 25.6, 22.9, 19.2, 18.4, −0.8.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>-((Tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-8-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)octanamide (<b>14</b>)</h3><div class="NLM_p last">To a solution of <b>10</b> (220 mg, 0.466 mmol) in THF (30 mL) and H<sub>2</sub>O (5 mL) was added LiOH (112 mg, 4.66 mmol, 10.0 equiv). The mixture was stirred overnight at room temperature. When the reaction was deemed complete as determined by TLC, the mixture was neutralized with 1 M aqueous HCl and concentrated under reduced pressure. To the residue was added DMSO (20 mL), triethylamine (472 mg, 4.66 mmol, 10.0 equiv), HOBT (95 mg, 0.699 mmol, 1.5 equiv), <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (82 mg, 0.699 mmol, 1.5 equiv), and EDC (179 mg, 0.933 mmol, 2.0 equiv), and the mixture was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 40:1) to yield <b>14</b> (169 mg, 0.302 mmol, 65%) as a pale-yellow oil. LRMS (ESI) <i>m</i>/<i>z</i> 557.7 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.09 (s, 1H), 8.80 (s, 1H), 8.21 (d, <i>J</i> = 2.4 Hz, 2H), 7.36 (d, <i>J</i> = 3.7 Hz, 1H), 6.79 (d, <i>J</i> = 3.7 Hz, 1H), 5.64 (s, 2H), 4.93 (s, 1H), 4.19 (t, <i>J</i> = 7.0 Hz, 2H), 3.95–3.85 (m, 1H), 3.60–3.50 (m, 1H), 3.52 (t, <i>J</i> = 8.0 Hz, 2H), 2.15–1.95 (m, 2H), 1.95–1.85 (m, 2H), 1.80–1.65 (m, 2H), 1.62–1.54 (m, 6H), 1.40–1.25 (m, 6H), 0.90 (t, <i>J</i> = 8.0 Hz, 2H), −0.08 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 171.2, 152.8, 152.5, 151.9, 139.8, 130.6, 128.9, 122.0, 114.7, 103.1, 101.6, 73.4, 67.2, 63.1, 53.3, 33.7, 30.6, 29.3, 29.1, 28.7, 26.9, 25.6, 19.3, 18.4, −0.8.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 4-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)butanamide (<b>15</b>)</h3><div class="NLM_p last">To a solution of <b>12</b> (41 mg, 0.144 mmol) in THF (20 mL) and H<sub>2</sub>O (5 mL) was added LiOH (35 mg, 1.44 mmol, 10.0 equiv).The mixture was stirred overnight at room temperature. When the reaction was deemed complete as determined by TLC, the mixture was neutralized with 1 M aqueous HCl and concentrated under reduced pressure. To the residue were added DMSO (10 mL), triethylamine (146 mg, 1.44 mmol, 10.0 equiv), HOBT (29 mg, 0.216 mmol, 1.5 equiv), EDC (55 mg, 0.288 mmol, 2.0 equiv), and <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (26 mg, 0.216 mmol, 2.0 equiv), and the mixture was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 30:1) to yield <b>15</b> (39 mg, 0.106 mmol, 74%) as a colorless oil. LRMS (ESI) <i>m</i>/<i>z</i> 371.4 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.13 (s, 1H), 10.23 (s, 1H), 8.72 (s, 1H), 8.17 (d, <i>J</i> = 12.3 Hz, 2H), 7.34 (d, <i>J</i> = 2.7 Hz, 1H), 6.68 (s, 1H), 5.05 (s, 1H), 4.30 (s, 2H), 4.05–3.85 (m, 1H), 3.63–3.58 (m, 1H), 2.30–2.20 (m, 2H), 2.25–2.10 (m, 2H), 1.90–1.75 (m, 2H), 1.75–1.50 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 170.2, 152.8, 151.7, 140.1, 131.2, 128.4, 126.3, 122.2, 114.7, 102.9, 101.1, 63.1, 51.7, 30.4, 28.7, 26.9, 25.7, 19.2.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 5-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)pentanamide (<b>16</b>)</h3><div class="NLM_p last">To a solution of <b>13</b> (110 mg, 0.214 mmol) in THF (20 mL) was added TBAF (560 mg, 2.14 mmol, 10.0 equiv). The resulting reaction mixture was heated to gentle reflux for 48 h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH, 20:1) to yield <b>16</b> (60 mg, 0.156 mmol, 73%) as a colorless oil. LRMS (ESI) <i>m</i>/<i>z</i> 385.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.51 (s, 1H), 9.01 (s, 1H), 8.80 (s, 1H), 8.23 (d, <i>J</i> = 10.5 Hz, 2H), 7.37 (d, <i>J</i> = 3.6 Hz, 1H), 6.77 (d, <i>J</i> = 3.6 Hz, 1H), 4.96 (s, 1H), 4.23 (t, <i>J</i> = 6.4 Hz, 2H), 4.05–3.80 (m, 1H), 3.65–3.60 (m, 1H), 2.14 (s, 2H), 1.99 (s, 2H), 1.76–1.56 (m, 8H).</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 6-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)hexanamide (<b>17</b>)</h3><div class="NLM_p last">To a solution of <b>8</b> (115 mg, 0.239 mmol) in THF (20 mL) and H<sub>2</sub>O (5 mL) was added LiOH (57 mg, 2.39 mmol, 10.0 equiv). The mixture was stirred overnight at room temperature. When the reaction was deemed complete as determined by TLC, the mixture was neutralized with 1 M aqueous HCl and concentrated under reduced pressure. To the residue were added DMSO (10 mL), triethylamine (242 mg, 2.39 mmol, 10.0 equiv), HOBT (48 mg, 0.359 mmol, 1.5 equiv), <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (42 mg, 0.359 mmol, 1.5 equiv), and EDC (92 mg, 0.478 mmol, 2.0 equiv), and the mixture was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 35:1) to yield <b>17</b> (20 mg, 0.050 mmol, 21%) as a colorless oil. LRMS (ESI) <i>m</i>/<i>z</i> 399.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.65 (s, 1H), 9.16 (s, 1H), 8.81 (s, 1H), 8.23 (d, <i>J</i> = 9.3 Hz, 2H), 7.37 (d, <i>J</i> = 2.3 Hz, 1H), 6.78 (d, <i>J</i> = 3.3 Hz, 1H), 4.95 (s, 1H), 4.20 (t, <i>J</i> = 6.3 Hz, 2H), 4.05–3.80 (m, 1H), 3.60–3.55 (m, 1H), 2.00–2.10 (m, 2H), 1.93–1.56 (m, 10H), 1.25–1.40 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 171.0, 152.9, 152.0, 151.8, 140.0, 130.8, 126.2, 122.0, 114.7, 103.2, 101.3, 63.2, 53.0, 33.6, 30.4, 28.7, 26.7, 25.7, 25.3, 19.3.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 7-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)heptanamide (<b>18</b>)</h3><div class="NLM_p last">To a solution of <b>9</b> (94 mg, 0.195 mmol) in THF (10 mL) and H<sub>2</sub>O (2 mL) was added LiOH (47 mg, 1.952 mmol, 10.0 equiv). The mixture was stirred overnight at room temperature. When the reaction was deemed complete as determined by TLC, the mixture was neutralized with 1 M aqueous HCl and concentrated under reduced pressure. To the residue were added DMSO (10 mL), triethylamine (198 mg, 1.952 mmol, 10.0 equiv), HOBT (40 mg, 0.293 mmol, 1.5 equiv), <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (34 mg, 0.293 mmol, 1.5 equiv), and EDC (75 mg, 0.390 mmol, 2.0 equiv), and the mixture was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 35:1) to yield <b>18</b> (26 mg, 0.063 mmol, 32%) as a pale-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 413.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.89 (s, 1H), 9.34 (s, 1H), 8.83 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 7.39–7.38 (m, 1H), 6.82 (d, <i>J</i> = 2.3 Hz, 1H), 5.01 (s, 1H), 4.24 (t, <i>J</i> = 6.7 Hz, 2H), 4.05–3.80 (m, 1H), 3.60–3.55 (m, 1H), 2.15–2.00 (m, 2H), 1.93–1.57 (m, 10H), 1.38–1.32 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 171.2, 153.0, 152.0, 151.8, 139.9, 130.9, 126.3, 122.1, 114.7, 103.1, 101.3, 63.1, 52.8, 33.4, 30.6, 28.8, 28.5, 26.3, 25.7, 19.3.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 8-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)octanamide (<b>19</b>)</h3><div class="NLM_p last">To a solution of <b>14</b> (169 mg, 0.302 mmol) in THF (20 mL) was added TBAF (790 mg, 3.02 mmol, 10.0 equiv). The resulting reaction mixture was heated to gentle reflux for 48 h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH, 20:1) to yield <b>19</b> (82 mg, 0.192 mmol, 64%) as a colorless oil. LRMS (ESI) <i>m</i>/<i>z</i> 427.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.91 (s, 1H), 9.27 (s, 1H), 8.82 (s, 1H), 8.25 (d, <i>J</i> = 1.8 Hz, 2H), 7.39 (d, <i>J</i> = 3.5 Hz, 1H), 6.79 (d, <i>J</i> = 3.5 Hz, 1H), 4.98 (s, 1H), 4.19 (t, <i>J</i> = 7.0 Hz, 2H), 3.96 (t, <i>J</i> = 9.0 Hz, 1H), 3.70–3.60 (m, 1H), 2.10–2.00 (m, 2H), 1.91–1.78 (m, 4H), 1.75–1.50 (m, 6H), 1.45–1.20 (m, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 171.3, 153.0, 152.1, 151.9, 139.9, 130.7, 126.1, 122.1, 114.6, 103.3, 101.3, 63.2, 53.3, 33.8, 30.6, 29.4, 29.1, 28.8, 27.0, 25.7, 24.8, 19.3.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 11-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)undecanamide (<b>20</b>)</h3><div class="NLM_p last">To a solution of <b>11</b> (76 mg, 0.141 mmol) in THF (20 mL) and H<sub>2</sub>O (5 mL) was added LiOH (34 mg, 1.41 mmol, 10.0 equiv). The mixture was stirred at 50 °C overnight. When the reaction was deemed complete as determined by TLC, the mixture was neutralized with 1 M aqueous HCl and concentrated under reduced pressure. To the residue were added DMSO (15 mL), triethylamine (143 mg, 1.41 mmol, 10.0 equiv), HOBT (29 mg, 0.212 mmol, 1.5 equiv), <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (33 mg, 0.282 mmol, 2.0 equiv), and EDC (54 mg, 0.282 mmol, 2.0 equiv), and the mixture was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 30:1) to yield <b>20</b> (44 mg, 0.093 mmol, 66%) as a white solid. LRMS (ESI) <i>m</i>/<i>z</i> 469.6 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.08 (s, 1H), 9.17 (s, 1H), 8.85 (s, 1H), 8.25 (d, <i>J</i> = 10.3 Hz, 2H), 7.39 (d, <i>J</i> = 3.4 Hz, 1H), 6.80 (s, 1H), 4.98 (s, 1H), 4.20 (t, <i>J</i> = 7.1 Hz, 2H), 3.95 (t, <i>J</i> = 9.4 Hz, 1H), 3.65–3.55 (m, 1H), 2.15–1.95 (m, 2H), 1.96–1.88 (m, 2H), 1.84–1.76 (m, 2H), 1.61–1.57 (m, 6H), 1.29–1.21 (m, 12H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 171.4, 153.0, 152.1, 151.8, 139.9, 130.6, 126.2, 122.1, 114.7, 103.3, 101.3, 63.3, 53.4, 34.1, 30.8, 30.0, 29.8, 29.8, 29.6, 28.7, 27.1, 26.0, 25.7, 19.3.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 4-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxybutanamide (<b>21</b>)</h3><div class="NLM_p last">To a solution of intermediate <b>15</b> (39 mg, 0.106 mmol) in 1,4-dioxane (10 mL) was added HCl (75 μL, 0.3 mmol, 4 M in dioxane, 3.0 equiv), and the reaction mixture was stirred at room temperature overnight. The solids were collected by filtration to afford compound <b>21</b> (25 mg, 0.873 mmol, 82%) as a pink solid. LRMS (ESI) <i>m</i>/<i>z</i> 287.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.88 (s, 1H), 8.83 (s, 1H), 8.45 (s, 1H), 7.86 (d, <i>J</i> = 3.6 Hz, 1H), 7.32 (d, <i>J</i> = 3.6 Hz, 1H), 4.40 (t, <i>J</i> = 6.8 Hz, 2H), 2.47–2.10 (m, 4H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ176.1, 153.4, 145.5, 144.8, 140.9, 134.6, 132.5, 114.0, 113.9, 104.6, 53.0, 31.5, 26.5. HPLC purity >99%.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 5-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxypentanamide (<b>22</b>)</h3><div class="NLM_p last">To a solution of <b>16</b> (60 mg, 0.156 mmol) in 1,4-dioxane (10 mL) was added HCl (117 μL, 0.468 mmol, 4 M in dioxane, 10.0 equiv), and the reaction mixture was stirred at room temperature overnight. The solids were collected by filtration to afford compound <b>22</b> (30 mg, 0.100 mmol, 64%) as a pale-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 301.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.41 (s, 1H), 10.37 (s, 1H), 8.74 (d, <i>J</i> = 4.1 Hz, 2H), 8.34 (s, 1H), 7.68 (s, 1H), 7.07 (d, <i>J</i> = 2.0 Hz, 1H), 4.24 (t, <i>J</i> = 6.8 Hz, 2H), 2.00 (t, <i>J</i> = 7.2 Hz, 2H), 1.90–1.75 (m, 2H), 1.55–1.43 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.8, 151.9, 149.2, 148.5, 138.9, 131.6, 127.8, 118.5, 112.5, 100.7, 51.3, 31.7, 29.3, 22.2. HPLC purity >95%.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 6-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>23</b>)</h3><div class="NLM_p last">To a solution of intermediates <b>17</b> (16 mg, 0.040 mmol) in 1,4-dioxane (5 mL) was added HCl (30 μL, 0.120 mmol, 4 M in dioxane, 3.0 equiv), and the reaction mixture was stirred at room temperature overnight. The solids were collected by filtration to afford compound <b>23</b> (7 mg, 0.022 mmol, 55%) as a pale-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 315.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.47 (s, 1H), 10.39 (s, 1H), 9.21 (s, 1H), 8.94 (s, 1H), 8.77 (s, 1H), 8.00 (dd, <i>J</i> = 3.6, 2.4 Hz, 1H), 7.42 (dd, <i>J</i> = 3.6, 1.6 Hz, 1H), 4.28 (t, <i>J</i> = 6.9 Hz, 2H), 1.95 (t, <i>J</i> = 7.4 Hz, 2H), 1.87 (dd, <i>J</i> = 14.9, 7.8 Hz, 2H), 1.60–1.48 (m, 2H), 1.30–1.20 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.1, 151.7, 144.4, 144.1, 139.9, 133.5, 131.1, 112.9, 111.8, 103.2, 51.9, 32.09, 29.2, 25.5, 24.6. HPLC purity >99%.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 7-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>24</b>)</h3><div class="NLM_p last">To a solution of <b>18</b> (26 mg, 0.063 mmol) in 1,4-dioxane (10 mL) was added HCl (47 μL, 0.189 mmol, 4 M in dioxane, 3.0 equiv), and the reaction mixture was stirred at room temperature overnight. The solids were collected by filtration to afford compound <b>24</b> (15 mg, 0.046 mmol, 72%) as a pale-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 329.2 [M + H]<sup>+</sup>. HRMS (ESI-MS) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>21</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup>, 329.1726; found, 329.1722. Mp 180.5–182.0 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (s, 1H), 10.32 (s, 1H), 8.83 (s, 2H), 8.42 (s, 1H), 7.78 (d, <i>J</i> = 2.3 Hz, 1H), 7.18 (d, <i>J</i> = 2.2 Hz, 1H), 4.24 (t, <i>J</i> = 7.0 Hz, 3H), 1.93 (t, <i>J</i> = 7.0 Hz, 2H), 1.88–1.78 (m, 2H), 1.54–1.39 (m, 2H), 1.34–1.17 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.3, 151.8, 147.6, 147.0, 139.1, 132.1, 128.9, 116.5, 112.3, 101.5, 51.7, 32.1, 29.4, 28.0, 25.6, 24.9. HPLC purity >95%.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 8-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyoctanamide (<b>25</b>)</h3><div class="NLM_p last">To a solution of <b>19</b> (82 mg, 0.192 mmol) in 1,4-dioxane (10 mL) was added HCl (144 μL, 0.576 mmol, 4 M in dioxane. 3.0 equiv), and the reaction mixture was stirred at room temperature overnight. The solids were collected by filtration to afford <b>25</b> (49 mg, 0.144 mmol, 75%) as a pale-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 343.4 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.19 (s, 1H), 10.33 (s, 1H), 9.07 (s, 1H), 8.91 (s, 1H), 8.63 (s, 1H), 7.94 (s, 1H), 7.34 (s, 1H), 4.27 (t, <i>J</i> = 7.0 Hz, 2H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.95–1.81 (m, 2H), 1.50–1.42 (m, 2H), 1.28–1.21 (m, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.0, 151.6, 145.0, 139.8, 133.2, 130.6, 111.8, 102.7, 51.9, 32.2, 29.4, 28.4, 28.1, 25.7, 25.0. HPLC purity >99%.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 11-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyundecanamide (<b>26</b>)</h3><div class="NLM_p last">To a solution of <b>20</b> (21 mg, 0.045 mmol) in 1,4-dioxane (10 mL) was added HCl (34 μL, 0.135 mmol, 4 M in dioxane, 3.0 equiv), and the reaction mixture was stirred at room temperature overnight. The solids were collected by filtration to afford compound <b>26</b> (16 mg, 0.042 mmol, 93%) as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 385.2 [M + H]<sup>+</sup>. Mp 151.0–153.0 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.25 (s, 1H), 10.31 (b, 1H), 9.11 (s, 1H), 8.91 (s, 1H), 8.68 (s, 1H), 7.95 (s, 1H), 7.35 (s, 1H), 4.27 (t, <i>J</i> = 6.8 Hz, 2H), 1.95–1.80 (m, 4H), 1.50–1.40 (m, 2H), 1.40–1.05 (m, 12H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.1, 151.6, 144.9, 144.4, 139.8, 133.3, 130.7, 113.4, 111.7, 102.8, 51.9, 32.2, 29.4, 28.8, 28.6, 28.5, 28.4, 25.8, 25.1, 24.4. HPLC purity >99%.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>tert</i>-Butyl (4-(3-(4-(7-Tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propyl)phenyl)carbamate (<b>27</b>)</h3><div class="NLM_p last">A mixture of <b>5</b> (34 mg, 0.1 mmol), potassium carbonate (28 mg, 0.2 mmol, 2.0 equiv), and <i>tert</i>-butyl (4-(3-iodopropyl)phenyl)carbamate (44 mg, 0.12 mmol, 1.2 equiv) in DMF (10 mL) was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 50:1) to yield <b>27</b> (43 mg, 0.075 mmol, 75%) as a white solid. LRMS (ESI) <i>m</i>/<i>z</i> 573.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.90 (s, 1H), 8.16 (s, 1H), 8.09 (m, 3H), 7.75 (d, <i>J</i> = 4.1 Hz, 1H), 7.29 (m, 4H), 7.08 (d, <i>J</i> = 8.5 Hz, 2H), 6.83 (d, <i>J</i> = 4.1 Hz, 1H), 6.49 (s, 1H), 4.17 (t, <i>J</i> = 7.0 Hz, 2H), 2.58 (t, <i>J</i> = 7.5 Hz, 2H), 2.38 (s, 3H), 2.35–2.15 (m, 2H), 1.51 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 171.8, 153.9, 153.5, 153.0, 152.5, 146.5, 139.9, 137.3, 135.8, 135.6, 131.0, 130.5, 129.6, 129.0, 127.0, 119.6, 116.5, 104.5, 81.1, 52.5, 32.5, 32.2, 29.0, 22.3.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 4-(1-(2-(1,3-Dioxolan-2-yl)ethyl)-1<i>H</i>-pyrazol-4-yl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>28</b>)</h3><div class="NLM_p last">A mixture of <b>5</b> (200 mg, 0.589 mmol), potassium carbonate (163 mg, 1.178 mmol, 2.0 equiv), and 2-(2-bromoethyl)-1,3-dioxolane (213 mg, 1.178 mmol, 2.0 equiv) in DMF (10 mL) was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 40:1) to yield <b>28</b> (230 mg, 0.524 mmol, 89%) as pale-yellow oil. LRMS (ESI) <i>m</i>/<i>z</i> 440.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 3-(4-(7-Tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanal (<b>29</b>)</h3><div class="NLM_p last">To a mixture of <b>28</b> (190 mg, 0.432 mmol) in acetone (20 mL) was added HCl (2.16 mL, 1 M in H<sub>2</sub>O, 2.16 mmol, 5.0 equiv), and the reaction mixture was stirred at 55 °C overnight. The mixture was extracted with DCM (3 × 20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to yield <b>29</b> (128 mg, 0.324 mmol, 75%) as pale-yellow oil which was used directly in the next step. LRMS (ESI) <i>m</i>/<i>z</i> 396.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Methyl 8-Oxo-8-((4-(3-(4-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propyl)phenyl)amino)octanoate (<b>30</b>)</h3><div class="NLM_p last">To a mixture of <b>27</b> (32 mg, 0.056 mmol) in ethyl acetate (20 mL) was added H<sub>2</sub>SO<sub>4</sub> (10 μL, 0.168 mmol, 3.0 equiv), and the reaction mixture was stirred at room temperature overnight. The mixture was then neutralized with 5 N aqueous NaHCO<sub>3</sub> and extracted with DCM (3 × 20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to yield 4-(3-(4-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propyl)aniline (26 mg, 0.055 mmol, 98%) as a pale-yellow solid which was used directly in the next step. LRMS (ESI) <i>m</i>/<i>z</i> 473.2 [M + H]<sup>+</sup>. A mixture of 4-(3-(4-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propyl)aniline (121 mg, 0.256 mmol), 8-methoxy-8-oxooctanoic acid (58 mg, 0.307 mmol, 1.2 equiv), triethylamine (52 mg, 0.512 mmol, 2.0 equiv), and HATU (146 mg, 0.384 mmol, 1.5 equiv) in DMF (15 mL) was stirred at 50 °C overnight. The crude was purified by column chromatography (DCM/MeOH, 40:1) to yield <b>30</b> (135 mg, 0.21 mmol, 82%) as a brown oil. LRMS (ESI) <i>m</i>/<i>z</i> 643.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.87 (s, 1H), 8.14 (s, 1H), 8.13–8.05 (m, 3H), 7.72 (d, <i>J</i> = 4.1 Hz, 1H), 7.70 (s, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.28 (d, <i>J</i> = 8 Hz, 2H), 7.06 (d, <i>J</i> = 8.4 Hz, 2H), 6.81 (d, <i>J</i> = 4.1 Hz, 1H), 4.15 (t, <i>J</i> = 7.0 Hz, 2H), 3.63 (s, 3H), 2.56 (t, <i>J</i> = 7.4 Hz, 2H), 2.35 (s, 3H), 2.34–2.24 (m, 4H), 2.25–2.15 (m, 2H), 1.72–1.64 (m, 2H), 1.64–1.55 (m, 2H), 1.40–1.28 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.8, 172.1, 153.8, 152.9, 152.4, 146.5, 139.9, 137.0, 136.8, 135.4, 130.9, 130.5, 129.4, 128.8, 126.9, 121.2, 120.7, 116.4, 104.4, 52.4, 52.1, 38.0, 34.5, 32.5, 32.1, 29.4, 29.3, 26.0, 25.3, 22.3.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Methyl 8-((4-(4-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)butanamido)phenyl)amino)-8-oxooctanoate (<b>31</b>)</h3><div class="NLM_p last">To a solution of <b>12</b> (83 mg, 0.289 mmol) in THF (20 mL) and H<sub>2</sub>O (5 mL) was added LiOH (69 mg, 2.89 mmol, 10.0 equiv). The mixture was stirred at room temperature overnight. When the reaction was deemed complete as determined by TLC, the mixture was neutralized with 1 M aqueous HCl and concentrated under reduced pressure. To the residue were added DMF (15 mL), <i>N</i>,<i>N</i>-diisopropylethylamine (374 mg, 2.89 mmol, 10.0 equiv), methyl 8-((4-aminophenyl)amino)-8-oxooctanoate (89 mg, 0.318 mmol, 1.1 equiv), and HATU (165 mg, 0.434 mmol, 1.5 equiv), and the mixture was stirred at 60 °C overnight. The crude was purified by column chromatography (DCM/MeOH, 15:1) to yield <b>31</b> (87 mg, 0.164 mmol, 57%) as a pink solid. LRMS (ESI) <i>m</i>/<i>z</i> 532.6 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.06 (s, 1H), 9.83 (s, 1H), 9.75 (s, 1H), 8.67 (d, <i>J</i> = 6.3 Hz, 2H), 8.29 (s, 1H), 7.56 (dd, <i>J</i> = 3.5, 2.4 Hz, 1H), 7.47 (s, 4H), 6.97 (dd, <i>J</i> = 3.6, 1.7 Hz, 1H), 4.28 (t, <i>J</i> = 6.7 Hz, 2H), 3.57 (s, 3H), 2.31–2.23 (m, 6H), 2.20–2.12 (m, 2H), 1.58–1.52 (m, 4H), 1.28 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.3, 170.8, 169.9, 152.0, 150.9, 150.1, 138.7, 134.6, 134.4, 131.0, 126.5, 120.7, 119.4, 119.3, 112.7, 99.8, 51.1, 51.1, 36.2, 33.2, 33.0, 28.3, 28.2, 25.6, 24.9, 24.3.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Methyl 8-Oxo-8-((4-((3-(4-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propyl)amino)phenyl)amino)octanoate (<b>32</b>)</h3><div class="NLM_p last">A mixture of <b>29</b> (100 mg, 0.253 mmol, 1.5 equiv), methyl 8-((4-aminophenyl)amino)-8-oxooctanoate (47 mg, 0.169 mmol) in MeOH (15 mL) was stirred at room temperature for 3 h. Then sodium cyanoborohydride (53 mg, 0.843 mmol, 5.0 equiv) was added, and the reaction mixture was stirred at room temperature overnight. The mixture was suspended in DCM (20 mL) and washed with H<sub>2</sub>O (20 mL). Drying of the organic phase over Na<sub>2</sub>SO<sub>4</sub> followed by removal of the solvent in vacuo afforded the crude product. The crude was purified by column chromatography (DCM/MeOH, 15:1) to yield <b>32</b> (85 mg, 0.129 mmol, 76%) as a colorless oil. LRMS (ESI) <i>m</i>/<i>z</i> 658.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.89 (s, 1H), 8.16 (s, 1H), 8.14 (s, 1H), 8.12–8.06 (m, 2H), 7.74 (d, <i>J</i> = 4.2 Hz, 1H), 7.31 (d, <i>J</i> = 8.2 Hz, 3H), 7.25 (d, <i>J</i> = 8.8 Hz, 1H), 7.05 (s, 1H), 6.78 (d, <i>J</i> = 4.1 Hz, 1H), 6.54 (d, <i>J</i> = 8.8 Hz, 1H), 4.32 (t, <i>J</i> = 6.5 Hz, 2H), 3.66 (s, 3H), 3.14 (t, <i>J</i> = 6.3 Hz, 2H), 2.39 (s, 3H), 2.32–2.28 (m, 4H), 2.25–2.15 (m, 2H), 1.77–1.67 (m, 2H), 1.68–1.58 (m, 2H), 1.45–1.30 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.9, 171.7, 153.9, 152.8, 152.5, 146.5, 140.1, 135.5, 131.2, 130.5, 129.4, 129.0, 127.1, 122.9, 121.6, 116.5, 114.0, 104.4, 52.2, 50.8, 41.7, 38.1, 34.6, 30.3, 29.5, 29.4, 26.1, 25.4, 22.4.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>N</i>1-(4-(3-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propyl)phenyl)-<i>N</i>8-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)octanediamide (<b>33</b>)</h3><div class="NLM_p last">To a solution of <b>30</b> (120 mg, 0.187 mmol) in THF (20 mL) and H<sub>2</sub>O (10 mL) was added LiOH (45 mg, 1.87 mmol, 10.0 equiv). The mixture was stirred at 50 °C for 36 h, neutralized with 1 M aqueous HCl, and concentrated under reduced pressure. To the residue were added DMSO (20 mL), triethylamine (189 mg, 1.87 mmol, 10.0 equiv), HOBT (38 mg, 0.28 mmol, 1.5 equiv), <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (44 mg, 0.373 mmol, 2.0 equiv), and EDC (72 mg, 0.373 mmol, 2.0 equiv), and the mixture was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 15:1) to yield <b>33</b> (28 mg, 0.049 mmol, 26%) as a pale yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 574.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.64 (s, 1H), 8.82 (s, 1H), 8.74 (s, 1H), 8.25 (s, 1H), 8.14 (s, 1H), 7.43 (d, <i>J</i> = 8.3 Hz, 2H), 7.36 (d, <i>J</i> = 3.6 Hz, 2H), 7.12 (d, <i>J</i> = 8.3 Hz, 2H), 6.78 (s, 1H), 5.05–4.91 (m, 1H), 4.21 (t, <i>J</i> = 6.8 Hz, 2H), 4.03–3.89 (m, 1H), 3.67–3.59 (m, 1H), 2.69–2.59 (m, 2H), 2.33–2.26 (m, 4H), 2.17–2.07 (m, 2H), 1.84–1.74 (m, 2H), 1.65–1.56 (m, 8H), 1.42–1.30 (m, 4H).</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> <i>N</i>1-(4-(4-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)butanamido)phenyl)-<i>N</i>8-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)octanediamide (<b>34</b>)</h3><div class="NLM_p last">To a solution of <b>31</b> (72 mg, 0.135 mmol) in THF (20 mL) and H<sub>2</sub>O (5 mL) was added LiOH (32 mg, 1.35 mmol, 10.0 equiv). The mixture was stirred at room temperature overnight. When the reaction was deemed complete as determined by TLC, the mixture was neutralized with 1 M aqueous HCl and concentrated under reduced pressure. To the residue were added DMF (15 mL), triethylamine (137 mg, 1.35 mmol, 10.0 equiv), <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (32 mg, 0.271 mmol, 2.0 equiv), and HATU (78 mg, 0.203 mmol, 1.5 equiv), and the mixture was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 30:1) to yield <b>34</b> (19 mg, 0.031 mmol, 23%) as a white solid which was used directly in the next step.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> <i>N</i>1-(4-((3-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propyl)amino)phenyl)-<i>N</i>8-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)octanediamide (<b>35</b>)</h3><div class="NLM_p last">To a solution of <b>32</b> (64 mg, 0.097 mmol) in THF (20 mL) and H<sub>2</sub>O (5 mL) was added LiOH (23 mg, 0.97 mmol, 10.0 equiv). The mixture was stirred at 50 °C for 48 h. When the reaction was deemed complete as determined by TLC, the mixture was neutralized with 1 M aqueous HCl and concentrated under reduced pressure. To the residue were added DMF (15 mL), triethylamine (98 mg, 0.973 mmol, 10.0 equiv), <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (23 mg, 0.194 mmol, 2.0 equiv), and HATU (56 mg, 0.146 mmol, 1.5 equiv), and the mixture was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 30:1) to yield <b>35</b> (28 mg, 0.047 mmol, 48%) as a white solid. LRMS (ESI) <i>m</i>/<i>z</i> 589.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.66 (s, 1H), 8.21 (d, <i>J</i> = 5.8 Hz, 2H), 7.31 (d, <i>J</i> = 3.6 Hz, 1H), 7.22 (dd, <i>J</i> = 8.9, 2.3 Hz, 2H), 6.68 (d, <i>J</i> = 3.6 Hz, 1H), 6.51 (d, <i>J</i> = 8.6 Hz, 2H), 4.88 (s, 1H), 4.30 (t, <i>J</i> = 6.6 Hz, 2H), 4.00–3.85 (m, 1H), 3.60–3.50 (m, 1H), 3.08 (t, <i>J</i> = 6.5 Hz, 2H), 2.23 (t, <i>J</i> = 7.4 Hz, 2H), 2.30–2.10 (m, 2H), 2.15–1.95 (m, 2H), 1.73 (t, <i>J</i> = 9.7 Hz, 3H), 1.61–1.51 (m, 7H), 1.35–1.25 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 172.7, 171.8, 152.3, 151.5, 151.3, 145.6, 140.1, 131.3, 129.1, 126.7, 122.8, 121.8, 114.7, 113.7, 102.9, 101.0, 63.0, 41.4, 37.4, 33.4, 30.2, 28.8, 28.7, 28.5, 25.9, 25.6, 19.1.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>N</i>1-(4-(3-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propyl)phenyl)-<i>N</i>8-hydroxyoctanediamide (<b>36</b>)</h3><div class="NLM_p last">To a solution of <b>33</b> (28 mg, 0.049 mmol) in 1,4-dioxane (10 mL) was added HCl (61 μL, 0.244 mmol, 4 M in dioxane, 3.0 equiv), and the reaction mixture was stirred at room temperature overnight. The solids were collected by filtration to afford <b>36</b> (9 mg, 0.018 mmol, 38%) as a pale yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 490.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.23 (s, 1H), 10.32 (s, 1H), 9.78 (s, 1H), 8.71 (d, <i>J</i> = 3.2 Hz, 2H), 8.33 (s, 1H), 7.63–7.59 (m, 1H), 7.50 (d, <i>J</i> = 8.4 Hz, 2H), 7.13 (d, <i>J</i> = 8.5 Hz, 2H), 7.02 (d, <i>J</i> = 2.0 Hz, 1H), 4.23 (t, <i>J</i> = 6.9 Hz, 2H), 2.58–2.48 (m, 2H), 2.26 (t, <i>J</i> = 7.4 Hz, 2H), 2.23–2.13 (m, 2H), 2.00–1.90 (m, 2H), 1.60–1.50 (m, 2H), 1.50–1.45 (m, 2H), 1.33–1.23 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.0, 169.1, 152.0, 150.1, 149.3, 138.8, 137.3, 135.5, 131.3, 128.4, 127.1, 119.2, 112.6, 100.3, 51.1, 36.3, 36.1, 32.2, 31.4, 31.4, 28.4, 25.0, 25.0. HPLC purity >95%.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>N</i>1-(4-(4-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)butanamido)phenyl)-<i>N</i>8-hydroxyoctanediamide (<b>37</b>)</h3><div class="NLM_p last">To a solution of <b>34</b> (19 mg, 0.031 mmol) in 1,4-dioxane (5 mL), THF (5 mL) was added HCl (23 μL, 0.93 mmol, 4 M in dioxane, 3.0 equiv), and the reaction mixture was stirred at room temperature overnight. The solids were collected by filtration to afford <b>37</b> (10 mg, 0.019 mmol, 61%) as a pink solid. LRMS (ESI) <i>m</i>/<i>z</i> 533.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.95 (s, 1H), 10.18 (s, 1H), 9.88 (s, 1H), 9.78 (s, 1H), 8.97 (s, 1H), 8.88 (s, 1H), 8.55 (s, 1H), 7.87 (s, 1H), 7.70 (s, 1H), 7.47 (s, 4H), 7.27 (s, 1H), 4.35 (t, <i>J</i> = 6.8 Hz, 2H), 2.32–2.23 (m, 6H), 2.25–2.15 (m, 2H), 1.58–1.52 (m, 4H), 1.33–1.23 (m, 4H). HPLC purity >95%.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>N</i>1-(4-((3-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propyl)amino)phenyl)-<i>N</i>8-hydroxyoctanediamide (<b>38</b>)</h3><div class="NLM_p last">To a solution of <b>35</b> (40 mg, 0.068 mmol) in 1,4-dioxane (5 mL) and THF (5 mL) was added HCl (51 μL, 0.204 mmol, 4 M in dioxane, 3.0 equiv), and the reaction mixture was stirred at room temperature overnight. The solids were collected by filtration to afford <b>38</b> (8 mg, 0.016 mmol, 23%) as a pink solid. LRMS (ESI) <i>m</i>/<i>z</i> 505.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.19 (s, 1H), 10.32 (s, 1H), 9.47 (s, 1H), 8.70 (s, 2H), 8.32 (s, 1H), 7.60 (s, 1H), 7.29 (d, <i>J</i> = 8.7 Hz, 2H), 6.99 (d, <i>J</i> = 2.5 Hz, 1H), 6.53 (d, <i>J</i> = 8.5 Hz, 2H), 4.33 (t, <i>J</i> = 6.7 Hz, 2H), 3.02 (t, <i>J</i> = 6.7 Hz, 2H), 2.20 (t, <i>J</i> = 7.3 Hz, 2H), 2.16–2.08 (m, 2H), 1.97–1.89 (m, 2H), 1.54–1.48 (m, 4H), 1.31–1.21 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.3, 169.1, 152.0, 150.2, 149.5, 138.8, 131.3, 129.3, 127.0, 120.9, 119.9, 112.7, 112.5, 100.1, 49.5, 40.7, 36.2, 32.2, 29.2, 28.4, 28.4, 25.2, 25.0. HPLC purity >97%.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> (<i>E</i>)-Methyl 3-(4-((3-(4-(7-Tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1 -yl)propyl)amino)phenyl)acrylate (<b>39</b>)</h3><div class="NLM_p last">A mixture of <b>29</b> (100 mg, 0.253 mmol, 1.5 equiv) and (<i>E</i>)-methyl 3-(4-aminophenyl)acrylate (30 mg, 0.169 mmol) in MeOH (15 mL) was stirred at room temperature for 3 h. Then sodium cyanoborohydride (53 mg, 0.846 mmol, 5.0 equiv) was added, and the reaction mixture was stirred at room temperature overnight. The mixture was suspended in DCM (20 mL) and washed with H<sub>2</sub>O (20 mL). Drying of the organic phase over Na<sub>2</sub>SO<sub>4</sub> followed by removal of the solvent in vacuo afforded the crude product. The crude was purified by column chromatography (DCM/MeOH, 50:1) to yield <b>39</b> (67 mg, 0.120 mmol, 71%) as a pale yellow oil. LRMS (ESI) <i>m</i>/<i>z</i> 557.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.90 (s, 1H), 8.16 (d, <i>J</i> = 8.3 Hz, 2H), 8.13–8.07 (m, 2H), 7.74 (d, <i>J</i> = 4.1 Hz, 1H), 7.58 (d, <i>J</i> = 15.9 Hz, 1H), 7.35–7.29 (m, 4H), 6.78 (d, <i>J</i> = 4.1 Hz, 1H), 6.54 (d, <i>J</i> = 8.7 Hz, 2H), 6.20 (d, <i>J</i> = 15.9 Hz, 1H), 4.33 (t, <i>J</i> = 6.5 Hz, 2H), 3.77 (s, 3H), 3.22 (t, <i>J</i> = 6.4 Hz, 2H), 2.39 (s, 3H), 2.29–2.17 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 168.9, 153.9, 152.7, 152.5, 150.4, 146.6, 145.8, 140.1, 135.5, 131.1, 130.7, 130.6, 129.0, 127.1, 124.4, 121.7, 116.5, 113.4, 113.2, 104.3, 52.1, 50.7, 41.0, 30.2, 22.4.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (<i>E</i>)-3-(4-((3-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propyl)amino)phenyl)-<i>N</i>-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)acrylamide (<b>40</b>)</h3><div class="NLM_p last">To a solution of <b>39</b> (211 mg, 0.379 mmol) in THF (30 mL) and H<sub>2</sub>O (10 mL) was added LiOH (91 mg, 3.79 mmol, 10.0 equiv). The mixture was stirred at 50 °C for 24 h, neutralized with 1 M aqueous HCl, and concentrated under reduced pressure. To the residue was added DMF (15 mL), triethylamine (384 mg, 3.79 mmol, 10.0 equiv), <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (89 mg, 0.758 mmol, 2.0 equiv), and HATU (217 mg, 0.569 mmol, 1.5 equiv), and the mixture was stirred at room temperature overnight. The crude was purified by column chromatography (DCM/MeOH, 30:1) to yield <b>40</b> (105 mg, 0.215 mmol, 57%) as a pale yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 488.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.11 (s, 1H), 8.73 (s, 1H), 8.24 (s, 1H), 8.18 (s, 1H), 7.54 (d, <i>J</i> = 15.7 Hz, 1H), 7.37–7.27 (m, 1H), 7.25–7.15 (m, 2H), 6.65 (d, <i>J</i> = 3.5 Hz, 1H), 6.51–6.41 (m, 2H), 6.16 (br, 1H), 4.99 (s, 1H), 4.29 (t, <i>J</i> = 6.5 Hz, 2H), 4.04–3.92 (m, 1H), 3.63–3.57 (m, 1H), 3.18–3.08 (m, 2H), 2.80–2.45 (br m, 2H), 2.25–2.09 (m, 2H), 1.86–1.72 (m, 2H), 1.60–1.45 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 152.7, 152.5, 151.5, 150.3, 140.1, 131.2, 130.4, 126.7, 126.5, 124.2, 122.0, 114.7, 113.0, 112.7, 103.5, 101.0, 63.3, 50.5, 40.6, 30.0, 28.7, 25.6, 19.3.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (<i>E</i>)-3-(4-((3-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propyl)amino)phenyl)-<i>N</i>-hydroxyacrylamide (<b>41</b>)</h3><div class="NLM_p last">To a solution of <b>40</b> (105 mg, 0.215 mmol) in 1,4-dioxane (10 mL), THF (10 mL) was added HCl (161 μL, 0.645 mmol, 4 M in dioxane, 3.0 equiv), and the reaction mixture was stirred at room temperature overnight. The solids were collected by filtration to afford <b>41</b> (78 mg, 0.193 mmol, 90%) as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 404.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.47 (s, 1H), 9.28 (s, 1H), 8.95 (s, 1H), 8.80 (s, 1H), 8.01 (dd, <i>J</i> = 3.6, 2.4 Hz, 1H), 7.42 (dd, <i>J</i> = 3.5, 1.5 Hz, 1H), 7.38–7.30 (m, 3H), 6.82 (s, 2H), 6.24 (d, <i>J</i> = 15.4 Hz, 1H), 4.44 (t, <i>J</i> = 6.7 Hz, 2H), 3.18–3.12 (m, 2H), 2.24–2.16 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.5, 151.6, 143.8, 143.4, 140.3, 138.5, 134.1, 131.4, 128.9, 114.5, 112.3, 111.6, 103.3, 49.8, 48.6, 28.3. HPLC purity >95%.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Methyl 7-(4-(7-Tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)octanoate (<b>43</b>)</h3><div class="NLM_p last">A mixture of <b>5</b> (265 mg, 0.78 mmol), potassium carbonate (216 mg, 1.56 mmol), and intermediate ester <b>42</b> (443 mg, 1.56 mmol) in DMF (20 mL) was stirred at room temperature overnight. The reaction mixture was suspended in ethyl acetate (30 mL) and washed with H<sub>2</sub>O (3 × 30 mL). Drying of the organic phase over Na<sub>2</sub>SO<sub>4</sub> followed by removal of the solvent in vacuo afforded the crude product. The crude was purified by column chromatography (ethyl acetate/hexane, 1:2) to yield <b>43</b> (114 mg, 0.363 mmol, 46%) as a colorless oil. LRMS (ESI) <i>m</i>/<i>z</i> 496.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.90 (s, 1H), 8.21 (s, 1H), 8.14 (s, 1H), 8.09 (d, <i>J</i> = 8.4 Hz, 2H), 7.76 (d, <i>J</i> = 4.1 Hz, 1H), 7.30 (d, <i>J</i> = 8.1 Hz, 2H), 6.86 (d, <i>J</i> = 4.1 Hz, 1H), 4.39–4.35 (m, 1H), 3.63 (s, 3H), 2.38 (s, 3H), 2.25 (t, <i>J</i> = 7.5 Hz, 2H), 2.01–1.86 (m, 1H), 1.86–1.69 (m, 1H), 1.60–1.50 (m, 5H), 1.35–1.20 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ174.0, 153.0, 152.2, 151.8, 145.8, 138.8, 134.9, 129.8, 128.6, 128.3, 126.4, 115.7, 103.9, 59.1, 51.4, 36.7, 33.8, 28.6, 25.7, 24.6, 21.7, 21.2.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 7-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)octanamide (<b>44</b>)</h3><div class="NLM_p last">To a solution of <b>43</b> (180 mg, 0.363 mmol) in THF (20 mL) and H<sub>2</sub>O (5 mL) was added LiOH (87 mg, 3.63 mmol, 10 equiv). The mixture was stirred at room temperature overnight. When the reaction was deemed complete as determined by TLC, the mixture was neutralized with 1 M aqueous HCl and concentrated under reduced pressure. To the residue were added DMSO (15 mL), triethylamine (367 mg, 3.63 mmol), HOBT (74 mg, 0.545 mmol), <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (85 mg, 0.726 mmol), and EDC (139 mg, 0.726 mmol), and the mixture was stirred at room temperature overnight. The reaction mixture was suspended in ethyl acetate (30 mL) and washed with H<sub>2</sub>O (3 × 30 mL). Drying of the organic phase over Na<sub>2</sub>SO<sub>4</sub> followed by removal of the solvent in vacuo afforded the crude product. The crude was purified by column chromatography (DCM/MeOH, 30:1) to yield <b>44</b> (101 mg, 0.237 mmol, 65%) as a pale yellow oil. LRMS (ESI) <i>m</i>/<i>z</i> 427.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ11.06 (s, 1H), 8.84 (s, 1H), 8.37 (d, <i>J</i> = 18.0 Hz, 1H), 8.26 (s, 1H), 7.41 (d, <i>J</i> = 3.1 Hz, 1H), 6.82 (d, <i>J</i> = 1.9 Hz, 1H), 5.02–4.96 (m, 1H), 4.43–4.38 (m, 1H), 4.01–3.83 (m, 1H), 3.65–3.50 (m, 1H), 2.05–1.95 (m, 2H), 1.87–1.72 (m, 4H), 1.70–1.48 (m, 8H), 1.40–1.03 (m, 8H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ170.6, 152.3, 151.0, 150.7, 139.0, 128.6, 125.8, 120.5, 113.9, 102.3, 100.9, 62.5, 58.7, 36.8, 36.7, 32.6, 29.7, 28.0, 25.0, 21.3, 18.6.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 7-(4-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyoctanamide (<b>45</b>)</h3><div class="NLM_p last">To a solution of <b>44</b> (101 mg, 0.237 mmol) in 1,4-dioxane (10 mL) was added HCl (132 μL, 0.711 mmol, 4 M in dioxane), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated to afford compound <b>45</b> (75 mg, 0.218 mmol, 92%) as a pale-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 343.2 [M + H]<sup>+</sup>. HRMS (ESI-MS) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup>, 343.1882; found, 343.1879. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ13.27 (s, 1H), 10.28 (s, 1H), 9.13 (s, 1H), 8.91 (s, 1H), 8.69 (s, 1H), 7.96–7.94 (m, 1H), 7.40–7.37 (m, 1H), 4.59–4.49 (m, 1H), 1.90 (t, <i>J</i> = 7.3 Hz, 2H), 1.83–1.70 (m, 2H), 1.50 (d, <i>J</i> = 6.7 Hz, 3H), 1.48–1.38 (m, 2H), 1.34–1.14 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ169.0, 151.6, 144.7, 144.4, 139.7, 131.9, 130.7, 111.7, 102.9, 58.4, 35.8, 32.1, 28.1, 25.1, 24.9, 20.9. HPLC purity >99%.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Molecular Modeling Experimental</h3><div class="NLM_p">The human JAK1 X-ray structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IVB">4IVB</a>)<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> JAK2 X-ray structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> human HDAC1 structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>),<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> human HDAC2 structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ">4LXZ</a>),<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and zebrafish HDAC6 structures (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a> (second catalytic domain) and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0G">5G0G</a> (first catalytic domain))<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> were downloaded from the Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">http://www.rcsb.org</a>) and prepared using the Protein Preparation Wizard in Maestro version 10.6 using standard settings.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> This included the addition of hydrogen atoms, bond assignments, removal of water molecules further than 5 Å from the ligand, protonation state assignment, optimization of the hydrogen bond network, and restrained minimization using the OPLS3 force field.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The HDAC proteins were superimposed using structural alignment, and the HDAC2 structure ligand <b>2</b> was duplicated into HDAC1. The HDAC6 protein sequence (identifier <a href="https://Q9UBN7" class="ext-link">Q9UBN7</a>) was downloaded from Uniprot (<a href="http://www.uniprot.org" class="extLink">http://www.uniprot.org</a>). A human HDAC6 homology model of each of the catalytic domains was built using the zebrafish structures as template. The homology between human and zebrafish HDAC6 catalytic domains is 75% with 60% sequence identity and 0% gaps, and alignments are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_001.pdf" class="ext-link">Supporting Information</a>. The energy based algorithm of Prime version 4.4<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> with default settings was used for homology building. Inhibitors and metal ions were included in the models.</div><div class="NLM_p last">The cocrystallized or soaked ligands were used as templates for manual docking. For HDAC modeling, the hydroxamate and linker part of <b>2</b> were retained and the remaining part of ligands <b>24</b> and <b>45</b> were built upon this template. In the JAK1 and JAK2 structures the pyrrolopyrimidine hinge binder was used as template. The JAK1, JAK2, HDAC1, and HDAC6 inhibitor–protein complexes were finally minimized using Macromodel 11.2.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> In the HDAC complexes, distance constraints between both the hydroxamate oxygen atoms and zinc (2.3 Å) as well as the three residues that hydrogen-bond with the hydroxamate (2.8 Å) were included. All residues more than 9 Å from the ligand were constrained before the complex was subjected to 500 steps of Polak–Ribiere conjugate gradient<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> minimization using the OPLS3 force field and GB/SA continuum solvation model.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Enzyme Assays</h3><div class="NLM_p">Enzyme inhibition assays for HDAC and kinase enzymes (kinase “Hotspot” profiling) were carried out by Reaction Biology Corporation (RBC) using an ATP concentration of 10 μM, and kinase panel profiling was carried out by DiscoveRx, as previously described.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Affinity-LC/MS (WAC) was carried out as follows: JAK2 (20 mM Tris-HCl, pH 8.0, 10% glycerol, and 0.4 M urea) protein was purchased from Prospec Bio, Israel. All reagents used were analytical grade. Compounds were dissolved in dimethyl sulfoxide (DMSO; Merck, NJ, USA) at a concentration of either 10 or 20 mM based on solubility. Samples for affinity-LC/MS (WAC) were prepared by further dilution of compounds to a working concentration between 10 and 50 μM in Milli-Q water. For chromatography, 20 mM ammonium acetate (AmAc; pH 6.8) (Merck, NJ, USA) was used as mobile phase. For protein immobilization, periodic acid and sodium cyanoborohydride (NaBH<sub>3</sub>CN) were purchased from Sigma-Aldrich (MO, USA).</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Preparation of Protein Affinity Columns</h4><div class="NLM_p">Spherical porous diol silica particles (average diameter of 5 μm, 300 Å pore size, and a surface area of 100 m<sup>2</sup>/g) from Kromasil, EKA Chemicals, Bohus, Sweden, were used as supporting matrix. JAK2 was immobilized on the silica by the Schiff base method. Before immobilization, the storage buffer of JAK2 (20 mM Tris-HCl, pH 8.0, 10% glycerol, and 0.4 M urea) was exchanged with 100 mM sodium phosphate, 300 mM sodium chloride, pH 7.5 (PBS), by centrifugation using Amicon Ultra-0.5 centrifugal filter (Merck Millipore, Darmstadt, Germany) with molecular weight cutoff of 3000 Da. The centrifugation was performed three times (14 000<i>g</i> for 30 min each) at 4 °C with PBS (500 μL). The concentration of JAK2 was measured after buffer exchange based on absorbance at 280 nm measured on a NanoDrop 2000 (Thermo Fisher Scientific, Wilmington, DE, USA). The diol silica was first oxidized with periodic acid, 100 mg/mL for 2 h at room temperature (22 °C) to produce aldehyde silica. After oxidation, the aldehyde silica slurry was allowed to react with JAK2 (0.28 mg/mL, 214 μL final slurry) and NaBH<sub>3</sub>CN (final concentration of 10 mg/mL) for 116 h on a rotator at 4 °C. The reaction was stopped by centrifugation (2000<i>g</i> for 2 min) and the supernatant removed. The resulting slurry was then washed with PBS (5 × 200 μL). The supernatant and waste were pooled together, and absorbance was measured at 280 nm on a NanoDrop 2000 to indirectly calculate the immobilization yield. Two reference columns with the same dimensions were produced by a similar procedure except 200 μL PBS (to produce aldehyde reference column) or 200 μL 1 M ethanolamine (to produce reference ethanolamine column) was used during immobilization instead of the JAK2 solution.</div><div class="NLM_p last">The resulting silica with immobilized JAK2 was packed into a stainless steel capillary column (35 mm × 0.5 mm) by an air-driven liquid pump (Haskel MS-110, Burbank, CA, USA) at 340 bar in 1 h using PBS as packing mobile phase. Columns were stored in 0.01% sodium azide in PBS (pH 7.4) at 4 °C when not in use.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Zonal Screening of Compounds on Single Quad LC/MS</h4><div class="NLM_p last">Compounds were tested on a LC/MS system fitted with a combination of HPLC (Agilent 1260 infinity) and a single quadrupole mass spectrometry (MS) detector (Agilent 6130B; Agilent Technologies, Germany). Ultraviolet (UV) detection was done at two different wavelengths of 214 nm for DMSO and 254 nm for other compounds (reference wavelength as 360 ± 4 nm). For MS detection, compound ionization was achieved by atmospheric pressure ionization electrospray (API-ES) in positive mode. MS parameters were set with dry gas temperature of 300 °C, nitrogen (N<sub>2</sub>) gas flow at 8 L/min and a nebulizer pressure of 25 psig. Capillary voltage of 3000 V and fragmentor of 110 V were used in positive mode. Compounds were evaluated in selected ion monitoring (SIM) mode with <i>m</i>/<i>z</i> set at [M + H]<sup>+</sup> ions for each analyte based on their identification during study on the reference column. Samples were analyzed at a flow rate of 20 μL/min on JAK2 and 15 μL/min on the reference column in 20 mM AmAc (pH 6.8) mobile phase with an injection volume of 0.4 μL. Chromatograms were acquired and analyzed with the Agilent OpenLab version A.02.01 (1.3.3) chromatography data system. Compounds were analyzed at a final concentration of 10 μM (with 0.05% DMSO) except for <b>41</b> which was tested at 50 μM (0.25% DMSO). Reference sample <b>S13</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_001.pdf" class="ext-link">Supporting Information</a>) was injected intermittently as a positive control to monitor the performance of the affinity column. Additionally, DMSO was monitored in each run as a void marker. Individual compounds were tested in triplicate (<i>n</i> = 3). Compounds were analyzed on the reference columns for 60–90 and 90 min (except for <b>41</b> which was run for 300 min) on the affinity column.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Data Acquisition</h4><div class="NLM_p last">Compound retention times (<i>t</i><sub>R</sub>) were obtained based on the peak apex of the extracted ion chromatograms (EIC). Calculation of apparent dissociation constant (<i>K</i><sub>D</sub>) of the analytes was based on their affinity toward the binding sites available on the protein surface as mentioned in <a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a>.<span class="NLM_disp-formula" id="eq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/jm-2017-006785_m001.gif" alt="" /></img><span class="labelSpan">(1)</span></span><a class="ref internalNav" href="#eq1" aria-label="Equation 1">Equation 1</a> is valid when <i>C</i><sub>a</sub> ≪ <i>K</i><sub>D</sub>, where <i>C</i><sub>a</sub> (μM) indicates the concentration of the analyte, <i>B</i><sub>tot</sub> is the amount of available sites on the affinity column (nmol), <i>F</i> is the flow rate (μL/min), and <i>t</i><sub>net</sub> is the net retention time (min). Estimation of <i>t</i><sub>net</sub> was done as per <a class="ref internalNav" href="#eq2" aria-label="eq 2">eq 2</a>, where <i>t</i><sub>protein</sub> (<i>t</i><sub>JAK2</sub>) = <i>t</i><sub>R</sub> of the analyte on the affinity column and <i>t</i><sub>Ref</sub> (<i>t</i><sub>aldehyde</sub> or <i>t</i><sub>ethanolamine</sub>) = <i>t</i><sub>R</sub> on the reference column.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a><span class="NLM_disp-formula" id="eq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/jm-2017-006785_m002.gif" alt="" /></img><span class="labelSpan">(2)</span></span><i>t</i><sub>JAK2</sub> or <i>t</i><sub>Ref</sub> was calculated by subtraction of the <i>t</i><sub>R</sub> of the void marker (DMSO) from the retention of the analyte on the affinity and reference columns, respectively. This is mathematically expressed as<span class="NLM_disp-formula" id="eq3a"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/jm-2017-006785_m003.gif" alt="" /></img><span class="labelSpan">(3)</span></span><span class="NLM_disp-formula" id="eq4"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/jm-2017-006785_m004.gif" alt="" /></img><span class="labelSpan">(4)</span></span>The coupling yield for the JAK2 affinity-LC/MS column was estimated at 10.3 mg/g (1.95 nmol) corresponding to a protein density of 0.33 mM. The percent loading of protein onto the column, expressed as <i>B</i><sub>tot</sub>, was estimated at 50% (0.97 nmol).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> On the basis of the immobilization achieved on the JAK2 column and the analysis time, the effective affinity range that can be quantified is approximately within the range of 0.6–125 μM.</div></div></div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Cellular Assays. Cell Proliferation Inhibition Assays</h3><div class="NLM_p last">Human breast cancer cell lines MCF-7 and MDA-MB231, prostate cancer cell line PC-3, and colon cell line HCT-116 were purchased from ATCC (Rockville, MD) and assays carried out as previously described.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Acute myeloid leukemia (AML) HL-60, erythroleukemia HEL92.1.7, acute T-cell leukemia jurkat, multiple myeloma cell lines KMS12BM, OPM2, XG-6, KG-1, AML cell lines KG1, and MOLM14 and NKT-cell lymphoma cell lines NKYS and KHYG were used as for assays previously described.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Immunoblotting</h3><div class="NLM_p last">Western blot analyses of KMS-12-BM and MOLM-14 cell lines were performed as previously described.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Determination of Toxicity in Transforming Growth Factor α Mouse Hepatocyte (TAMH) and AC10 Human Cardiomyocyte Cells</h3><div class="NLM_p last">TAMH cell assay was carried out as previously described.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> AC-10 cells were seeded at a cell density of 5000 cells/well (75 000 cells/mL) in a 96-well plate (NUNC) a day before drug treatment. Cells were then treated across a wide concentration range starting from a top concentration of 100 μM (final DMSO %: 0.5%, 0.5 μL of drug in 99.5 μL of media in every well). Stock concentrations used were 100 μM, 10 μM, and 1 μM), and final dilute concentrations were 100, 50, 25, 12.5, 6.25, 3.125, 1.5, 0.78, and 0.315 μM. Drug-treated cells were then incubated at 37 °C for 24 h. After 24 h, cell viability was determined with CellTiter-Glo cell viability assay (Promega Corporation) as per manufacturer’s instructions. The cell–reagent mixture was then transferred to a solid white flat-bottom 96-well plate (Greiner) for luminescence reading. Luminescence was then recorded with an integration time of 0.25 s with a Tecan Infinite M200 microplate reader. On the basis of the analyses from the above-mentioned concentration range, cell viability assay was repeated with a more focused drug concentration range as required to obtained consistent IC<sub>50</sub> data.</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Determination of in Vitro Metabolic Stability in Male (MRLM) and Female Rat Liver Microsomes (FRLM)</h3><div class="NLM_p last">Liver microsomal incubations were conducted in triplicate as previously described.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Aqueous Solubility</h3><div class="NLM_p last">A 20 mM stock solution of <b>24</b> was prepared in DMSO. Then 10 μL of the stock solution was added to 990 μL of buffer. The mixture was sonicated and vortexed. From the resulting turbid solution, 300 μL was transferred to three wells of a MultiScreen HTS- PCF filter plate. The plate was covered and incubated with gentle shaking (250 rpm, 3 or 24 h) at room temperature (22.5 ± 2.5 °C). After the period of incubation, the filter plate was placed on a vacuum manifold and the contents were filtered into a 96-well UV plate. After filtration, 80 μL of filtrate was transferred from each well to another well in a 96-well UV plate. Acetonitrile (20 μL) was added to each well, and the sample solutions were further diluted by adding another 200 μL of universal buffer. Absorbances of the solutions were read at 310 nm. A calibration curve was determined with concentrations of 200, 100, 50, 25, 12.5, and 6.25 μM and the solubility of the samples determined in triplicate.</div></div><div id="sec5_4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Pharmacokinetics in BALB/c Mice</h3><div class="NLM_p last">This work was carried out by TheraIndx Lifesciences Pvt Ltd., India. This study was performed following all ethical practices as laid down in the guidelines for animal care (Registration No. 1852/PO/Rc/S/16/CPCSEA). The study was approved by the Institutional Animals Ethics Committee (IAEC) of the test facility (Protocol No. IAEC/01/2016/024). The pharmacokinetics (PK) of <b>24</b> and <b>45</b> were characterized in BALB/c mice following single intravenous (iv) and oral (po) doses of 2 and 10 mg/kg, respectively. Animals were housed at a constant temperature (range 22 ± 2 °C) and humidity (range 45–60%). Animals were provided with 12 h light and 12 h dark artificial photoperiod. For po dosing suspensions, the vehicle used was 0.25% CMC containing 0.25% Tween 80 in in water. For iv dosing solutions (2 mg/kg), the vehicle used was DMSO/PEG400/ethanol (absolute)/sterile water at ratio of 10:40:20:30 (v/v). A clear solution of concentration 0.4 mg/mL was obtained. The formulations were prepared on the day of the study. Groups of animals (<i>n</i> = 12/route) were administered single iv bolus doses of 2.0 mg/kg (5 mL/kg dose volume) or oral dose of 10 mg/kg by gavage, at a dose volume of 10 mL/kg. Postdose, blood samples were collected from mice at 2 min (iv) and 5 min (oral), 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h. At the indicated time points, and prior to sampling, mice were anesthetized with isoflurane before sampling. From each mouse, two blood samples were drawn; the first was nonterminal (∼0.1 mL blood) done by saphenous vein puncture and the second terminal, by retro-orbital plexus puncture using heparinized mice capillary tubes. Blood was collected in 2 mL Eppendorf tubes containing 0.01 mL of 10% K<sub>2</sub>EDTA as anticoagulant, mixed gently, and placed in ice before centrifugation. Blood was centrifuged at 10 000 rpm for 5 min, and plasma was harvested and stored at −80<b>°</b>C until analysis. Levels of each compound in plasma were quantified by LSMSMS using a Shimadzu SIL-HTc with an Atlantis dC18 (4.6 mm × 50 mm, 3 μm) column and a API-5500 (ABS Sciex) mass spectrometer. Mobile phase used was acetonitrile and 0.2% formic acid in Milli-Q water.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00678">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02247" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02247" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00678" class="ext-link">10.1021/acs.jmedchem.7b00678</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional synthesis of compounds, NMR and HPLC spectra for final compounds, additional immunoblotting data, selected IC<sub>50</sub> curves, RLM and oral PK data for <b>24</b>, docking of <b>45</b> to HDAC1/6 and JAK1/2, and PK of <b>45</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_007.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_008.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_009.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_010.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_011.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_012.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_001.pdf">jm7b00678_si_001.pdf (15.56 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_002.csv">jm7b00678_si_002.csv (1.94 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_003.pdb">jm7b00678_si_003.pdb (390.22 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_004.pdb">jm7b00678_si_004.pdb (236.91 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_005.pdb">jm7b00678_si_005.pdb (414.79 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_006.pdb">jm7b00678_si_006.pdb (273.0 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_007.pdb">jm7b00678_si_007.pdb (268.3 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_008.pdb">jm7b00678_si_008.pdb (390.52 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_009.pdb">jm7b00678_si_009.pdb (237.21 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_010.pdb">jm7b00678_si_010.pdb (415.07 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_011.pdb">jm7b00678_si_011.pdb (273.3 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_012.pdb">jm7b00678_si_012.pdb (268.6 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00678" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sten Ohlson</span> - <span class="hlFld-Affiliation affiliation">School
of Biological Sciences, Nanyang Technological
University (NTU), 637551, Singapore</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7a293512160915143a140e0f541f1e0f54091d"><span class="__cf_email__" data-cfemail="04574b6c68776b6a446a70712a6160712a7763">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian W. Dymock</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, National University of Singapore, 18 Science Drive 4, 117543, Singapore</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2374-5756" title="Orcid link">http://orcid.org/0000-0002-2374-5756</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#412336252f343201262c20282d6f222e2c"><span class="__cf_email__" data-cfemail="f39184979d8680b3949e929a9fdd909c9e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lianbin Yao</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, National University of Singapore, 18 Science Drive 4, 117543, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nurulhuda Mustafa</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 10, 117549, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eng Chong Tan</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan</span>; 
    <span class="hlFld-Affiliation affiliation">Taiwan
International Graduate Program in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, 115, Taiwan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anders Poulsen</span> - <span class="hlFld-Affiliation affiliation">Experimental
Therapeutics Centre, 31 Biopolis Way, 03-01 Nanos, 138669, Singapore</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, National University of Singapore, 3 Science Drive 3, 117543, Singapore</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2790-9340" title="Orcid link">http://orcid.org/0000-0002-2790-9340</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Prachi Singh</span> - <span class="hlFld-Affiliation affiliation">School
of Biological Sciences, Nanyang Technological
University (NTU), 637551, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minh-Dao Duong-Thi</span> - <span class="hlFld-Affiliation affiliation">School
of Biological Sciences, Nanyang Technological
University (NTU), 637551, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeannie X. T. Lee</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 10, 117549, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pondy Murugappan Ramanujulu</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, National University of Singapore, 18 Science Drive 4, 117543, Singapore</span>; 
    <span class="hlFld-Affiliation affiliation">Centre
for Life Sciences Level 5, Life Sciences Institute, National University of Singapore, 28 Medical Drive, 117456, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wee Joo Chng</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 10, 117549, Singapore</span>; 
    <span class="hlFld-Affiliation affiliation">Cancer
Science Institute, National University of
Singapore, 117599, Singapore</span>; 
    <span class="hlFld-Affiliation affiliation">National
University Cancer Institute of Singapore, National University Health
System, 119074, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey J. Y. Yen</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>N.M. and E.C.T. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d129e7561-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25731" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25731" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors gratefully acknowledge Sheela David Packiaraj and Associate Professor Ho Han Kiat for providing TAMH and AC10 data and Dr Yang Shilli and Professor Paul Ho for RLM data. This research was funded by a generous grant from the National Medical Research Council of Singapore (NMRC CBRG Grant NMRC/CBRG12Nov114 (B.W.D./S.O.)). W.J.C. is supported by a NMRC Clinician Scientist Investigator Award and partly supported by a Singapore Cancer Syndicate Grant, the National Research Foundation Singapore, and the Singapore Ministry of Education under the Research Centers of Excellence initiative. J.J.Y.Y. is supported by Research Grant NSC 102-2320-B-001-007-MY3 from the Ministry of Science and Technology, Taiwan.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i86" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i86"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i87" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i87"> Abbreviations Used</h2><tr><td class="NLM_term">DML</td><td class="NLM_def"><p class="first last">designed multiple ligand</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i88">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83368" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83368" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 48 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Stewart, B. W.; Wild, C. P.</span> <span class="citation_source-book">World Cancer Report 2014</span>. <span class="NLM_publisher-name">World Health Organization, International Agency for Research on Cancer</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=B.+W.+Stewart&author=C.+P.+Wild&title=World+Cancer+Report+2014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DB.%2BW.%26btitle%3DWorld%2520Cancer%2520Report%25202014%26pub%3DWorld%2520Health%2520Organization%252C%2520International%2520Agency%2520for%2520Research%2520on%2520Cancer%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Combinatorial drug therapy for cancer in the post-genomic era</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">692</span><span class="refDoi"> DOI: 10.1038/nbt.2284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2Fnbt.2284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=22781697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=679-692&author=B.+Al-Lazikaniauthor=U.+Banerjiauthor=P.+Workman&title=Combinatorial+drug+therapy+for+cancer+in+the+post-genomic+era&doi=10.1038%2Fnbt.2284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial drug therapy for cancer in the post-genomic era</span></div><div class="casAuthors">Al-Lazikani, Bissan; Banerji, Udai; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted.  Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups.  This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach.  However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility.  One soln. to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon5IOOPfsgR7Vg90H21EOLACvtfcHk0lgwXpBpChSnDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGmtLg%253D&md5=a61b1b222a7146a92366f57cb0e708ca</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2284%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DCombinatorial%2520drug%2520therapy%2520for%2520cancer%2520in%2520the%2520post-genomic%2520era%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D679%26epage%3D692%26doi%3D10.1038%2Fnbt.2284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7887</span><span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lgwXpBpChSnDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Kiu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, S. E.</span><span> </span><span class="NLM_article-title">Biology and significance of the JAK/STAT signalling pathways</span> <span class="citation_source-journal">Growth Factors</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.3109/08977194.2012.660936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.3109%2F08977194.2012.660936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=22339650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVahtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=88-106&author=H.+Kiuauthor=S.+E.+Nicholson&title=Biology+and+significance+of+the+JAK%2FSTAT+signalling+pathways&doi=10.3109%2F08977194.2012.660936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and significance of the JAK/STAT signalling pathways</span></div><div class="casAuthors">Kiu, Hiu; Nicholson, Sandra E.</div><div class="citationInfo"><span class="NLM_cas:title">Growth Factors</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">88-106</span>CODEN:
                <span class="NLM_cas:coden">GRFAEC</span>;
        ISSN:<span class="NLM_cas:issn">0897-7194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Since its discovery 2 decades ago, the activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway by numerous cytokines and growth factors has resulted in it becoming 1 of the most well-studied intracellular signaling networks.  The field has progressed from the identification of the individual components to high-resoln. crystal structures of both JAK and STAT, and an understanding of the complexities of the mol. activation and deactivation cycle which results in a diverse, yet highly specific and regulated pattern of transcriptional responses.  While there is still more to learn, we now appreciate how disruption and deregulation of this pathway can result in clin. disease and look forward to adoption of the next generation of JAK inhibitors in routine clin. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM2feFVqfQ77Vg90H21EOLACvtfcHk0lif7NKw89UVcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVahtbo%253D&md5=d81b34c514392de2c2179229633e9a55</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3109%2F08977194.2012.660936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08977194.2012.660936%26sid%3Dliteratum%253Aachs%26aulast%3DKiu%26aufirst%3DH.%26aulast%3DNicholson%26aufirst%3DS.%2BE.%26atitle%3DBiology%2520and%2520significance%2520of%2520the%2520JAK%252FSTAT%2520signalling%2520pathways%26jtitle%3DGrowth%2520Factors%26date%3D2012%26volume%3D30%26spage%3D88%26epage%3D106%26doi%3D10.3109%2F08977194.2012.660936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Harrison, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiladjian, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Ali, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gisslinger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltzman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stalbovskaya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuitty, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoops, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vannucchi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barosi, G.</span><span> </span><span class="NLM_article-title">JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">787</span><span class="NLM_x">–</span> <span class="NLM_lpage">798</span><span class="refDoi"> DOI: 10.1056/NEJMoa1110556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1056%2FNEJMoa1110556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=22375970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2qurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=787-798&author=C.+Harrisonauthor=J.+J.+Kiladjianauthor=H.+K.+Al-Aliauthor=H.+Gisslingerauthor=R.+Waltzmanauthor=V.+Stalbovskayaauthor=M.+McQuittyauthor=D.+S.+Hunterauthor=R.+Levyauthor=L.+Knoopsauthor=F.+Cervantesauthor=A.+M.+Vannucchiauthor=T.+Barbuiauthor=G.+Barosi&title=JAK+inhibition+with+ruxolitinib+versus+best+available+therapy+for+myelofibrosis&doi=10.1056%2FNEJMoa1110556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</span></div><div class="casAuthors">Harrison, Claire; Kiladjian, Jean-Jacques; Al-Ali, Haifa Kathrin; Gisslinger, Heinz; Waltzman, Roger; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah S.; Levy, Richard; Knoops, Laurent; Cervantes, Francisco; Vannucchi, Alessandro M.; Barbui, Tiziano; Barosi, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">787-798</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Treatment options for myelofibrosis are limited.  We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis.  METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy.  The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% redn. in spleen vol. at week 48 and at week 24, resp., as assessed with the use of magnetic resonance imaging or computed tomog.  RESULTS: A total of 28% of the patients in the ruxolitinib group had at least a 35% redn. in spleen vol. at week 48, as compared with 0% in the group receiving the best available therapy (P<0.001); the corresponding percentages at week 24 were 32% and 0% (P<0.001).  At 48 wk, the mean palpable spleen length had decreased by 56% with ruxolitinib but had increased by 4% with the best available therapy.  The median duration of response with ruxolitinib was not reached, with 80% of patients still having a response at a median follow-up of 12 mo.  Patients in the ruxolitinib group had an improvement in overall quality-of-life measures and a redn. in symptoms assocd. with myelofibrosis.  The most common hematol. abnormalities of grade 3 or higher in either group were thrombocytopenia and anemia, which were managed with a dose redn., interruption of treatment, or transfusion.  One patient in each group discontinued treatment owing to thrombocytopenia, and none discontinued owing to anemia.  Nonhematol. adverse events were rare and mostly grade 1 or 2.  Two cases of acute myeloid leukemia were reported with the best available therapy.  CONCLUSIONS: Continuous ruxolitinib therapy, as compared with the best available therapy, was assocd. with marked and durable redns. in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.  An influence on overall survival has not yet been shown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP7WEm5MUTc7Vg90H21EOLACvtfcHk0lif7NKw89UVcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2qurs%253D&md5=80494b8923fa49536383523066b22b19</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1110556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1110556%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DKiladjian%26aufirst%3DJ.%2BJ.%26aulast%3DAl-Ali%26aufirst%3DH.%2BK.%26aulast%3DGisslinger%26aufirst%3DH.%26aulast%3DWaltzman%26aufirst%3DR.%26aulast%3DStalbovskaya%26aufirst%3DV.%26aulast%3DMcQuitty%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DD.%2BS.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DKnoops%26aufirst%3DL.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DBarbui%26aufirst%3DT.%26aulast%3DBarosi%26aufirst%3DG.%26atitle%3DJAK%2520inhibition%2520with%2520ruxolitinib%2520versus%2520best%2520available%2520therapy%2520for%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D787%26epage%3D798%26doi%3D10.1056%2FNEJMoa1110556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span> </span><span class="NLM_article-title">Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span><span class="refDoi"> DOI: 10.1124/jpet.113.209304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1124%2Fjpet.113.209304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=24218541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=165-173&author=M.+E.+Dowtyauthor=M.+I.+Jessonauthor=S.+Ghoshauthor=J.+Leeauthor=D.+M.+Meyerauthor=S.+Krishnaswamiauthor=N.+Kishore&title=Preclinical+to+clinical+translation+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+in+rheumatoid+arthritis&doi=10.1124%2Fjpet.113.209304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis</span></div><div class="casAuthors">Dowty, Martin E.; Jesson, Michael I.; Ghosh, Sarbani; Lee, Jamie; Meyer, Debra M.; Krishnaswami, Sriram; Kishore, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-173, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A crit. piece in the translation of preclin. studies to clin. trials is the detn. of dosing regimens that allow max. therapeutic benefit with min. toxicity.  The preclin. pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clin. PK/PD data from patients with rheumatoid arthritis (RA).  Preclin. evaluations included target modulation and PK/PD modeling based on continuous s.c. infusion or oral once- or twice-daily (BID) dosing paradigms in mice.  The human PK/PD profile was obtained from pooled data from four phase 2 studies in patients with RA, and maximal effect models were used to evaluate efficacy after 12 wk of tofacitinib treatment (1-15 mg BID).  In mCIA, the main driver of efficacy was inhibition of cytokine receptor signaling mediated by JAK1 heterodimers, but not JAK2 homodimers, and continuous daily inhibition was not required to maintain efficacy.  Projected efficacy could be predicted from total daily exposure irresp. of the oral dosing paradigm, with a total steady-state plasma concn. achieving 50% of the maximal response (Cave50) of ∼100 nM.  Tofacitinib potency (ED50) in clin. studies was ∼3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of ∼40 nM, derived using Disease Activity Scores from patients with RA.  The collective clin. and preclin. data indicated the importance of Cave as a driver of efficacy, rather than max. or min. plasma concn. (Cmax or Cmin), where Cave50 values were within ∼2-fold of each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDs-lnT0HFF7Vg90H21EOLACvtfcHk0liNp2VIype6hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D&md5=faed45ef8eabb5e1bde0819702f26ffa</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.209304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.209304%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DKishore%26aufirst%3DN.%26atitle%3DPreclinical%2520to%2520clinical%2520translation%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D165%26epage%3D173%26doi%3D10.1124%2Fjpet.113.209304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Kim, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.-s.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, Y.</span><span> </span><span class="NLM_article-title">Benzimidazole derivatives as potent JAK1-selective inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7596</span><span class="NLM_x">–</span> <span class="NLM_lpage">7602</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7596-7602&author=M.+K.+Kimauthor=H.+Shinauthor=K.-s.+Parkauthor=H.+Kimauthor=J.+Parkauthor=K.+Kimauthor=J.+Namauthor=H.+Chooauthor=Y.+Chong&title=Benzimidazole+derivatives+as+potent+JAK1-selective+inhibitors&doi=10.1021%2Facs.jmedchem.5b01263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01263%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DShin%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DK.-s.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DNam%26aufirst%3DJ.%26aulast%3DChoo%26aufirst%3DH.%26aulast%3DChong%26aufirst%3DY.%26atitle%3DBenzimidazole%2520derivatives%2520as%2520potent%2520JAK1-selective%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7596%26epage%3D7602%26doi%3D10.1021%2Facs.jmedchem.5b01263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu-Farseeva, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span> </span><span class="NLM_article-title">Selective JAK inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1439</span><span class="NLM_x">–</span> <span class="NLM_lpage">1471</span><span class="refDoi"> DOI: 10.4155/fmc.14.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.4155%2Ffmc.14.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=25329199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1439-1471&author=B.+W.+Dymockauthor=E.+G.+Yangauthor=Y.+Chu-Farseevaauthor=L.+Yao&title=Selective+JAK+inhibitors&doi=10.4155%2Ffmc.14.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Selective JAK inhibitors</span></div><div class="casAuthors">Dymock, Brian W.; Yang, Eugene Guorong; Chu-Farseeva, Yuyi; Yao, Lianbin</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1471</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders.  Recent progress in the discovery of selective inhibitors has been significant, with selective compds. now reported for each isoform.  This article summarizes the current state-of-the-art with a discussion of the most recently described selective compds.  X-ray co-crystal structures reveal the mol. reasons for the obsd. biochem. selectivity.  A concluding anal. of JAK inhibitors in the clinic highlights increased clin. trial activity and diversity of indications.  Selective JAK inhibitors, as single agents or in combination regimens, have a very promising future in the treatment of oncol., immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6G9eFT7Ww27Vg90H21EOLACvtfcHk0liNp2VIype6hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jI&md5=343aa75228918e6e4e063adb1fed96f1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.92%26sid%3Dliteratum%253Aachs%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DChu-Farseeva%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DL.%26atitle%3DSelective%2520JAK%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1439%26epage%3D1471%26doi%3D10.4155%2Ffmc.14.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gao, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F. J.</span><span> </span><span class="NLM_article-title">Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms</span> <span class="citation_source-journal">Exp. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1016/j.exphem.2012.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.exphem.2012.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=23111066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVKnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=261-270&author=S.+M.+Gaoauthor=C.+Q.+Chenauthor=L.+Y.+Wangauthor=L.+L.+Hongauthor=J.+B.+Wuauthor=P.+H.+Dongauthor=F.+J.+Yu&title=Histone+deacetylases+inhibitor+sodium+butyrate+inhibits+JAK2%2FSTAT+signaling+through+upregulation+of+SOCS1+and+SOCS3+mediated+by+HDAC8+inhibition+in+myeloproliferative+neoplasms&doi=10.1016%2Fj.exphem.2012.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms</span></div><div class="casAuthors">Gao, Shen-meng; Chen, Chi-qi; Wang, Lu-yao; Hong, Li-li; Wu, Jian-bo; Dong, Pei-hong; Yu, Fu-jun</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-270.e4</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Constitutive activation of Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) signaling has an important role in the oncogenesis of myeloproliferative neoplasms (MPNs) and leukemia.  Histone deacetylases (HDACs) inhibitors have been reported to possess anticancer activity through different mechanisms.  However, whether HDACs inhibitors suppress JAK2/STAT signaling in MPNs is still unknown.  In this study, we show that the HDAC inhibitor sodium butyrate (SB) inhibited JAK2/STAT signaling and increased the expression of suppressors of cytokine signaling 1 (SOCS1) and SOCS3, both of which are the potent feedback inhibitors of JAK2/STAT signaling.  SB upregulated the expression of SOCS1 and SOCS3 by triggering the promoter-assocd. histone acetylation of SOCS1 and SOCS3 in K562 and HEL cell lines.  Importantly, we found that upon knockdown of each class I HDACs, only knockdown of HDAC8 resulted in the increased expression of SOCS1 and SOCS3.  Moreover, overexpression of SOCS1 and SOCS3 significantly inhibited cell growth and suppressed JAK2/STAT signaling in K562 and HEL cells.  Furthermore, SB increased the transcript levels of SOCS1 and SOCS3 and inhibited the clonogenic activity of hematopoietic progenitors from patients with MPNs.  Taken together, these data establish a new anticancer mechanism that SB inhibits JAK2/STAT signaling through HDAC8-mediated upregulation of SOCS1 and SOCS3.  Thus, HDACs inhibitors may have therapeutic potential for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUyHeZIFKSQrVg90H21EOLACvtfcHk0lgEkGHh7zquxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVKnsg%253D%253D&md5=b57bcdeb8347c2b49060cacf3014a66f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2012.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2012.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DS.%2BM.%26aulast%3DChen%26aufirst%3DC.%2BQ.%26aulast%3DWang%26aufirst%3DL.%2BY.%26aulast%3DHong%26aufirst%3DL.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BB.%26aulast%3DDong%26aufirst%3DP.%2BH.%26aulast%3DYu%26aufirst%3DF.%2BJ.%26atitle%3DHistone%2520deacetylases%2520inhibitor%2520sodium%2520butyrate%2520inhibits%2520JAK2%252FSTAT%2520signaling%2520through%2520upregulation%2520of%2520SOCS1%2520and%2520SOCS3%2520mediated%2520by%2520HDAC8%2520inhibition%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DExp.%2520Hematol.%26date%3D2013%26volume%3D41%26spage%3D261%26epage%3D270%26doi%3D10.1016%2Fj.exphem.2012.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Quintás-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span><span class="refDoi"> DOI: 10.1016/j.leukres.2012.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.leukres.2012.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=22475363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvF2hsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=1124-1127&author=A.+Quint%C3%A1s-Cardamaauthor=H.+Kantarjianauthor=Z.+Estrovauthor=G.+Borthakurauthor=J.+Cortesauthor=S.+Verstovsek&title=Therapy+with+the+histone+deacetylase+inhibitor+pracinostat+for+patients+with+myelofibrosis&doi=10.1016%2Fj.leukres.2012.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Kantarjian, Hagop; Estrov, Zeev; Borthakur, Gautam; Cortes, Jorge; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1124-1127</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Approx. half of the patients with myelofibrosis (MF) carry mutant JAK2V617F proteins.  JAK2V617F has been recently shown to translocate to the nucleus and modify specific histones, thus regulating transcription.  We report on a phase II study testing the activity and tolerability of the histone deacetylase inhibitor pracinostat given at 60 mg every other day for three weeks per mo in 22 patients with intermediate or high risk MF.  Eight (36%) patients experienced clin. benefit, with 6 (27%) experiencing redns. in splenomegaly (median 3 cm, range 1-4 cm).  According to International Working Group criteria, 2 (9%) patients had clin. improvement (anemia response in both cases).  The most frequent side effect assocd. to pracinostat therapy was fatigue, which occurred in 20 (91%) patients (grade 2 in 3 patients).  Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 13%, 0%, and 21%, resp.  Twenty-one patients permanently discontinued pracinostat, mainly due to lack of efficacy.  In conclusion, pracinostat at the dose tested is reasonably tolerated and has modest activity in patients with MF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWKtgUKtLxerVg90H21EOLACvtfcHk0lgEkGHh7zquxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvF2hsr4%253D&md5=f91f89904ae5bc95102b7b533f2d598f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2012.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2012.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DTherapy%2520with%2520the%2520histone%2520deacetylase%2520inhibitor%2520pracinostat%2520for%2520patients%2520with%2520myelofibrosis%26jtitle%3DLeuk.%2520Res.%26date%3D2012%26volume%3D36%26spage%3D1124%26epage%3D1127%26doi%3D10.1016%2Fj.leukres.2012.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">New patented histone deacetylase inhibitors</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1727</span><span class="NLM_x">–</span> <span class="NLM_lpage">1757</span><span class="refDoi"> DOI: 10.1517/13543770903393789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1517%2F13543770903393789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=19939190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WhtLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1727-1757&author=H.+Wangauthor=B.+W.+Dymock&title=New+patented+histone+deacetylase+inhibitors&doi=10.1517%2F13543770903393789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">New patented histone deacetylase inhibitors</span></div><div class="casAuthors">Wang, Haishan; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1727-1757</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Following FDA approval of vorinostat in 2006, several novel HDAC inhibitors (HDACis) have entered clin. trials, and there are numerous published patent applications claiming novel HDACis which were optimized as potential drug candidates, designed for regional or systemic release, and created as dual or multifunctional inhibitors.  Given the breadth and depth of recent reporting of novel HDACis, there has emerged a need to review the field from a chemist's perspective in one compact article.  Areas covered in this review: This review provides a summary of published patent applications claiming novel HDACis from 2007 until mid-2009, covering mainly classes I, II and IV anticancer HDACis including those that have recently advanced to the clinic.  What the reader will gain: Readers will rapidly gain an overview of the majority of HDACi scaffolds with representative structure-activity relationships; they will learn how these new compds. were created, how their drug like properties were improved and which companies are the main players in the field.  Take home message: Although competition in this field is intense, the future application of HDACis to treat human disease either as single agents or in combination with existing drugs holds real promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9k6M0WIgm2rVg90H21EOLACvtfcHk0lgPZDs-ntfVzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WhtLfK&md5=673162bef16012b32a8122c8fefd92ee</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F13543770903393789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903393789%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DNew%2520patented%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1727%26epage%3D1757%26doi%3D10.1517%2F13543770903393789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span> </span><span class="NLM_article-title">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.1038/nbt1272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+sulfoxide+to+vorinostat%3A+development+of+this+histone+deacetylase+inhibitor+as+an+anticancer+drug&doi=10.1038%2Fnbt1272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0lgPZDs-ntfVzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520sulfoxide%2520to%2520vorinostat%253A%2520development%2520of%2520this%2520histone%2520deacetylase%2520inhibitor%2520as%2520an%2520anticancer%2520drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90%26doi%3D10.1038%2Fnbt1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Yang, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustafa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanujulu, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chng, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">8233</span><span class="NLM_x">–</span> <span class="NLM_lpage">8262</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+janus+kinase+2+%28JAK2%29+and+histone+deacetlyase+%28HDAC%29+bispecific+inhibitors+based+on+pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0liWWEwTm34HFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetlyase%2520%2528HDAC%2529%2520bispecific%2520inhibitors%2520based%2520on%2520pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Zwergel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stazi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, A.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: updated studies in various epigenetic-related diseases</span> <span class="citation_source-journal">J. Clin. Epigenet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.21767/2472-1158.100015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.21767%2F2472-1158.100015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=1-15&author=C.+Zwergelauthor=G.+Staziauthor=S.+Valenteauthor=A.+Mai&title=Histone+deacetylase+inhibitors%3A+updated+studies+in+various+epigenetic-related+diseases&doi=10.21767%2F2472-1158.100015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.21767%2F2472-1158.100015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21767%252F2472-1158.100015%26sid%3Dliteratum%253Aachs%26aulast%3DZwergel%26aufirst%3DC.%26aulast%3DStazi%26aufirst%3DG.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DMai%26aufirst%3DA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520updated%2520studies%2520in%2520various%2520epigenetic-related%2520diseases%26jtitle%3DJ.%2520Clin.%2520Epigenet.%26date%3D2016%26volume%3D2%26spage%3D1%26epage%3D15%26doi%3D10.21767%2F2472-1158.100015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Guha, M.</span><span> </span><span class="NLM_article-title">HDAC inhibitors still need a home run, despite recent approval</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">226</span><span class="refDoi"> DOI: 10.1038/nrd4583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2Fnrd4583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=25829268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1artLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=225-226&author=M.+Guha&title=HDAC+inhibitors+still+need+a+home+run%2C+despite+recent+approval&doi=10.1038%2Fnrd4583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors still need a home run, despite recent approval</span></div><div class="casAuthors">Guha, Malini</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">225-226</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A beleaguered class of epigenetic modulators continues to struggle for oncol. success, but new insights into their mechanisms in cancer may yet offer hope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotdd1X74wEP7Vg90H21EOLACvtfcHk0liWWEwTm34HFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1artLs%253D&md5=011db36451b31bc7d19e8ffab8281af8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrd4583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4583%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26atitle%3DHDAC%2520inhibitors%2520still%2520need%2520a%2520home%2520run%252C%2520despite%2520recent%2520approval%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D225%26epage%3D226%26doi%3D10.1038%2Fnrd4583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Evrot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andraos, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolemeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dammassa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baffert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radimerski, T.</span><span> </span><span class="NLM_article-title">JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6230</span><span class="NLM_x">–</span> <span class="NLM_lpage">6241</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1158%2F1078-0432.CCR-13-0905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=24081976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyku7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6230-6241&author=E.+Evrotauthor=N.+Ebelauthor=V.+Romanetauthor=C.+Roelliauthor=R.+Andraosauthor=Z.+Qianauthor=A.+Dolemeyerauthor=E.+Dammassaauthor=D.+Sterkerauthor=R.+Cozensauthor=F.+Hofmannauthor=M.+Murakamiauthor=F.+Baffertauthor=T.+Radimerski&title=JAK1%2F2+and+Pan-deacetylase+inhibitor+combination+therapy+yields+improved+efficacy+in+preclinical+mouse+models+of+JAK2V617F-driven+disease&doi=10.1158%2F1078-0432.CCR-13-0905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease</span></div><div class="casAuthors">Evrot, Emeline; Ebel, Nicolas; Romanet, Vincent; Roelli, Claudia; Andraos, Rita; Qian, Zhiyan; Doelemeyer, Arno; Dammassa, Ernesta; Sterker, Dario; Cozens, Robert; Hofmann, Francesco; Murakami, Masato; Baffert, Fabienne; Radimerski, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6230-6241</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The myeloproliferative neoplasm myelofibrosis is characterized by frequent deregulation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling, and JAK inhibitors were shown to reduce splenomegaly and ameliorate disease-related symptoms.  However, the mutant clone and bone marrow fibrosis persist in the majority of patients.  Using preclin. models, we explored whether JAK and pan-deacetylase inhibitor combination yielded addnl. benefits.  Exptl. Design: The combination of the JAK1/2 inhibitor ruxolitinib and panobinostat was investigated using two different mouse models of JAK2V617F-driven disease.  A Ba/F3 JAK2V617F cell-driven leukemic disease model was used to identify tolerated and efficacious doses.  The drugs were then evaluated alone and in combination in a mouse model of myeloproliferative neoplasm-like disease based on transplantation of bone marrow transduced with a retrovirus expressing JAK2V617F.  Exposures were detd. in blood and tissues, and phosphorylated STAT5 and acetylated histone H3 pharmacodynamic readouts were assessed in spleen and bone marrow.  Histol. anal. was conducted on spleen and bone marrow, including staining of reticulin fibers in the latter organ.  Results: The combination of ruxolitinib and panobinostat was found to have a more profound effect on splenomegaly, as well as on bone marrow and spleen histol., compared with either agent alone, and the anal. of pharmacodynamic readouts showed that ruxolitinib and panobinostat have nonoverlapping and complementary effects.  Conclusion: Combining JAK1/2 and pan-deacetylase inhibitors was fairly well tolerated and resulted in improved efficacy in mouse models of JAK2V617F-driven disease compared with the single agents.  Thus, the combination of ruxolitinib and panobinostat may represent a promising novel therapeutic modality for myeloproliferative neoplasms.  Clin Cancer Res; 19(22); 6230-41. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEzgbAtJVQ27Vg90H21EOLACvtfcHk0lh00x3xWsg_2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyku7jM&md5=ff3662f4ba7be74aa3395046e9516e04</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0905%26sid%3Dliteratum%253Aachs%26aulast%3DEvrot%26aufirst%3DE.%26aulast%3DEbel%26aufirst%3DN.%26aulast%3DRomanet%26aufirst%3DV.%26aulast%3DRoelli%26aufirst%3DC.%26aulast%3DAndraos%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DDolemeyer%26aufirst%3DA.%26aulast%3DDammassa%26aufirst%3DE.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DBaffert%26aufirst%3DF.%26aulast%3DRadimerski%26aufirst%3DT.%26atitle%3DJAK1%252F2%2520and%2520Pan-deacetylase%2520inhibitor%2520combination%2520therapy%2520yields%2520improved%2520efficacy%2520in%2520preclinical%2520mouse%2520models%2520of%2520JAK2V617F-driven%2520disease%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D6230%26epage%3D6241%26doi%3D10.1158%2F1078-0432.CCR-13-0905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">de Lera, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganesan, A.</span><span> </span><span class="NLM_article-title">Epigenetic polypharmacology: from combination therapy to multitargeted drugs</span> <span class="citation_source-journal">Clin. Epigenet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1186/s13148-016-0271-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1186%2Fs13148-016-0271-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=26753011" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=1-21&author=A.+R.+de+Leraauthor=A.+Ganesan&title=Epigenetic+polypharmacology%3A+from+combination+therapy+to+multitargeted+drugs&doi=10.1186%2Fs13148-016-0271-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs13148-016-0271-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13148-016-0271-9%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLera%26aufirst%3DA.%2BR.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DEpigenetic%2520polypharmacology%253A%2520from%2520combination%2520therapy%2520to%2520multitargeted%2520drugs%26jtitle%3DClin.%2520Epigenet.%26date%3D2016%26volume%3D8%26spage%3D1%26epage%3D21%26doi%3D10.1186%2Fs13148-016-0271-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Bieliauskas, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflum, M. K.</span><span> </span><span class="NLM_article-title">Isoform-selective histone deacetylase inhibitors</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1402</span><span class="NLM_x">–</span> <span class="NLM_lpage">1413</span><span class="refDoi"> DOI: 10.1039/b703830p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1039%2Fb703830p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=18568166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFejsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2008&pages=1402-1413&author=A.+V.+Bieliauskasauthor=M.+K.+Pflum&title=Isoform-selective+histone+deacetylase+inhibitors&doi=10.1039%2Fb703830p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-selective histone deacetylase inhibitors</span></div><div class="casAuthors">Bieliauskas, Anton V.; Pflum, Mary Kay H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1402-1413</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer.  As a result, multiple small mol. HDAC inhibitors are in various phases of clin. trials as anti-cancer drugs.  The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes.  This tutorial review focuses on the recent progress toward the identification of class-selective and isoform-selective HDAC inhibitors.  The emerging trends suggest that subtle differences in the active sites of the HDAC isoforms can be exploited to dictate selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXOB_YFWaeZrVg90H21EOLACvtfcHk0lh00x3xWsg_2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFejsbs%253D&md5=326e20da0623a00114f43e5c459c9920</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1039%2Fb703830p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb703830p%26sid%3Dliteratum%253Aachs%26aulast%3DBieliauskas%26aufirst%3DA.%2BV.%26aulast%3DPflum%26aufirst%3DM.%2BK.%26atitle%3DIsoform-selective%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2008%26volume%3D37%26spage%3D1402%26epage%3D1413%26doi%3D10.1039%2Fb703830p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Russell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tayebi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migone, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span><span class="refDoi"> DOI: 10.1126/science.270.5237.797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1126%2Fscience.270.5237.797" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=797-800&author=S.+M.+Russellauthor=N.+Tayebiauthor=H.+Nakajimaauthor=M.+C.+Riedyauthor=J.+L.+Robertsauthor=M.+J.+Amanauthor=T.+S.+Migoneauthor=M.+Noguchiauthor=M.+L.+Markertauthor=R.+H.+Buckleyauthor=J.+J.+O%E2%80%99Sheaauthor=W.+J.+Leonard&title=Mutation+of+Jak3+in+a+patient+with+SCID%3A+essential+role+of+Jak3+in+lymphoid+development&doi=10.1126%2Fscience.270.5237.797"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5237.797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5237.797%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DS.%2BM.%26aulast%3DTayebi%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DRoberts%26aufirst%3DJ.%2BL.%26aulast%3DAman%26aufirst%3DM.%2BJ.%26aulast%3DMigone%26aufirst%3DT.%2BS.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DMarkert%26aufirst%3DM.%2BL.%26aulast%3DBuckley%26aufirst%3DR.%2BH.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DMutation%2520of%2520Jak3%2520in%2520a%2520patient%2520with%2520SCID%253A%2520essential%2520role%2520of%2520Jak3%2520in%2520lymphoid%2520development%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D797%26epage%3D800%26doi%3D10.1126%2Fscience.270.5237.797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Alicea-Velazquez, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span> </span><span class="NLM_article-title">The use of structural biology in Janus kinase targeted drug discovery</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">546</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span><span class="refDoi"> DOI: 10.2174/138945011794751528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.2174%2F138945011794751528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=21126226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=546-555&author=N.+L.+Alicea-Velazquezauthor=T.+J.+Boggon&title=The+use+of+structural+biology+in+Janus+kinase+targeted+drug+discovery&doi=10.2174%2F138945011794751528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The use of structural biology in Janus kinase targeted drug discovery</span></div><div class="casAuthors">Alicea-Velazquez, Nilda L.; Boggon, Titus J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">546-555</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (or Jak kinases) mediate cytokine and growth factor signal transduction.  Acquired or inherited Jak mutations can result in dysregulation of Jak-mediated signal transduction and can be crit. to disease acquisition in neoplasias including acute myeloid, acute lymphoblastic and acute megakaryoblastic leukemias, and in rare X-linked severe combined immunodeficiency.  The discovery of an acquired Jak2 point mutation, V617F, in significant nos. of patients with classical myeloproliferative disorders has increased the interest in development of Jak2-specific tyrosine kinase inhibitors and consequently there are now over 20 publically available structures of Jak kinase domains that describe all four family members, Jak1, Jak2, Jak3, and Tyk2.  Here we review the recent advances in understanding the druggable structure and function of the Jak family, with a focus on the structural biol. of the Jak kinase domain.  We will discuss how these advances impact the development of Jak-targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJwEtMK-lOu7Vg90H21EOLACvtfcHk0lilVK-32yak2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOkurg%253D&md5=5e76fc7eda3ffe580dc4e28044a88c2c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F138945011794751528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011794751528%26sid%3Dliteratum%253Aachs%26aulast%3DAlicea-Velazquez%26aufirst%3DN.%2BL.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520use%2520of%2520structural%2520biology%2520in%2520Janus%2520kinase%2520targeted%2520drug%2520discovery%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26spage%3D546%26epage%3D555%26doi%3D10.2174%2F138945011794751528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munger, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepicelli, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">3647</span><span class="NLM_x">–</span> <span class="NLM_lpage">3656</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1158%2F0008-5472.CAN-09-3360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=20388807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.+J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.+G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.+X.+Xuauthor=S.+DellaRoccaauthor=H.+X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2%2C+exerts+potent+anticancer+activity&doi=10.1158%2F0008-5472.CAN-09-3360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity</span></div><div class="casAuthors">Lai, Cheng-Jung; Bao, Rudi; Tao, Xu; Wang, Jing; Atoyan, Ruzanna; Qu, Hui; Wang, Da-Gong; Yin, Ling; Samson, Maria; Forrester, Jeffrey; Zifcak, Brian; Xu, Guang-Xin; DellaRocca, Steven; Zhai, Hai-Xiao; Cai, Xiong; Munger, William E.; Keegan, Mitchell; Pepicelli, Carmen V.; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3647-3656</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers.  However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.  To overcome these limitations, we created a novel small mol., CUDC-101, which simultaneously inhibits histone deacetylase and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in cancer cells.  Because of its integrated histone deacetylase inhibition, CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.  CUDC-101 displayed potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.  Our results show that CUDC-101 has the potential to dramatically improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.  Further, they provide a framework to create individual small mols. that simultaneously antagonize multiple biochem. distinct oncogenic targets, suggesting a general paradigm to surpass conventional, single-target cancer therapeutics.  Cancer Res; 70(9); 3647-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscJsyultc3bVg90H21EOLACvtfcHk0lhjnzOdRaQJ8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D&md5=bc30667b0890e3c505c9608de6fa0c68</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3360%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%252C%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656%26doi%3D10.1158%2F0008-5472.CAN-09-3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Williams, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucet, I. S.</span><span> </span><span class="NLM_article-title">Dissecting specificity in the janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span><span class="refDoi"> DOI: 10.1016/j.jmb.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains&doi=10.1016%2Fj.jmb.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0lhjnzOdRaQJ8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232%26doi%3D10.1016%2Fj.jmb.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Butler, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">10842</span><span class="NLM_x">–</span> <span class="NLM_lpage">10846</span><span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+design+and+simple+chemistry+yield+a+superior%2C+neuroprotective+HDAC6+inhibitor%2C+tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0lgUt7SJKkfMww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520design%2520and%2520simple%2520chemistry%2520yield%2520a%2520superior%252C%2520neuroprotective%2520HDAC6%2520inhibitor%252C%2520tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alex, A.</span><span> </span><span class="NLM_article-title">Ligand efficiency: a useful metric for lead selection</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+a+useful+metric+for+lead+selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eY1i0Ip7zhWqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520a%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Tarcsay, A. k.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyíri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keserű, G. r. M.</span><span> </span><span class="NLM_article-title">Impact of lipophilic efficiency on compound quality</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1260</span><span class="refDoi"> DOI: 10.1021/jm201388p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201388p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1252-1260&author=A.+k.+Tarcsayauthor=K.+Ny%C3%ADriauthor=G.+r.+M.+Keser%C5%B1&title=Impact+of+lipophilic+efficiency+on+compound+quality&doi=10.1021%2Fjm201388p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Lipophilic Efficiency on Compound Quality</span></div><div class="casAuthors">Tarcsay, Akos; Nyiri, Kinga; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1252-1260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lipophilic efficiency indexes such as LLE and LELP were suggested to support balanced optimization of potency and ADMET profile.  Here we investigated the performance of LLE and LELP on multiple data sets representing different stages of drug discovery including fragment and HTS hits and leads, development candidates, phase II compds., and launched drugs.  Analyzing their impact on ADME and safety properties and binding thermodn., we found that both LLE and LELP help identifying better quality compds.  LLE is sensible for the development stages but does not prefer fragment-type hits, while LELP has an advantage for this class of compds. and discriminates preferred starting points effectively.  Both LLE and LELP have significant impact on ADME and safety profiles; however, LELP outperforms LLE in risk assessment at least on the present data set.  On the basis of the results reported here, monitoring lipophilic efficiency metrics could contribute significantly to compd. quality and might improve the output of medicinal chem. programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxB8xs6-5DL7Vg90H21EOLACvtfcHk0lgUt7SJKkfMww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D&md5=2536abef781f52806013016971c78bcb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm201388p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201388p%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3DA.%2Bk.%26aulast%3DNy%25C3%25ADri%26aufirst%3DK.%26aulast%3DKeser%25C5%25B1%26aufirst%3DG.%2Br.%2BM.%26atitle%3DImpact%2520of%2520lipophilic%2520efficiency%2520on%2520compound%2520quality%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1252%26epage%3D1260%26doi%3D10.1021%2Fjm201388p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2000</span><span class="NLM_x">–</span> <span class="NLM_lpage">2009</span><span class="refDoi"> DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.+X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.+J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-ethynylphenylamino%29-7-methoxyquinazolin-6-yloxy%29-N-hydroxyheptanamide+%28CUDC-101%29+as+a+potent+multi-acting+HDAC%2C+EGFR%2C+and+HER2+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lg3NadeQVd2Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2520%2528CUDC-101%2529%2520as%2520a%2520potent%2520multi-acting%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Duong-Thi, M.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meiby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergström, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fex, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaksson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlson, S.</span><span> </span><span class="NLM_article-title">Weak affinity chromatography as a new approach for fragment screening in drug discovery</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">414</span><span class="NLM_x">, </span> <span class="NLM_fpage">138</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span><span class="refDoi"> DOI: 10.1016/j.ab.2011.02.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.ab.2011.02.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2011&pages=138-146&author=M.-D.+Duong-Thiauthor=E.+Meibyauthor=M.+Bergstr%C3%B6mauthor=T.+Fexauthor=R.+Isakssonauthor=S.+Ohlson&title=Weak+affinity+chromatography+as+a+new+approach+for+fragment+screening+in+drug+discovery&doi=10.1016%2Fj.ab.2011.02.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2011.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2011.02.022%26sid%3Dliteratum%253Aachs%26aulast%3DDuong-Thi%26aufirst%3DM.-D.%26aulast%3DMeiby%26aufirst%3DE.%26aulast%3DBergstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DFex%26aufirst%3DT.%26aulast%3DIsaksson%26aufirst%3DR.%26aulast%3DOhlson%26aufirst%3DS.%26atitle%3DWeak%2520affinity%2520chromatography%2520as%2520a%2520new%2520approach%2520for%2520fragment%2520screening%2520in%2520drug%2520discovery%26jtitle%3DAnal.%2520Biochem.%26date%3D2011%26volume%3D414%26spage%3D138%26epage%3D146%26doi%3D10.1016%2Fj.ab.2011.02.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Ohlson, S.; Duong-Thi, M.-D.</span> <span class="citation_source-book">Emerging Technologies for Fragment Screening</span>; <span class="NLM_publisher-name">Wiley-VCH Verlag</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">67</span>, pp  <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1002%2F9783527683604.ch08" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=173-195&author=S.+Ohlson&author=M.-D.+Duong-Thi&title=Emerging+Technologies+for+Fragment+Screening"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2F9783527683604.ch08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527683604.ch08%26sid%3Dliteratum%253Aachs%26aulast%3DOhlson%26aufirst%3DS.%26btitle%3DEmerging%2520Technologies%2520for%2520Fragment%2520Screening%26pub%3DWiley-VCH%2520Verlag%26date%3D2016%26volume%3D67%26spage%3D173%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span> </span><span class="NLM_article-title">A small molecule–kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floyd&title=A+small+molecule%E2%80%93kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lh2Sl5ZtJ_2jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26atitle%3DA%2520small%2520molecule%25E2%2580%2593kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lh2Sl5ZtJ_2jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Vishwakarma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shastry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulathingal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijaykanth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajesh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathinasamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kachhadia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilambi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajgopal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, S.</span><span> </span><span class="NLM_article-title">Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span><span class="refDoi"> DOI: 10.1016/j.intimp.2013.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.intimp.2013.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=23541634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlWjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=72-78&author=S.+Vishwakarmaauthor=L.+R.+Iyerauthor=M.+Muleyauthor=P.+K.+Singhauthor=A.+Shastryauthor=A.+Saxenaauthor=J.+Kulathingalauthor=G.+Vijaykanthauthor=J.+Raghulauthor=N.+Rajeshauthor=S.+Rathinasamyauthor=V.+Kachhadiaauthor=N.+Kilambiauthor=S.+Rajgopalauthor=G.+Balasubramanianauthor=S.+Narayanan&title=Tubastatin%2C+a+selective+histone+deacetylase+6+inhibitor+shows+anti-inflammatory+and+anti-rheumatic+effects&doi=10.1016%2Fj.intimp.2013.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects</span></div><div class="casAuthors">Vishwakarma, Santosh; Iyer, Lakshmi R.; Muley, Milind; Singh, Pankaj Kumar; Shastry, Arun; Saxena, Ambrish; Kulathingal, Jayanarayan; Vijaykanth, G.; Raghul, J.; Rajesh, Navin; Rathinasamy, Suresh; Kachhadia, Virendra; Kilambi, Narasimhan; Rajgopal, Sridharan; Balasubramanian, Gopalan; Narayanan, Shridhar</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-78</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Epigenetic modifications represent a promising new approach to modulate cell functions as obsd. in autoimmune diseases.  Emerging evidence suggests the utility of HDAC inhibitors in the treatment of chronic immune and inflammatory disorders.  However, class and isoform selective inhibition of HDAC is currently favored as it limits the toxicity that was obsd. with pan-HDAC inhibitors.  HDAC6, a member of the HDAC family, whose major substrate is α-tubulin, is being increasingly implicated in the pathogenesis of inflammatory disorders.  The present study was carried out to study the potential anti-inflammatory and anti-rheumatic effects of HDAC6 selective inhibitor Tubastatin.  Tubastatin, a potent human HDAC6 inhibitor with an IC50 of 11 nM showed significant inhibition of TNF-α and IL-6 in LPS stimulated human THP-1 macrophages with an IC50 of 272 nM and 712 nM, resp.  Addnl., Tubastatin inhibited NO secretion in murine Raw 264.7 macrophages dose dependently with an IC50 of 4.2 μM and induced α-tubulin hyperacetylation corresponding to HDAC6 inhibition in THP-1 cells without affecting the cell viability.  Tubastatin showed significant inhibition of paw vol. at 30 mg/kg i.p. in a Freund's complete adjuvant (FCA) induced animal model of inflammation.  The disease modifying activity of Tubastatin was also evident in collagen induced arthritis DBA1 mouse model at 30 mg/kg i.p.  The significant attenuation of clin. scores (∼ 70%) by Tubastatin was confirmed histopathol. and was found comparable to dexamethasone (∼ 90% inhibition of clin. scores).  Tubastatin showed significant inhibition of IL-6 in paw tissues of arthritic mice.  The present work has demonstrated anti-inflammatory and antirheumatic effects of a selective HDAC6 inhibitor Tubastatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVjF7tHATlYbVg90H21EOLACvtfcHk0lh72PSnMNTTGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlWjsr4%253D&md5=1810b101113330405d3923cbadb628b7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2013.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2013.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DVishwakarma%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DL.%2BR.%26aulast%3DMuley%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DShastry%26aufirst%3DA.%26aulast%3DSaxena%26aufirst%3DA.%26aulast%3DKulathingal%26aufirst%3DJ.%26aulast%3DVijaykanth%26aufirst%3DG.%26aulast%3DRaghul%26aufirst%3DJ.%26aulast%3DRajesh%26aufirst%3DN.%26aulast%3DRathinasamy%26aufirst%3DS.%26aulast%3DKachhadia%26aufirst%3DV.%26aulast%3DKilambi%26aufirst%3DN.%26aulast%3DRajgopal%26aufirst%3DS.%26aulast%3DBalasubramanian%26aufirst%3DG.%26aulast%3DNarayanan%26aufirst%3DS.%26atitle%3DTubastatin%252C%2520a%2520selective%2520histone%2520deacetylase%25206%2520inhibitor%2520shows%2520anti-inflammatory%2520and%2520anti-rheumatic%2520effects%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2013%26volume%3D16%26spage%3D72%26epage%3D78%26doi%3D10.1016%2Fj.intimp.2013.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">–</span> <span class="NLM_lpage">4658</span><span class="refDoi"> DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.+1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0lh72PSnMNTTGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.%25201%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Coe, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rademacher, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bammler, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farin, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plymate, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fausto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. D.</span><span> </span><span class="NLM_article-title">Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1277</span><span class="NLM_x">–</span> <span class="NLM_lpage">1290</span><span class="refDoi"> DOI: 10.1021/tx7001349</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx7001349" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1277-1290&author=K.+J.+Coeauthor=Y.+Jiaauthor=H.+K.+Hoauthor=P.+Rademacherauthor=T.+K.+Bammlerauthor=R.+P.+Beyerauthor=F.+M.+Farinauthor=L.+Woodkeauthor=S.+R.+Plymateauthor=N.+Faustoauthor=S.+D.+Nelson&title=Comparison+of+the+cytotoxicity+of+the+nitroaromatic+drug+flutamide+to+its+cyano+analogue+in+the+hepatocyte+cell+line+TAMH%3A+evidence+for+complex+I+inhibition+and+mitochondrial+dysfunction+using+toxicogenomic+screening&doi=10.1021%2Ftx7001349"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Ftx7001349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx7001349%26sid%3Dliteratum%253Aachs%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DHo%26aufirst%3DH.%2BK.%26aulast%3DRademacher%26aufirst%3DP.%26aulast%3DBammler%26aufirst%3DT.%2BK.%26aulast%3DBeyer%26aufirst%3DR.%2BP.%26aulast%3DFarin%26aufirst%3DF.%2BM.%26aulast%3DWoodke%26aufirst%3DL.%26aulast%3DPlymate%26aufirst%3DS.%2BR.%26aulast%3DFausto%26aufirst%3DN.%26aulast%3DNelson%26aufirst%3DS.%2BD.%26atitle%3DComparison%2520of%2520the%2520cytotoxicity%2520of%2520the%2520nitroaromatic%2520drug%2520flutamide%2520to%2520its%2520cyano%2520analogue%2520in%2520the%2520hepatocyte%2520cell%2520line%2520TAMH%253A%2520evidence%2520for%2520complex%2520I%2520inhibition%2520and%2520mitochondrial%2520dysfunction%2520using%2520toxicogenomic%2520screening%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1277%26epage%3D1290%26doi%3D10.1021%2Ftx7001349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Davidson, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palenzuela, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaac, N. D.</span><span> </span><span class="NLM_article-title">Novel cell lines derived from adult human ventricular cardiomyocytes</span> <span class="citation_source-journal">J. Mol. Cell. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span><span class="refDoi"> DOI: 10.1016/j.yjmcc.2005.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.yjmcc.2005.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=15913645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGgtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2005&pages=133-147&author=M.+M.+Davidsonauthor=C.+Nestiauthor=L.+Palenzuelaauthor=W.+F.+Walkerauthor=E.+Hernandezauthor=L.+Protasauthor=M.+Hiranoauthor=N.+D.+Isaac&title=Novel+cell+lines+derived+from+adult+human+ventricular+cardiomyocytes&doi=10.1016%2Fj.yjmcc.2005.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Novel cell lines derived from adult human ventricular cardiomyocytes</span></div><div class="casAuthors">Davidson, Mercy M.; Nesti, Claudia; Palenzuela, Lluis; Walker, Winsome F.; Hernandez, Evelyn; Protas, Lev; Hirano, Michio; Isaac, Nithila D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">133-147</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background. - We have established proliferating human cardiomyocyte cell lines derived from non-proliferating primary cultures of adult ventricular heart tissue, using a novel method that may be applicable to many post-mitotic primary cultures.  Methods and results. - Primary cells from human ventricular tissue, were fused with SV40 transformed, uridine auxotroph human fibroblasts, devoid of mitochondrial DNA.  This was followed by selection in uridine-free medium to eliminate unfused fibroblasts.  The fused cells were subcloned and screened for cell type-specific markers.  Four clones (AC1, AC10, AC12, AC16) that express markers characteristic of cardiomyocytes were studied.  Clones were homogeneous morphol., and expressed transcription factors (GATA4, MYCD, NFATc4), contractile proteins such as α- and β-myosin heavy chain, α-cardiac actin, troponin I, desmoplakin, α actinin, the muscle-specific intermediate filament protein, desmin, the cardiomyocyte-specific peptide hormones, BNP, the L-type calcium channel α1C subunit and gap junction proteins, connexin-43 and connexin-40.  Furthermore, dye-coupling studies confirmed the presence of functional gap junctions.  EM ultra structural anal. revealed the presence of myofibrils in the subsarcolemmal region, indicating a precontractile developmental stage.  When grown in mitogen-depleted medium, the AC cells stopped proliferating and formed a multinucleated syncytium.  When the SV40 oncogene was silenced using the RNAi technique, AC16 cells switched from a proliferating to a more differentiated quiescent state, with the formation of multinucleated syncyntium.  Concurrently, the cells expressed BMP2, an important signaling mol. for induction of cardiac-specific markers, that was not expressed by the proliferating cells.  The presence of the combination of transcription factors in addn. to muscle-specific markers is a good indication for the presence of a cardiac transcription program in these cells.  Conclusions. - Based on the expression of myogenic markers and a fully functional respiratory chain, the AC cells have retained the nuclear DNA and the mitochondrial DNA of the primary cardiomyocytes.  They can be frozen and thawed repeatedly and can differentiate when grown in mitogen-free medium.  These cell lines are potentially useful in vitro models to study developmental regulation of cardiomyocytes in normal and pathol. states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCsbmml_wFm7Vg90H21EOLACvtfcHk0lhhxZRDrcMU7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGgtLY%253D&md5=41e9f3a6924a93e8b2d46ea6365b0e7d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2005.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2005.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DM.%2BM.%26aulast%3DNesti%26aufirst%3DC.%26aulast%3DPalenzuela%26aufirst%3DL.%26aulast%3DWalker%26aufirst%3DW.%2BF.%26aulast%3DHernandez%26aufirst%3DE.%26aulast%3DProtas%26aufirst%3DL.%26aulast%3DHirano%26aufirst%3DM.%26aulast%3DIsaac%26aufirst%3DN.%2BD.%26atitle%3DNovel%2520cell%2520lines%2520derived%2520from%2520adult%2520human%2520ventricular%2520cardiomyocytes%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2005%26volume%3D39%26spage%3D133%26epage%3D147%26doi%3D10.1016%2Fj.yjmcc.2005.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">West, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span> </span><span class="NLM_article-title">New and emerging HDAC inhibitors for cancer treatment</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1172/JCI69738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1172%2FJCI69738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=24382387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=30-39&author=A.+C.+Westauthor=R.+W.+Johnstone&title=New+and+emerging+HDAC+inhibitors+for+cancer+treatment&doi=10.1172%2FJCI69738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">New and emerging HDAC inhibitors for cancer treatment</span></div><div class="casAuthors">West, Alison C.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci.  The identification of these enzymes and their partner proteins has driven the rapid development of small-mol. inhibitors that target the cancer epigenome.  Herein, the authors discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis.  The authors examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpELUU7P0B_grVg90H21EOLACvtfcHk0ljjqJdyGaD7lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D&md5=ab59960223b33e89725f6539b031f531</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1172%2FJCI69738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69738%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DA.%2BC.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DNew%2520and%2520emerging%2520HDAC%2520inhibitors%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D30%26epage%3D39%26doi%3D10.1172%2FJCI69738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Hubbert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardiola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nixon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, T.-P.</span><span> </span><span class="NLM_article-title">HDAC6 is a microtubule-associated deacetylase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">458</span><span class="refDoi"> DOI: 10.1038/417455a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2F417455a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=12024216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=455-458&author=C.+Hubbertauthor=A.+Guardiolaauthor=R.+Shaoauthor=Y.+Kawaguchiauthor=A.+Itoauthor=A.+Nixonauthor=M.+Yoshidaauthor=X.-F.+Wangauthor=T.-P.+Yao&title=HDAC6+is+a+microtubule-associated+deacetylase&doi=10.1038%2F417455a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is a microtubule-associated deacetylase</span></div><div class="casAuthors">Hubbert, Charlotte; Guardiola, Amaris; Shao, Rong; Kawaguchi, Yoshiharu; Ito, Akihiro; Nixon, Andrew; Yoshida, Minoru; Wang, Xiao-Fan; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6887</span>),
    <span class="NLM_cas:pages">455-458</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reversible acetylation of α-tubulin has been implicated in regulating microtubule stability and function.  The distribution of acetylated α-tubulin is tightly controlled and stereotypic.  Acetylated α-tubulin is most abundant in stable microtubules but is absent from dynamic cellular structures such as neuronal growth cones and the leading edges of fibroblasts.  However, the enzymes responsible for regulating tubulin acetylation and deacetylation are not known.  Here we report that a member of the histone deacetylase family, HDAC6, functions as a tubulin deacetylase.  HDAC6 is localized exclusively in the cytoplasm, where it assocs. with microtubules and localizes with the microtubule motor complex contg. p150glued.  In vivo, the overexpression of HDAC6 leads to a global deacetylation of α-tubulin, whereas a decrease in HDAC6 increases α-tubulin acetylation.  In vitro, purified HDAC6 potently deacetylates α-tubulin in assembled microtubules.  Furthermore, overexpression of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-mediated deacetylation regulates microtubule-dependent cell motility.  Our results show that HDAC6 is the tubulin deacetylase, and provide evidence that reversible acetylation regulates important biol. processes beyond histone metab. and gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp76Er3MrWtO7Vg90H21EOLACvtfcHk0ljjqJdyGaD7lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D&md5=f18cbb0af388925c606e822358ba3da6</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2F417455a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F417455a%26sid%3Dliteratum%253Aachs%26aulast%3DHubbert%26aufirst%3DC.%26aulast%3DGuardiola%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DR.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DNixon%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.-F.%26aulast%3DYao%26aufirst%3DT.-P.%26atitle%3DHDAC6%2520is%2520a%2520microtubule-associated%2520deacetylase%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D455%26epage%3D458%26doi%3D10.1038%2F417455a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J. B.</span><span> </span><span class="NLM_article-title">Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5023</span><span class="NLM_x">–</span> <span class="NLM_lpage">5038</span><span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.+B.+Telliez&title=Discovery+and+development+of+janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0ljjqJdyGaD7lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">D’Amours, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sallmann, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixit, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span> </span><span class="NLM_article-title">Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">3771</span><span class="NLM_x">–</span> <span class="NLM_lpage">3778</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=11707529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD3MXot12nsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2001&pages=3771-3778&author=D.+D%E2%80%99Amoursauthor=F.+R.+Sallmannauthor=V.+M.+Dixitauthor=G.+G.+Poirier&title=Gain-of-function+of+poly%28ADP-ribose%29+polymerase-1+upon+cleavage+by+apoptotic+proteases%3A+implications+for+apoptosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis</span></div><div class="casAuthors">D'Amours, Damien; Sallmann, Frederic R.; Dixit, Vishva M.; Poirier, Guy G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3771-3778</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Poly(ADP-ribosyl)ation is an important mechanism for the maintenance of genomic integrity in response to DNA damage.  The enzyme responsible for poly(ADP-ribose) synthesis, poly(ADP-ribose) polymerase 1 (PARP-1), has been implicated in two distinct modes of cell death induced by DNA damage, namely apoptosis and necrosis.  During the execution phase of apoptosis, PARP-1 is specifically proteolyzed by caspases to produce an N-terminal DNA-binding domain (DBD) and a C-terminal catalytic fragment.  The functional consequence of this proteolytic event is not known.  However, it has recently been shown that overactivation of full-length PARP-1 can result in energy depletion and necrosis in dying cells.  Here, the authors investigate the mol. basis for the differential involvement of PARP-1 in these two types of cellular demise.  The authors show that the C-terminal apoptotic fragment of PARP-1 loses its DNA-dependent catalytic activity upon cleavage with caspase 3.  However, the N-terminal apoptotic fragment, retains a strong DNA-binding activity and totally inhibits the catalytic activity of uncleaved PARP-1.  This dominant-neg. behavior was confirmed and extended in cellular exts. where DNA repair was completely inhibited by nanomolar concns. of the N-terminal fragment.  Furthermore, overexpression of the apoptotic DBD in mouse fibroblast inhibits endogenous PARP-1 activity very efficiently in vivo, thereby confirming the authors' biochem. observations.  Taken together, these expts. indicate that the apoptotic DBD of PARP-1 acts cooperatively with the proteolytic inactivation of the enzyme to trans-inhibit NAD hydrolysis and to maintain the energy levels of the cell.  These results are consistent with a model in which cleavage of PARP-1 promotes apoptosis by preventing DNA repair-induced survival and by blocking energy depletion-induced necrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouW9f4pYihjrVg90H21EOLACvtfcHk0lhNoDZaeJmO9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXot12nsrk%253D&md5=18622ce2e1abc4ca30c3d3e92d471b6f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Amours%26aufirst%3DD.%26aulast%3DSallmann%26aufirst%3DF.%2BR.%26aulast%3DDixit%26aufirst%3DV.%2BM.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26atitle%3DGain-of-function%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520upon%2520cleavage%2520by%2520apoptotic%2520proteases%253A%2520implications%2520for%2520apoptosis%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2001%26volume%3D114%26spage%3D3771%26epage%3D3778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Danial, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korsmeyer, S. J.</span><span> </span><span class="NLM_article-title">Cell death: critical control points</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1016/S0092-8674(04)00046-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2FS0092-8674%2804%2900046-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=14744432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtValsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=205-219&author=N.+N.+Danialauthor=S.+J.+Korsmeyer&title=Cell+death%3A+critical+control+points&doi=10.1016%2FS0092-8674%2804%2900046-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cell death: Critical control points</span></div><div class="casAuthors">Danial, Nika N.; Korsmeyer, Stanley J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-219</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review and discussion.  Programmed cell death (apoptosis) is a distinct genetic and biochem. pathway essential to metazoans.  An intact death pathway is required for successful embryonic development and the maintenance of normal tissue homeostasis.  Apoptosis has proven to be tightly interwoven with other essential cell pathways.  The identification of crit. control points in the cell death pathway has yielded fundamental insights for basic biol., as well as provided rational targets for new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfuRt2EjV6WLVg90H21EOLACvtfcHk0lhNoDZaeJmO9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtValsrY%253D&md5=de853177ac091305b7f237e58108f579</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900046-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900046-7%26sid%3Dliteratum%253Aachs%26aulast%3DDanial%26aufirst%3DN.%2BN.%26aulast%3DKorsmeyer%26aufirst%3DS.%2BJ.%26atitle%3DCell%2520death%253A%2520critical%2520control%2520points%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D205%26epage%3D219%26doi%3D10.1016%2FS0092-8674%2804%2900046-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crackett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaines, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avitabile-Woo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span> </span><span class="NLM_article-title">Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">–</span> <span class="NLM_lpage">4785</span><span class="refDoi"> DOI: 10.1021/jm4004895</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+Koehlerauthor=P.+Bir+Kohliauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+van+Abbemaauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+hydroxyethyl+imidazopyrrolopyridines+as+potent+JAK1+inhibitors+with+favorable+physicochemical+properties+and+high+selectivity+over+JAK2&doi=10.1021%2Fjm4004895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2</span></div><div class="casAuthors">Zak, Mark; Hurley, Christopher A.; Ward, Stuart I.; Bergeron, Philippe; Barrett, Kathy; Balazs, Mercedesz; Blair, Wade S.; Bull, Richard; Chakravarty, Paroma; Chang, Christine; Crackett, Peter; Deshmukh, Gauri; DeVoss, Jason; Dragovich, Peter S.; Eigenbrot, Charles; Ellwood, Charles; Gaines, Simon; Ghilardi, Nico; Gibbons, Paul; Gradl, Stefan; Gribling, Peter; Hamman, Chris; Harstad, Eric; Hewitt, Peter; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Koehler, Michael F. T.; Bir Kohli, Pawan; Labadie, Sharada; Lee, Wyne P.; Liao, Jiangpeng; Liimatta, Marya; Mendonca, Rohan; Narukulla, Raman; Pulk, Rebecca; Reeve, Austin; Savage, Scott; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; van Abbema, Anne; Aliagas, Ignacio; Avitabile-Woo, Barbara; Xiao, Yisong; Yang, Jing; Kulagowski, Janusz J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4764-4785</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors.  X-ray structures of a C-2 hydroxyethyl analog in complex with both JAK1 and JAK2 revealed differential ligand/protein interactions between the two isoforms and offered an explanation for the obsd. selectivity.  Anal. of historical data from related mols. was used to develop a set of physicochem. compd. design parameters to impart desirable properties such as acceptable membrane permeability, potent whole blood activity, and a high degree of metabolic stability.  This work culminated in the identification of a highly JAK1 selective compd. (31) exhibiting favorable oral bioavailability across a range of preclin. species and robust efficacy in a rat CIA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP0DlLtJCYq7Vg90H21EOLACvtfcHk0lh80g5pNZOtAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D&md5=0b0d1950adebf325cc434344f57ca139</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520hydroxyethyl%2520imidazopyrrolopyridines%2520as%2520potent%2520JAK1%2520inhibitors%2520with%2520favorable%2520physicochemical%2520properties%2520and%2520high%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785%26doi%3D10.1021%2Fjm4004895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Millard, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celardo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordiyenko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowley, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwabe, J. W.</span><span> </span><span class="NLM_article-title">Class I HDACs share a common mechanism of regulation by inositol phosphates</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1016/j.molcel.2013.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.molcel.2013.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=23791785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVygu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2013&pages=57-67&author=C.+J.+Millardauthor=P.+J.+Watsonauthor=I.+Celardoauthor=Y.+Gordiyenkoauthor=S.+M.+Cowleyauthor=C.+V.+Robinsonauthor=L.+Fairallauthor=J.+W.+Schwabe&title=Class+I+HDACs+share+a+common+mechanism+of+regulation+by+inositol+phosphates&doi=10.1016%2Fj.molcel.2013.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates</span></div><div class="casAuthors">Millard, Christopher J.; Watson, Peter J.; Celardo, Ivana; Gordiyenko, Yuliya; Cowley, Shaun M.; Robinson, Carol V.; Fairall, Louise; Schwabe, John W. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-67</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Class I histone deacetylases (HDAC1, HDAC2, and HDAC3) are recruited by cognate corepressor proteins into specific transcriptional repression complexes that target HDAC activity to chromatin resulting in chromatin condensation and transcriptional silencing.  The authors previously reported the structure of HDAC3 in complex with the SMRT corepressor.  This structure revealed inositol-tetraphosphate [Ins(1,4,5,6)P4] at the interface of the two proteins.  It was previously unclear whether the role of Ins(1,4,5,6)P4 is to act as a structural cofactor or a regulator of HDAC3 activity.  Here the authors report the structure of HDAC1 in complex with MTA1 from the NuRD complex.  The ELM2-SANT domains from MTA1 wrap completely around HDAC1 occupying both sides of the active site such that the adjacent BAH domain is ideally positioned to recruit nucleosomes to the active site of the enzyme.  Functional assays of both the HDAC1 and HDAC3 complexes reveal that Ins(1,4,5,6)P4 is a bona fide conserved regulator of class I HDAC complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYPhL0103LkLVg90H21EOLACvtfcHk0lh80g5pNZOtAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVygu74%253D&md5=05a4267bf965b5a6217873217044ef2a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2013.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2013.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DMillard%26aufirst%3DC.%2BJ.%26aulast%3DWatson%26aufirst%3DP.%2BJ.%26aulast%3DCelardo%26aufirst%3DI.%26aulast%3DGordiyenko%26aufirst%3DY.%26aulast%3DCowley%26aufirst%3DS.%2BM.%26aulast%3DRobinson%26aufirst%3DC.%2BV.%26aulast%3DFairall%26aufirst%3DL.%26aulast%3DSchwabe%26aufirst%3DJ.%2BW.%26atitle%3DClass%2520I%2520HDACs%2520share%2520a%2520common%2520mechanism%2520of%2520regulation%2520by%2520inositol%2520phosphates%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D51%26spage%3D57%26epage%3D67%26doi%3D10.1016%2Fj.molcel.2013.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Lauffer, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mintzer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zilberleyb, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flicke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritscher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorowicz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modrusan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koth, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupardus, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminker, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, P.</span><span> </span><span class="NLM_article-title">Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">26926</span><span class="NLM_x">–</span> <span class="NLM_lpage">26943</span><span class="refDoi"> DOI: 10.1074/jbc.M113.490706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1074%2Fjbc.M113.490706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=23897821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=26926-26943&author=B.+E.+Laufferauthor=R.+Mintzerauthor=R.+Fongauthor=S.+Mukundauthor=C.+Tamauthor=I.+Zilberleybauthor=B.+Flickeauthor=A.+Ritscherauthor=G.+Fedorowiczauthor=R.+Valleroauthor=D.+F.+Ortwineauthor=J.+Gunznerauthor=Z.+Modrusanauthor=L.+Neumannauthor=C.+M.+Kothauthor=P.+J.+Lupardusauthor=J.+S.+Kaminkerauthor=C.+E.+Heiseauthor=P.+Steiner&title=Histone+deacetylase+%28HDAC%29+inhibitor+kinetic+rate+constants+correlate+with+cellular+histone+acetylation+but+not+transcription+and+cell+viability&doi=10.1074%2Fjbc.M113.490706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span></div><div class="casAuthors">Lauffer, Benjamin E. L.; Mintzer, Robert; Fong, Rina; Mukund, Susmith; Tam, Christine; Zilberleyb, Inna; Flicke, Birgit; Ritscher, Allegra; Fedorowicz, Grazyna; Vallero, Roxanne; Ortwine, Daniel F.; Gunzner, Janet; Modrusan, Zora; Neumann, Lars; Koth, Christopher M.; Lupardus, Patrick J.; Kaminker, Joshua S.; Heise, Christopher E.; Steiner, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">26926-26943</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crit. in the control of gene expression, and dysregulation of their activity has been implicated in a broad range of diseases, including cancer, cardiovascular, and neurol. diseases.  HDAC inhibitors (HDACi) employing different zinc chelating functionalities such as hydroxamic acids and benzamides have shown promising results in cancer therapy.  Although it has also been suggested that HDACi with increased isoenzyme selectivity and potency may broaden their clin. utility and minimize side effects, the translation of this idea to the clinic remains to be investigated.  Moreover, a detailed understanding of how HDACi with different pharmacol. properties affect biol. functions in vitro and in vivo is still missing.  Here, we show that a panel of benzamide-contg. HDACi are slow tight-binding inhibitors with long residence times unlike the hydroxamate-contg. HDACi vorinostat and trichostatin-A.  Characterization of changes in H2BK5 and H4K14 acetylation following HDACi treatment in the neuroblastoma cell line SH-SY5Y revealed that the timing and magnitude of histone acetylation mirrored both the assocn. and dissocn. kinetic rates of the inhibitors.  In contrast, cell viability and microarray gene expression anal. indicated that cell death induction and changes in transcriptional regulation do not correlate with the dissocn. kinetic rates of the HDACi.  Therefore, our study suggests that detg. how the selective and kinetic inhibition properties of HDACi affect cell function will help to evaluate their therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2goaOx8CDGbVg90H21EOLACvtfcHk0ljJgF3rROP28Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM&md5=af1074c79e8abd932313f4ae13333a98</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.490706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.490706%26sid%3Dliteratum%253Aachs%26aulast%3DLauffer%26aufirst%3DB.%2BE.%26aulast%3DMintzer%26aufirst%3DR.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DFlicke%26aufirst%3DB.%26aulast%3DRitscher%26aufirst%3DA.%26aulast%3DFedorowicz%26aufirst%3DG.%26aulast%3DVallero%26aufirst%3DR.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNeumann%26aufirst%3DL.%26aulast%3DKoth%26aufirst%3DC.%2BM.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DKaminker%26aufirst%3DJ.%2BS.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DSteiner%26aufirst%3DP.%26atitle%3DHistone%2520deacetylase%2520%2528HDAC%2529%2520inhibitor%2520kinetic%2520rate%2520constants%2520correlate%2520with%2520cellular%2520histone%2520acetylation%2520but%2520not%2520transcription%2520and%2520cell%2520viability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D26926%26epage%3D26943%26doi%3D10.1074%2Fjbc.M113.490706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Hai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christianson, D. W.</span><span> </span><span class="NLM_article-title">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1038/nchembio.2134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2Fnchembio.2134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=27454933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=741-747&author=Y.+Haiauthor=D.+W.+Christianson&title=Histone+deacetylase+6+structure+and+molecular+basis+of+catalysis+and+inhibition&doi=10.1038%2Fnchembio.2134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span></div><div class="casAuthors">Hai, Yang; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">741-747</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a crit. target for drug design because of its role in oncogenic transformation and cancer metastasis, and is unique among all histone deacetylases in that it contains tandem catalytic domains designated CD1 and CD2.  We now report the crystal structures of CD2 from Homo sapiens HDAC6 and of CD1 and CD2 from Danio rerio HDAC6.  We correlated these structures with activity measurements using 13 different substrates.  The catalytic activity of CD2 from both species exhibited broad substrate specificity, whereas that of CD1 was highly specific for substrates bearing C-terminal acetyllysine residues.  Crystal structures of substrate complexes yielded unprecedented snapshots of the catalytic mechanism.  Addnl., crystal structures of complexes with eight different inhibitors, including belinostat and panobinostat (currently used in cancer chemotherapy), the macrocyclic tetrapeptide HC toxin, and the HDAC6-specific inhibitor N-hydroxy-4-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl)benzamide, revealed surprising new insight regarding changes in Zn2+ coordination and isoenzyme-specific inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqCfziGBHBRLVg90H21EOLACvtfcHk0ljJgF3rROP28Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ&md5=e167bc6f66e00923da4f2bced2b306b9</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2134%26sid%3Dliteratum%253Aachs%26aulast%3DHai%26aufirst%3DY.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520deacetylase%25206%2520structure%2520and%2520molecular%2520basis%2520of%2520catalysis%2520and%2520inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D741%26epage%3D747%26doi%3D10.1038%2Fnchembio.2134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span>Schrödinger, L L.C., 2014. New York, NY, U.S.<a href="http://www.schrodinger.com" class="extLink">http://www.schrodinger.com</a> (accessed April 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Schr%C3%B6dinger%2C+L+L.C.%2C+2014.+New+York%2C+NY%2C+U.S.http%3A%2F%2Fwww.schrodinger.com+%28accessed+April+10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Harder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damm, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maple, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reboul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupyan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlgren, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaus, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerutti, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krilov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span> </span><span class="NLM_article-title">OPLS3: a force field providing broad coverage of drug-like small molecules and proteins</span> <span class="citation_source-journal">J. Chem. Theory Comput.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">–</span> <span class="NLM_lpage">296</span><span class="refDoi"> DOI: 10.1021/acs.jctc.5b00864</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.5b00864" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=281-296&author=E.+Harderauthor=W.+Dammauthor=J.+Mapleauthor=C.+Wuauthor=M.+Reboulauthor=J.+Y.+Xiangauthor=L.+Wangauthor=D.+Lupyanauthor=M.+K.+Dahlgrenauthor=J.+L.+Knightauthor=J.+W.+Kausauthor=D.+S.+Ceruttiauthor=G.+Krilovauthor=W.+L.+Jorgensenauthor=R.+Abelauthor=R.+A.+Friesner&title=OPLS3%3A+a+force+field+providing+broad+coverage+of+drug-like+small+molecules+and+proteins&doi=10.1021%2Facs.jctc.5b00864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins</span></div><div class="casAuthors">Harder, Edward; Damm, Wolfgang; Maple, Jon; Wu, Chuanjie; Reboul, Mark; Xiang, Jin Yu; Wang, Lingle; Lupyan, Dmitry; Dahlgren, Markus K.; Knight, Jennifer L.; Kaus, Joseph W.; Cerutti, David S.; Krilov, Goran; Jorgensen, William L.; Abel, Robert; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-296</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The parametrization and validation of the OPLS3 force field for small mols. and proteins are reported.  Enhancements with respect to the previous version (OPLS2.1) include the addn. of off-atom charge sites to represent halogen bonding and aryl nitrogen lone pairs as well as a complete refit of peptide dihedral parameters to better model the native structure of proteins.  To adequately cover medicinal chem. space, OPLS3 employs over an order of magnitude more ref. data and assocd. parameter types relative to other commonly used small mol. force fields (e.g., MMFF and OPLS_2005).  As a consequence, OPLS3 achieves a high level of accuracy across performance benchmarks that assess small mol. conformational propensities and solvation.  The newly fitted peptide dihedrals lead to significant improvements in the representation of secondary structure elements in simulated peptides and native structure stability over a no. of proteins.  Together, the improvements made to both the small mol. and protein force field lead to a high level of accuracy in predicting protein-ligand binding measured over a wide range of targets and ligands (less than 1 kcal/mol RMS error) representing a 30% improvement over earlier variants of the OPLS force field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY_jrOhcBRgrVg90H21EOLACvtfcHk0ljuiB4UqmFatQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE&md5=42663f8cfa84b80a67132bbb13b9b7ce</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.5b00864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.5b00864%26sid%3Dliteratum%253Aachs%26aulast%3DHarder%26aufirst%3DE.%26aulast%3DDamm%26aufirst%3DW.%26aulast%3DMaple%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DReboul%26aufirst%3DM.%26aulast%3DXiang%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLupyan%26aufirst%3DD.%26aulast%3DDahlgren%26aufirst%3DM.%2BK.%26aulast%3DKnight%26aufirst%3DJ.%2BL.%26aulast%3DKaus%26aufirst%3DJ.%2BW.%26aulast%3DCerutti%26aufirst%3DD.%2BS.%26aulast%3DKrilov%26aufirst%3DG.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DOPLS3%253A%2520a%2520force%2520field%2520providing%2520broad%2520coverage%2520of%2520drug-like%2520small%2520molecules%2520and%2520proteins%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2016%26volume%3D12%26spage%3D281%26epage%3D296%26doi%3D10.1021%2Facs.jctc.5b00864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Polak, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribiere, G.</span><span> </span><span class="NLM_article-title">Note sur la convergence de méthodes de directions conjuguées</span> <span class="citation_source-journal">Rev. Fr. Info Res. Op.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1969</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1051/m2an/196903R100351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1051%2Fm2an%2F196903R100351" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1969&pages=35-43&author=E.+Polakauthor=G.+Ribiere&title=Note+sur+la+convergence+de+m%C3%A9thodes+de+directions+conjugu%C3%A9es&doi=10.1051%2Fm2an%2F196903R100351"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1051%2Fm2an%2F196903R100351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1051%252Fm2an%252F196903R100351%26sid%3Dliteratum%253Aachs%26aulast%3DPolak%26aufirst%3DE.%26aulast%3DRibiere%26aufirst%3DG.%26atitle%3DNote%2520sur%2520la%2520convergence%2520de%2520m%25C3%25A9thodes%2520de%2520directions%2520conjugu%25C3%25A9es%26jtitle%3DRev.%2520Fr.%2520Info%2520Res.%2520Op.%26date%3D1969%26volume%3D3%26spage%3D35%26epage%3D43%26doi%3D10.1051%2Fm2an%2F196903R100351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Hasel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Still, W. C.</span><span> </span><span class="NLM_article-title">A rapid approximation to the solvent accessible surface areas of atoms</span> <span class="citation_source-journal">Tetrahedron Comput. Methodol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1016/0898-5529(88)90015-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2F0898-5529%2888%2990015-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1988&pages=103-116&author=W.+Haselauthor=T.+F.+Hendricksonauthor=W.+C.+Still&title=A+rapid+approximation+to+the+solvent+accessible+surface+areas+of+atoms&doi=10.1016%2F0898-5529%2888%2990015-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid approximation to the solvent-accessible surface areas of atoms</span></div><div class="casAuthors">Hasel, Winnfried; Hendrickson, Thomas F.; Still, W. Clark</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Computer Methodology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-16</span>CODEN:
                <span class="NLM_cas:coden">TCMTE6</span>;
        ISSN:<span class="NLM_cas:issn">0898-5529</span>.
    </div><div class="casAbstract">An anal. expression for approx. at. and mol. van der Waals and solvent accessible surface areas is described.  The treatment is based on the probabilistic method of Wodak and Janin (1980) but with modifications which allow it to be applied to the calcn. of at. surface areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEtlzGPkwT_7Vg90H21EOLACvtfcHk0ljuiB4UqmFatQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D&md5=98b3e7fab9432dccb1ff22f726d54fbf</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0898-5529%2888%2990015-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0898-5529%252888%252990015-2%26sid%3Dliteratum%253Aachs%26aulast%3DHasel%26aufirst%3DW.%26aulast%3DHendrickson%26aufirst%3DT.%2BF.%26aulast%3DStill%26aufirst%3DW.%2BC.%26atitle%3DA%2520rapid%2520approximation%2520to%2520the%2520solvent%2520accessible%2520surface%2520areas%2520of%2520atoms%26jtitle%3DTetrahedron%2520Comput.%2520Methodol.%26date%3D1988%26volume%3D1%26spage%3D103%26epage%3D116%26doi%3D10.1016%2F0898-5529%2888%2990015-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Bergström, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiick, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlson, S.</span><span> </span><span class="NLM_article-title">Cholera toxin inhibitors studied with high–performance liquid affinity chromatography: a robust method to evaluate receptor–ligand interactions</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2008.00758.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1111%2Fj.1747-0285.2008.00758.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=19152642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FotFyguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2009&pages=132-141&author=M.+Bergstr%C3%B6mauthor=S.+Liuauthor=K.+L.+Kiickauthor=S.+Ohlson&title=Cholera+toxin+inhibitors+studied+with+high%E2%80%93performance+liquid+affinity+chromatography%3A+a+robust+method+to+evaluate+receptor%E2%80%93ligand+interactions&doi=10.1111%2Fj.1747-0285.2008.00758.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Cholera toxin inhibitors studied with high-performance liquid affinity chromatography: a robust method to evaluate receptor-ligand interactions</span></div><div class="casAuthors">Bergstrom Maria; Liu Shuang; Kiick Kristi L; Ohlson Sten</div><div class="citationInfo"><span class="NLM_cas:title">Chemical biology & drug design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">132-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Anti-adhesion drugs may be an alternative to antibiotics to control infection of micro-organisms.  The well-characterized interaction between cholera toxin and the cellular glycolipid GM1 makes it an attractive model for inhibition studies in general.  In this report, we demonstrate a high-performance liquid affinity chromatography approach called weak affinity chromatography to evaluate cholera toxin inhibitors.  The cholera toxin B-subunit was covalently coupled to porous silica and a (weak) affinity column was produced.  The K(D) values of galactose and meta-nitrophenyl alpha-D-galactoside were determined with weak affinity chromatography to be 52 and 1 mM, respectively, which agree well with IC(50) values previously reported.  To increase inhibition potency multivalent inhibitors have been developed and the interaction with multivalent glycopolypeptides was also evaluated.  The affinity of these compounds was found to correlate with the galactoside content but K(D) values were not obtained because of the inhomogeneous response and slow off-rate from multivalent interactions.  Despite the limitations in obtaining direct K(D) values of the multivalent galactopolypeptides, weak affinity chromatography represents an additional and valuable tool in the evaluation of monovalent as well as multivalent cholera toxin inhibitors.  It offers multiple advantages, such as a low sample consumption, high reproducibility and short analysis time, which are often not observed in other methods of analysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-AB2cNMO0u75XHngOXiV_fW6udTcc2eboS7WuIBU0Nbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FotFyguw%253D%253D&md5=366eb8b8017308e715cc8be80c3661c3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2008.00758.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2008.00758.x%26sid%3Dliteratum%253Aachs%26aulast%3DBergstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DKiick%26aufirst%3DK.%2BL.%26aulast%3DOhlson%26aufirst%3DS.%26atitle%3DCholera%2520toxin%2520inhibitors%2520studied%2520with%2520high%25E2%2580%2593performance%2520liquid%2520affinity%2520chromatography%253A%2520a%2520robust%2520method%2520to%2520evaluate%2520receptor%25E2%2580%2593ligand%2520interactions%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2009%26volume%3D73%26spage%3D132%26epage%3D141%26doi%3D10.1111%2Fj.1747-0285.2008.00758.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 50 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yuhao Ren, Shanshan Li, Ren Zhu, Chengying Wan, Dongmei Song, Jiawen Zhu, Guiping Cai, Sihui Long, Lingyi Kong, <span class="NLM_string-name hlFld-ContribAuthor">Wenying Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7468-7482. <a href="https://doi.org/10.1021/acs.jmedchem.1c00136" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00136</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00136%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BSTAT3%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual-Pathway%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BSolid%252BCancer%26aulast%3DRen%26aufirst%3DYuhao%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D24012021%26date%3D27052021%26volume%3D64%26issue%3D11%26spage%3D7468%26epage%3D7482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kalpana Tilekar, Jessica D. Hess, Neha Upadhyay, Alessandra Lo Bianco, Markus Schweipert, Antonio Laghezza, Fulvio Loiodice, Franz-Josef Meyer-Almes, Renato J. Aguilera, Antonio Lavecchia, <span class="NLM_string-name hlFld-ContribAuthor">Ramaa C S</span>. </span><span class="cited-content_cbyCitation_article-title">Thiazolidinedione “Magic Bullets” Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6949-6971. <a href="https://doi.org/10.1021/acs.jmedchem.1c00491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThiazolidinedione%252B%2525E2%252580%25259CMagic%252BBullets%2525E2%252580%25259D%252BSimultaneously%252BTargeting%252BPPAR%2525CE%2525B3%252Band%252BHDACs%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BInvestigations%252Bof%252Btheir%252BIn%252BVitro%252Band%252BIn%252BVivo%252BAntitumor%252BEffects%26aulast%3DTilekar%26aufirst%3DKalpana%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D18032021%26date%3D18052021%26volume%3D64%26issue%3D10%26spage%3D6949%26epage%3D6971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ryan R. Davis, Baoli Li, Sang Y. Yun, Alice Chan, Pradeep Nareddy, Steven Gunawan, Muhammad Ayaz, Harshani R. Lawrence, Gary W. Reuther, Nicholas J. Lawrence, <span class="NLM_string-name hlFld-ContribAuthor">Ernst Schönbrunn</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (4)
                                     , 2228-2241. <a href="https://doi.org/10.1021/acs.jmedchem.0c01952" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01952</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01952%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BInsights%252Binto%252BJAK2%252BInhibition%252Bby%252BRuxolitinib%25252C%252BFedratinib%25252C%252Band%252BDerivatives%252BThereof%26aulast%3DDavis%26aufirst%3DRyan%2BR.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D17112020%26date%3D11022021%26volume%3D64%26issue%3D4%26spage%3D2228%26epage%3D2241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuewu Liang, Shuai Tang, Xuyi Liu, Yingluo Liu, Qifu Xu, Xiaomin Wang, Abdusaid Saidahmatov, Chunpu Li, Jiang Wang, Yu Zhou, Yingjie Zhang, Meiyu Geng, Min Huang, <span class="NLM_string-name hlFld-ContribAuthor">Hong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02111%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPyrrolo%25255B2%25252C3-d%25255Dpyrimidine-based%252BDerivatives%252Bas%252BPotent%252BJAK%25252FHDAC%252BDual%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRefractory%252BSolid%252BTumors%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2021%26date%3D2020%26date%3D07122020%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tingting Liu, Yichao Wan, Yuliang Xiao, Chengcai Xia, <span class="NLM_string-name hlFld-ContribAuthor">Guiyun Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 8977-9002. <a href="https://doi.org/10.1021/acs.jmedchem.0c00491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual-Target%252BInhibitors%252BBased%252Bon%252BHDACs%25253A%252BNovel%252BAntitumor%252BAgents%252Bfor%252BCancer%252BTherapy%26aulast%3DLiu%26aufirst%3DTingting%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D23032020%26date%3D30042020%26date%3D22042020%26volume%3D63%26issue%3D17%26spage%3D8977%26epage%3D9002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shulei Zhu, Qianqian Shen, Yinglei Gao, Lei Wang, Yanfen Fang, Yi Chen, <span class="NLM_string-name hlFld-ContribAuthor">Wei Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor–SN38 Conjugates for Targeted Drug Accumulation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5421-5441. <a href="https://doi.org/10.1021/acs.jmedchem.0c00305" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00305</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00305%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BHSP90%252BInhibitor%2525E2%252580%252593SN38%252BConjugates%252Bfor%252BTargeted%252BDrug%252BAccumulation%26aulast%3DZhu%26aufirst%3DShulei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20022020%26date%3D11052020%26date%3D30042020%26volume%3D63%26issue%3D10%26spage%3D5421%26epage%3D5441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ashish Thakur, Gregory J. Tawa, Mark J. Henderson, Carina Danchik, Suiyang Liu, Pranav Shah, Amy Q. Wang, Garrett Dunn, Md Kabir, Elias C. Padilha, Xin Xu, Anton Simeonov, Surender Kharbanda, Richard Stone, <span class="NLM_string-name hlFld-ContribAuthor">Gurmit Grewal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4256-4292. <a href="https://doi.org/10.1021/acs.jmedchem.0c00193" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BQuinazolin-4-one-Based%252BHydroxamic%252BAcids%252Bas%252BDual%252BPI3K%25252FHDAC%252BInhibitors%26aulast%3DThakur%26aufirst%3DAshish%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03022020%26date%3D08042020%26date%3D26032020%26volume%3D63%26issue%3D8%26spage%3D4256%26epage%3D4292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kehui Zhang, Fangfang Lai, Songwen Lin, Ming Ji, Jingbo Zhang, Yan Zhang, Jing Jin, Rong Fu, Deyu Wu, Hua Tian, Nina Xue, Li Sheng, Xiaowen Zou, Yan Li, Xiaoguang Chen, <span class="NLM_string-name hlFld-ContribAuthor">Heng Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 6992-7014. <a href="https://doi.org/10.1021/acs.jmedchem.9b00390" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00390%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B4-Methyl%252BQuinazoline%252BDerivatives%252Bas%252BAnticancer%252BAgents%252BSimultaneously%252BTargeting%252BPhosphoinositide%252B3-Kinases%252Band%252BHistone%252BDeacetylases%26aulast%3DZhang%26aufirst%3DKehui%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03032019%26date%3D29052019%26date%3D22052019%26volume%3D62%26issue%3D15%26spage%3D6992%26epage%3D7014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuewu Liang, Jie Zang, Xiaoyang Li, Shuai Tang, Min Huang, Meiyu Geng, C. James Chou, Chunpu Li, Yichun Cao, Wenfang Xu, Hong Liu, <span class="NLM_string-name hlFld-ContribAuthor">Yingjie Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (8)
                                     , 3898-3923. <a href="https://doi.org/10.1021/acs.jmedchem.8b01597" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01597</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01597%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BJanus%252BKinase%252B%252528JAK%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BHematological%252BMalignancies%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D14102018%26date%3D03042019%26date%3D22032019%26volume%3D62%26issue%3D8%26spage%3D3898%26epage%3D3923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yepeng Luan, Jerry Li, Jean A. Bernatchez, <span class="NLM_string-name hlFld-ContribAuthor">Rongshi Li</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (7)
                                     , 3171-3183. <a href="https://doi.org/10.1021/acs.jmedchem.8b00189" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00189</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00189%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252Band%252BHistone%252BDeacetylase%252BHybrid%252BInhibitors%252Bfor%252BCancer%252BTherapy%26aulast%3DLuan%26aufirst%3DYepeng%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D05022018%26date%3D16112018%26date%3D12112018%26volume%3D62%26issue%3D7%26spage%3D3171%26epage%3D3183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joshua Meyers, Nicola E. A. Chessum, Salyha Ali, N. Yi Mok, Birgit Wilding, A. Elisa Pasqua, Martin Rowlands, Michael J. Tucker, Lindsay E. Evans, Carl S. Rye, Lisa O’Fee, Yann-Vaï Le Bihan, Rosemary Burke, Michael Carter, Paul Workman, Julian Blagg, Nathan Brown, Rob L. M. van Montfort, Keith Jones, <span class="NLM_string-name hlFld-ContribAuthor">Matthew D. Cheeseman</span>. </span><span class="cited-content_cbyCitation_article-title">Privileged Structures and Polypharmacology within and between Protein Families. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (12)
                                     , 1199-1204. <a href="https://doi.org/10.1021/acsmedchemlett.8b00364" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00364</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00364%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPrivileged%252BStructures%252Band%252BPolypharmacology%252Bwithin%252Band%252Bbetween%252BProtein%252BFamilies%26aulast%3DMeyers%26aufirst%3DJoshua%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09082018%26date%3D16112018%26date%3D26112018%26date%3D16112018%26volume%3D9%26issue%3D12%26spage%3D1199%26epage%3D1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yahui Huang, Guoqiang Dong, Huanqiu Li, Na Liu, Wannian Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 6056-6074. <a href="https://doi.org/10.1021/acs.jmedchem.8b00393" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00393</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BJanus%252BKinase%252B2%252B%252528JAK2%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%252Bas%252Ba%252BNovel%252BStrategy%252Bfor%252Bthe%252BCombinational%252BTreatment%252Bof%252BLeukemia%252Band%252BInvasive%252BFungal%252BInfections%26aulast%3DHuang%26aufirst%3DYahui%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D10032018%26date%3D14072018%26date%3D25062018%26volume%3D61%26issue%3D14%26spage%3D6056%26epage%3D6074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jie Zang, Xuewu Liang, Yongxue Huang, Yuping Jia, Xiaoyang Li, Wenfang Xu, C. James Chou, <span class="NLM_string-name hlFld-ContribAuthor">Yingjie Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5304-5322. <a href="https://doi.org/10.1021/acs.jmedchem.8b00384" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00384</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPazopanib-Based%252BHDAC%252Band%252BVEGFR%252BDual%252BInhibitors%252BTargeting%252BCancer%252BEpigenetics%252Band%252BAngiogenesis%252BSimultaneously%26aulast%3DZang%26aufirst%3DJie%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09032018%26date%3D07062018%26date%3D22052018%26volume%3D61%26issue%3D12%26spage%3D5304%26epage%3D5322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kun Fang, Guoqiang Dong, Yu Li, Shipeng He, Ying Wu, Shanchao Wu, Wei Wang, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (4)
                                     , 312-317. <a href="https://doi.org/10.1021/acsmedchemlett.7b00487" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00487%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BNovel%252BIndoleamine%252B2%25252C3-Dioxygenase%252B1%252B%252528IDO1%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%26aulast%3DFang%26aufirst%3DKun%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D26112017%26date%3D26032018%26date%3D02042018%26date%3D26032018%26volume%3D9%26issue%3D4%26spage%3D312%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Pan</span>, <span class="hlFld-ContribAuthor ">Yanrong  Dan</span>, <span class="hlFld-ContribAuthor ">Dafeng  Guo</span>, <span class="hlFld-ContribAuthor ">Junhao  Jiang</span>, <span class="hlFld-ContribAuthor ">Dongzhi  Ran</span>, <span class="hlFld-ContribAuthor ">Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Binghua  Tian</span>, <span class="hlFld-ContribAuthor ">Jianyong  Yuan</span>, <span class="hlFld-ContribAuthor ">Yu  Yu</span>, <span class="hlFld-ContribAuthor ">Zongjie  Gan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113672. <a href="https://doi.org/10.1016/j.ejmech.2021.113672" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113672</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113672%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4-pyrimidinediamine%252Bderivatives%252Bas%252Bpotent%252Bdual%252Binhibitors%252Bof%252BALK%252Band%252BHDAC%26aulast%3DPan%26aufirst%3DTao%26date%3D2021%26volume%3D224%26spage%3D113672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ma  Su</span>, <span class="hlFld-ContribAuthor ">Xingyu  Gong</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , 745-761. <a href="https://doi.org/10.1080/17460441.2021.1877656" title="DOI URL">https://doi.org/10.1080/17460441.2021.1877656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1877656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1877656%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAn%252Bupdate%252Bon%252Bthe%252Bemerging%252Bapproaches%252Bfor%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitor%252Bdrug%252Bdiscovery%252Band%252Bfuture%252Bperspectives%26aulast%3DSu%26aufirst%3DMa%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D7%26spage%3D745%26epage%3D761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinghua  Ren</span>, <span class="hlFld-ContribAuthor ">Wenqian  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Current status in the discovery of dual BET/HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127829. <a href="https://doi.org/10.1016/j.bmcl.2021.127829" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127829</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127829%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCurrent%252Bstatus%252Bin%252Bthe%252Bdiscovery%252Bof%252Bdual%252BBET%25252FHDAC%252Binhibitors%26aulast%3DRen%26aufirst%3DQinghua%26date%3D2021%26volume%3D38%26spage%3D127829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arshdeep  Singh</span>, <span class="hlFld-ContribAuthor ">Ting-Yu  Chang</span>, <span class="hlFld-ContribAuthor ">Navdeep  Kaur</span>, <span class="hlFld-ContribAuthor ">Kai-Cheng  Hsu</span>, <span class="hlFld-ContribAuthor ">Yun  Yen</span>, <span class="hlFld-ContribAuthor ">Tony Eight  Lin</span>, <span class="hlFld-ContribAuthor ">Mei-Jung  Lai</span>, <span class="hlFld-ContribAuthor ">Sung-Bau  Lee</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>215 </em>, 113169. <a href="https://doi.org/10.1016/j.ejmech.2021.113169" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113169%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCAP%252Brigidification%252Bof%252BMS-275%252Band%252Bchidamide%252Bleads%252Bto%252Benhanced%252Bantiproliferative%252Beffects%252Bmediated%252Bthrough%252BHDAC1%25252C%252B2%252Band%252Btubulin%252Bpolymerization%252Binhibition%26aulast%3DSingh%26aufirst%3DArshdeep%26date%3D2021%26volume%3D215%26spage%3D113169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandria M.  Chan</span>, <span class="hlFld-ContribAuthor ">Steven  Fletcher</span>. </span><span class="cited-content_cbyCitation_article-title">Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (2)
                                     , 178-196. <a href="https://doi.org/10.1039/D0MD00286K" title="DOI URL">https://doi.org/10.1039/D0MD00286K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00286K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00286K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DShifting%252Bthe%252Bparadigm%252Bin%252Btreating%252Bmulti-factorial%252Bdiseases%25253A%252Bpolypharmacological%252Bco-inhibitors%252Bof%252BHDAC6%26aulast%3DChan%26aufirst%3DAlexandria%2BM.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D2%26spage%3D178%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neha  Upadhyay</span>, <span class="hlFld-ContribAuthor ">Kalpana  Tilekar</span>, <span class="hlFld-ContribAuthor ">Fulvio  Loiodice</span>, <span class="hlFld-ContribAuthor ">Natalia Yu.  Anisimova</span>, <span class="hlFld-ContribAuthor ">Tatiana S.  Spirina</span>, <span class="hlFld-ContribAuthor ">Darina V.  Sokolova</span>, <span class="hlFld-ContribAuthor ">Galina B.  Smirnova</span>, <span class="hlFld-ContribAuthor ">Jun-yong  Choe</span>, <span class="hlFld-ContribAuthor ">Franz-Josef  Meyer-Almes</span>, <span class="hlFld-ContribAuthor ">Vadim S.  Pokrovsky</span>, <span class="hlFld-ContribAuthor ">Antonio  Lavecchia</span>, <span class="hlFld-ContribAuthor ">CS  Ramaa</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>107 </em>, 104527. <a href="https://doi.org/10.1016/j.bioorg.2020.104527" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104527%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPharmacophore%252Bhybridization%252Bapproach%252Bto%252Bdiscover%252Bnovel%252Bpyrazoline-based%252Bhydantoin%252Banalogs%252Bwith%252Banti-tumor%252Befficacy%26aulast%3DUpadhyay%26aufirst%3DNeha%26date%3D2021%26volume%3D107%26spage%3D104527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aleksandra  Majchrzak-Celińska</span>, <span class="hlFld-ContribAuthor ">Anna  Warych</span>, <span class="hlFld-ContribAuthor ">Mikołaj  Szoszkiewicz</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing. </span><span class="cited-content_cbyCitation_journal-name">Genes</span><span> <strong>2021,</strong> <em>12 </em>
                                    (2)
                                     , 208. <a href="https://doi.org/10.3390/genes12020208" title="DOI URL">https://doi.org/10.3390/genes12020208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/genes12020208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fgenes12020208%26sid%3Dliteratum%253Aachs%26jtitle%3DGenes%26atitle%3DNovel%252BApproaches%252Bto%252BEpigenetic%252BTherapies%25253A%252BFrom%252BDrug%252BCombinations%252Bto%252BEpigenetic%252BEditing%26aulast%3DMajchrzak-Celi%25C5%2584ska%26aufirst%3DAleksandra%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D2%26spage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinghua  Ren</span>, <span class="hlFld-ContribAuthor ">Wenqian  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Current status in the discovery of dual BET/HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127671. <a href="https://doi.org/10.1016/j.bmcl.2020.127671" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127671</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127671%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCurrent%252Bstatus%252Bin%252Bthe%252Bdiscovery%252Bof%252Bdual%252BBET%25252FHDAC%252Binhibitors%26aulast%3DRen%26aufirst%3DQinghua%26date%3D2021%26volume%3D31%26spage%3D127671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gargi Nikhil  Vaidya</span>, <span class="hlFld-ContribAuthor ">Pooja  Rana</span>, <span class="hlFld-ContribAuthor ">Ashwini  Venkatesh</span>, <span class="hlFld-ContribAuthor ">Deep Rohan  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Darshan  Contractor</span>, <span class="hlFld-ContribAuthor ">Dinesh Parshuram  Satpute</span>, <span class="hlFld-ContribAuthor ">Mithilesh  Nagpure</span>, <span class="hlFld-ContribAuthor ">Alok  Jain</span>, <span class="hlFld-ContribAuthor ">Dinesh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Paradigm shift of “classical” HDAC inhibitors to “hybrid” HDAC inhibitors in therapeutic interventions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112844. <a href="https://doi.org/10.1016/j.ejmech.2020.112844" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112844%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DParadigm%252Bshift%252Bof%252B%2525E2%252580%25259Cclassical%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bto%252B%2525E2%252580%25259Chybrid%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bin%252Btherapeutic%252Binterventions%26aulast%3DVaidya%26aufirst%3DGargi%2BNikhil%26date%3D2021%26volume%3D209%26spage%3D112844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amr K.A.  Bass</span>, <span class="hlFld-ContribAuthor ">Mona S.  El-Zoghbi</span>, <span class="hlFld-ContribAuthor ">El-Shimaa M.  Nageeb</span>, <span class="hlFld-ContribAuthor ">Mamdouh F.A.  Mohamed</span>, <span class="hlFld-ContribAuthor ">Mohamed  Badr</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112904. <a href="https://doi.org/10.1016/j.ejmech.2020.112904" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112904%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComprehensive%252Breview%252Bfor%252Banticancer%252Bhybridized%252Bmultitargeting%252BHDAC%252Binhibitors%26aulast%3DBass%26aufirst%3DAmr%2BK.A.%26date%3D2021%26volume%3D209%26spage%3D112904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vinayak  Palve</span>, <span class="hlFld-ContribAuthor ">Yi  Liao</span>, <span class="hlFld-ContribAuthor ">Lily L.  Remsing Rix</span>, <span class="hlFld-ContribAuthor ">Uwe  Rix</span>. </span><span class="cited-content_cbyCitation_article-title">Turning liabilities into opportunities: Off-target based drug repurposing in cancer. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>68 </em>, 209-229. <a href="https://doi.org/10.1016/j.semcancer.2020.02.003" title="DOI URL">https://doi.org/10.1016/j.semcancer.2020.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2020.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2020.02.003%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DTurning%252Bliabilities%252Binto%252Bopportunities%25253A%252BOff-target%252Bbased%252Bdrug%252Brepurposing%252Bin%252Bcancer%26aulast%3DPalve%26aufirst%3DVinayak%26date%3D2021%26volume%3D68%26spage%3D209%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Gao</span>, <span class="hlFld-ContribAuthor ">Hang  Zhang</span>, <span class="hlFld-ContribAuthor ">Frédéric  Lirussi</span>, <span class="hlFld-ContribAuthor ">Carmen  Garrido</span>, <span class="hlFld-ContribAuthor ">Xiang-Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Tian  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>182 </em>, 114224. <a href="https://doi.org/10.1016/j.bcp.2020.114224" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114224%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DDual%252Binhibitors%252Bof%252Bhistone%252Bdeacetylases%252Band%252Bother%252Bcancer-related%252Btargets%25253A%252BA%252Bpharmacological%252Bperspective%26aulast%3DGao%26aufirst%3DYuan%26date%3D2020%26volume%3D182%26spage%3D114224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaopeng  Peng</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Sun</span>, <span class="hlFld-ContribAuthor ">Peihua  Kuang</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112831. <a href="https://doi.org/10.1016/j.ejmech.2020.112831" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112831%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bon%252BHDAC%252Binhibitors%252Bwith%252Bdual%252Btargeting%252Bcapabilities%252Bfor%252Bcancer%252Btreatment%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2020%26volume%3D208%26spage%3D112831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernhard  Biersack</span>, <span class="hlFld-ContribAuthor ">Sibel  Polat</span>, <span class="hlFld-ContribAuthor ">Michael  Höpfner</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer properties of chimeric HDAC and kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2020,</strong> <em>184 </em><a href="https://doi.org/10.1016/j.semcancer.2020.11.005" title="DOI URL">https://doi.org/10.1016/j.semcancer.2020.11.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2020.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2020.11.005%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DAnticancer%252Bproperties%252Bof%252Bchimeric%252BHDAC%252Band%252Bkinase%252Binhibitors%26aulast%3DBiersack%26aufirst%3DBernhard%26date%3D2020%26volume%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Subhasish  Tapadar</span>, <span class="hlFld-ContribAuthor ">Shaghayegh  Fathi</span>, <span class="hlFld-ContribAuthor ">Bocheng  Wu</span>, <span class="hlFld-ContribAuthor ">Carrie Q.  Sun</span>, <span class="hlFld-ContribAuthor ">Idris  Raji</span>, <span class="hlFld-ContribAuthor ">Samuel G.  Moore</span>, <span class="hlFld-ContribAuthor ">Rebecca S.  Arnold</span>, <span class="hlFld-ContribAuthor ">David A.  Gaul</span>, <span class="hlFld-ContribAuthor ">John A.  Petros</span>, <span class="hlFld-ContribAuthor ">Adegboyega K.  Oyelere</span>. </span><span class="cited-content_cbyCitation_article-title">Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (11)
                                     , 3095. <a href="https://doi.org/10.3390/cancers12113095" title="DOI URL">https://doi.org/10.3390/cancers12113095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12113095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12113095%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DLiver-Targeting%252BClass%252BI%252BSelective%252BHistone%252BDeacetylase%252BInhibitors%252BPotently%252BSuppress%252BHepatocellular%252BTumor%252BGrowth%252Bas%252BStandalone%252BAgents%26aulast%3DTapadar%26aufirst%3DSubhasish%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D11%26spage%3D3095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua P.  Smalley</span>, <span class="hlFld-ContribAuthor ">Shaun M.  Cowley</span>, <span class="hlFld-ContribAuthor ">James T.  Hodgkinson</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional HDAC Therapeutics: One Drug to Rule Them All?. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (19)
                                     , 4394. <a href="https://doi.org/10.3390/molecules25194394" title="DOI URL">https://doi.org/10.3390/molecules25194394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25194394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25194394%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBifunctional%252BHDAC%252BTherapeutics%25253A%252BOne%252BDrug%252Bto%252BRule%252BThem%252BAll%25253F%26aulast%3DSmalley%26aufirst%3DJoshua%2BP.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D19%26spage%3D4394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel R.  de Lera</span>, <span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Two-hit wonders: The expanding universe of multitargeting epigenetic agents. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>57 </em>, 135-154. <a href="https://doi.org/10.1016/j.cbpa.2020.05.009" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTwo-hit%252Bwonders%25253A%252BThe%252Bexpanding%252Buniverse%252Bof%252Bmultitargeting%252Bepigenetic%252Bagents%26aulast%3Dde%2BLera%26aufirst%3DAngel%2BR.%26date%3D2020%26volume%3D57%26spage%3D135%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing  Hao</span>, <span class="hlFld-ContribAuthor ">Wen  Xing</span>, <span class="hlFld-ContribAuthor ">Jiajia  Yuan</span>, <span class="hlFld-ContribAuthor ">Yingshao  Wang</span>, <span class="hlFld-ContribAuthor ">Jiaojiao  Bai</span>, <span class="hlFld-ContribAuthor ">Jie  Bai</span>, <span class="hlFld-ContribAuthor ">Yuan  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2020,</strong> <em>38 </em>
                                    (3)
                                     , 610-620. <a href="https://doi.org/10.1007/s10637-019-00794-4" title="DOI URL">https://doi.org/10.1007/s10637-019-00794-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-019-00794-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-019-00794-4%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DCotargeting%252Bthe%252BJAK%25252FSTAT%252Bsignaling%252Bpathway%252Band%252Bhistone%252Bdeacetylase%252Bby%252Bruxolitinib%252Band%252Bvorinostat%252Belicits%252Bsynergistic%252Beffects%252Bagainst%252Bmyeloproliferative%252Bneoplasms%26aulast%3DHao%26aufirst%3DXing%26date%3D2020%26date%3D2019%26volume%3D38%26issue%3D3%26spage%3D610%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunlong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hang  Dong</span>, <span class="hlFld-ContribAuthor ">Qifu  Xu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (4)
                                     , 263-274. <a href="https://doi.org/10.1080/13543776.2020.1725470" title="DOI URL">https://doi.org/10.1080/13543776.2020.1725470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1725470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1725470%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DHistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitors%252Bin%252Bcancer%25253A%252Ba%252Bpatent%252Breview%252B%2525282017-present%252529%26aulast%3DZhao%26aufirst%3DChunlong%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D4%26spage%3D263%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaorui  Xie</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Yunfei  Wei</span>, <span class="hlFld-ContribAuthor ">Heliang  Du</span>, <span class="hlFld-ContribAuthor ">Yuanbo  Xu</span>, <span class="hlFld-ContribAuthor ">Qihao  Xu</span>, <span class="hlFld-ContribAuthor ">Yongkui  Jing</span>, <span class="hlFld-ContribAuthor ">Linxiang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 111991. <a href="https://doi.org/10.1016/j.ejmech.2019.111991" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111991</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111991%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252B18%2525CE%2525B2-glycyrrhetinic%252Bacid%252Bconjugate%252Bwith%252BVorinostat%252Bdegrades%252BHDAC3%252Band%252BHDAC6%252Bwith%252Bimproved%252Bantitumor%252Beffects%26aulast%3DHuang%26aufirst%3DMin%26date%3D2020%26volume%3D188%26spage%3D111991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Uttara  Soumyanarayanan</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Shozeb  Haider</span>, <span class="hlFld-ContribAuthor ">Adina Huey  Fang Nee</span>, <span class="hlFld-ContribAuthor ">Jie Xin  Tong</span>, <span class="hlFld-ContribAuthor ">Kevin S.W.  Tan</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>184 </em>, 111755. <a href="https://doi.org/10.1016/j.ejmech.2019.111755" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111755</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111755%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252Bpotent%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252B3%25252F6%252Bselective%252Bdual%252Binhibitor%26aulast%3DSoumyanarayanan%26aufirst%3DUttara%26date%3D2019%26volume%3D184%26spage%3D111755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fotios  Tsopelas</span>, <span class="hlFld-ContribAuthor ">Anna  Tsantili-Kakoulidou</span>. </span><span class="cited-content_cbyCitation_article-title">Advances with weak affinity chromatography for fragment screening. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2019,</strong> <em>14 </em>
                                    (11)
                                     , 1125-1135. <a href="https://doi.org/10.1080/17460441.2019.1648425" title="DOI URL">https://doi.org/10.1080/17460441.2019.1648425</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2019.1648425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2019.1648425%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAdvances%252Bwith%252Bweak%252Baffinity%252Bchromatography%252Bfor%252Bfragment%252Bscreening%26aulast%3DTsopelas%26aufirst%3DFotios%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D11%26spage%3D1125%26epage%3D1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuewu  Liang</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (15)
                                     , 1849-1852. <a href="https://doi.org/10.4155/fmc-2019-0168" title="DOI URL">https://doi.org/10.4155/fmc-2019-0168</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0168%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DNovel-targeted%252Btherapy%252Bfor%252Bhematological%252Bmalignancies%252Bwith%252BJAK%252Band%252BHDAC%252Bdual%252Binhibitors%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2019%26volume%3D11%26issue%3D15%26spage%3D1849%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takashi  Tsuji</span>, <span class="hlFld-ContribAuthor ">Mitsuhiro  Yamaguchi</span>, <span class="hlFld-ContribAuthor ">Junichi  Kuroyanagi</span>, <span class="hlFld-ContribAuthor ">Shinji  Furuzono</span>, <span class="hlFld-ContribAuthor ">Masahiro  Konishi</span>, <span class="hlFld-ContribAuthor ">Koji  Terayama</span>, <span class="hlFld-ContribAuthor ">Jun  Tanaka</span>, <span class="hlFld-ContribAuthor ">Motoko  Saito</span>, <span class="hlFld-ContribAuthor ">Yoshiyuki  Kobayashi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel pyridazine derivatives as glucose transporter type 4 (GLUT4) translocation activators. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (14)
                                     , 1785-1790. <a href="https://doi.org/10.1016/j.bmcl.2019.05.013" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.05.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.05.013%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252Bpyridazine%252Bderivatives%252Bas%252Bglucose%252Btransporter%252Btype%252B4%252B%252528GLUT4%252529%252Btranslocation%252Bactivators%26aulast%3DTsuji%26aufirst%3DTakashi%26date%3D2019%26volume%3D29%26issue%3D14%26spage%3D1785%26epage%3D1790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feifei  Yang</span>, <span class="hlFld-ContribAuthor ">Na  Zhao</span>, <span class="hlFld-ContribAuthor ">Di  Ge</span>, <span class="hlFld-ContribAuthor ">Yihua  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Next-generation of selective histone deacetylase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (34)
                                     , 19571-19583. <a href="https://doi.org/10.1039/C9RA02985K" title="DOI URL">https://doi.org/10.1039/C9RA02985K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA02985K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA02985K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DNext-generation%252Bof%252Bselective%252Bhistone%252Bdeacetylase%252Binhibitors%26aulast%3DYang%26aufirst%3DFeifei%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D34%26spage%3D19571%26epage%3D19583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chu  Tang</span>, <span class="hlFld-ContribAuthor ">Yang  Du</span>, <span class="hlFld-ContribAuthor ">Qian  Liang</span>, <span class="hlFld-ContribAuthor ">Zhen  Cheng</span>, <span class="hlFld-ContribAuthor ">Jie  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">A selenium-containing selective histone deacetylase 6 inhibitor for targeted
              in vivo
              breast tumor imaging and therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Materials Chemistry B</span><span> <strong>2019,</strong> <em>7 </em>
                                    (22)
                                     , 3528-3536. <a href="https://doi.org/10.1039/C9TB00383E" title="DOI URL">https://doi.org/10.1039/C9TB00383E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9TB00383E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9TB00383E%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Materials%2520Chemistry%2520B%26atitle%3DA%252Bselenium-containing%252Bselective%252Bhistone%252Bdeacetylase%252B6%252Binhibitor%252Bfor%252Btargeted%252Bin%252Bvivo%252Bbreast%252Btumor%252Bimaging%252Band%252Btherapy%26aulast%3DTang%26aufirst%3DChu%26date%3D2019%26date%3D2019%26volume%3D7%26issue%3D22%26spage%3D3528%26epage%3D3536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulia  Stazi</span>, <span class="hlFld-ContribAuthor ">Rossella  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>, <span class="hlFld-ContribAuthor ">Andrea  Mattevi</span>, <span class="hlFld-ContribAuthor ">Sergio  Valente</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2019,</strong> <em>50 </em>, 89-100. <a href="https://doi.org/10.1016/j.cbpa.2019.03.002" title="DOI URL">https://doi.org/10.1016/j.cbpa.2019.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2019.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2019.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DHistone%252Bdeacetylases%252Bas%252Ban%252Bepigenetic%252Bpillar%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bhybrid%252Binhibitors%252Bin%252Bcancer%26aulast%3DStazi%26aufirst%3DGiulia%26date%3D2019%26volume%3D50%26spage%3D89%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephanie  Guerra</span>, <span class="hlFld-ContribAuthor ">Karen  Cichowski</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Cancer at the Intersection of Signaling and Epigenetics. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Cancer Biology</span><span> <strong>2019,</strong> <em>3 </em>
                                    (1)
                                     , 365-384. <a href="https://doi.org/10.1146/annurev-cancerbio-030617-050400" title="DOI URL">https://doi.org/10.1146/annurev-cancerbio-030617-050400</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-cancerbio-030617-050400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-cancerbio-030617-050400%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Cancer%2520Biology%26atitle%3DTargeting%252BCancer%252Bat%252Bthe%252BIntersection%252Bof%252BSignaling%252Band%252BEpigenetics%26aulast%3DGuerra%26aufirst%3DStephanie%26date%3D2019%26volume%3D3%26issue%3D1%26spage%3D365%26epage%3D384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-yi  Chu-Farseeva</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Eng Chong  Tan</span>, <span class="hlFld-ContribAuthor ">Jeffrey J.Y.  Yen</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 593-619. <a href="https://doi.org/10.1016/j.ejmech.2018.09.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bpotent%252Bdual%252Binhibitors%252Bof%252BJAK2%252Band%252BHDAC%252Bbased%252Bon%252Bfusing%252Bthe%252Bpharmacophores%252Bof%252BXL019%252Band%252Bvorinostat%26aulast%3DChu-Farseeva%26aufirst%3DYu-yi%26date%3D2018%26volume%3D158%26spage%3D593%26epage%3D619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heba M.  Hesham</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (6)
                                     , 2058-2109. <a href="https://doi.org/10.1002/med.21505" title="DOI URL">https://doi.org/10.1002/med.21505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21505%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DChimeric%252BHDAC%252Binhibitors%25253A%252BComprehensive%252Breview%252Bon%252Bthe%252BHDAC-based%252Bstrategies%252Bdeveloped%252Bto%252Bcombat%252Bcancer%26aulast%3DHesham%26aufirst%3DHeba%2BM.%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D6%26spage%3D2058%26epage%3D2109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiwei  Chen</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Wenlu  Li</span>, <span class="hlFld-ContribAuthor ">Jingxian  Yin</span>, <span class="hlFld-ContribAuthor ">Yueying  Zhang</span>, <span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Chunmei  Gao</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (14)
                                     , 3958-3966. <a href="https://doi.org/10.1016/j.bmc.2018.06.016" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.06.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.06.016%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Banticancer%252Bevaluation%252Bof%252Bacridine%252Bhydroxamic%252Bacid%252Bderivatives%252Bas%252Bdual%252BTopo%252Band%252BHDAC%252Binhibitors%26aulast%3DChen%26aufirst%3DJiwei%26date%3D2018%26volume%3D26%26issue%3D14%26spage%3D3958%26epage%3D3966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sten  Ohlson</span>, <span class="hlFld-ContribAuthor ">Minh-Dao  Duong-Thi</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment screening for drug leads by weak affinity chromatography (WAC-MS). </span><span class="cited-content_cbyCitation_journal-name">Methods</span><span> <strong>2018,</strong> <em>146 </em>, 26-38. <a href="https://doi.org/10.1016/j.ymeth.2018.01.011" title="DOI URL">https://doi.org/10.1016/j.ymeth.2018.01.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ymeth.2018.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ymeth.2018.01.011%26sid%3Dliteratum%253Aachs%26jtitle%3DMethods%26atitle%3DFragment%252Bscreening%252Bfor%252Bdrug%252Bleads%252Bby%252Bweak%252Baffinity%252Bchromatography%252B%252528WAC-MS%252529%26aulast%3DOhlson%26aufirst%3DSten%26date%3D2018%26volume%3D146%26spage%3D26%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianbin  Yao</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Sten  Ohlson</span>, <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (15)
                                     , 2636-2640. <a href="https://doi.org/10.1016/j.bmcl.2018.06.037" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.06.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.06.037%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMerging%252Bof%252Bruxolitinib%252Band%252Bvorinostat%252Bleads%252Bto%252Bhighly%252Bpotent%252Binhibitors%252Bof%252BJAK2%252Band%252Bhistone%252Bdeacetylase%252B6%252B%252528HDAC6%252529%26aulast%3DYao%26aufirst%3DLianbin%26date%3D2018%26volume%3D28%26issue%3D15%26spage%3D2636%26epage%3D2640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahmud  Hasan</span>, <span class="hlFld-ContribAuthor ">Rehana K.  Leak</span>, <span class="hlFld-ContribAuthor ">Robert E.  Stratford</span>, <span class="hlFld-ContribAuthor ">Darius P.  Zlotos</span>, <span class="hlFld-ContribAuthor ">Paula A.  Witt-Enderby</span>. </span><span class="cited-content_cbyCitation_article-title">Drug conjugates-an emerging approach to treat breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology Research & Perspectives</span><span> <strong>2018,</strong> <em>6 </em>
                                    (4)
                                     , e00417. <a href="https://doi.org/10.1002/prp2.417" title="DOI URL">https://doi.org/10.1002/prp2.417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/prp2.417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fprp2.417%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520Research%2520%2526%2520Perspectives%26atitle%3DDrug%252Bconjugates-an%252Bemerging%252Bapproach%252Bto%252Btreat%252Bbreast%252Bcancer%26aulast%3DHasan%26aufirst%3DMahmud%26date%3D2018%26date%3D2018%26volume%3D6%26issue%3D4%26spage%3De00417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianbin  Yao</span>, <span class="hlFld-ContribAuthor ">Sten  Ohlson</span>, <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (8)
                                     , 1357-1362. <a href="https://doi.org/10.1016/j.bmcl.2018.03.009" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.03.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.03.009%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Btriple%252Binhibitors%252Bof%252Bjanus%252Bkinase%252B%252528JAK%252529%25252C%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Band%252BHeat%252BShock%252BProtein%252B90%252B%252528HSP90%252529%26aulast%3DYao%26aufirst%3DLianbin%26date%3D2018%26volume%3D28%26issue%3D8%26spage%3D1357%26epage%3D1362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of pan-HDAC inhibitor <b>2</b> (vorinostat, SAHA),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> the JAK1/2 selective inhibitor <b>1</b> (ruxolitinib, INCB018424),<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and the JAK2-HDAC dual inhibitor <b>3</b> (EY3238).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic showing design of a merged JAK-HDAC pharmacophore taking advantage of the solvent binding channel in JAK1/2 and the probable interactions to be gained by a merged inhibitor at the entrance to the HDAC substrate binding pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Compounds <b>4</b>–<b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, rt, overnight, 81–97% (note: <b>8</b> is isolated as an ethyl ester from ethyl 6-bromohexanoate); (b) LiBF<sub>4</sub>, MeCN, reflux, 24 h, 50%; (c) (i) LiOH, THF/H<sub>2</sub>O, rt, overnight; (ii) <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, HOBT, EDC, Et<sub>3</sub>N, DMSO, rt, overnight, 21–74%; (d) TBAF, MeCN, reflux, 48 h, 64–73%; (e) HCl/dioxane, THF, rt, overnight, 55–93%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>27</b>–<b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>A</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 16 h, 75%; (b) (i) <b>B</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 18 h, 89%; (ii) 1 M HCl, acetone, 55 °C, used crude; (c) (i) H<sub>2</sub>SO<sub>4</sub>, EtOAc, DCM, rt, overnight, 98%; (ii) <b>C</b>, HATU, Et<sub>3</sub>N, DMF, 60 °C, 24 h, 82%; (d) (i) LiOH, THF/H<sub>2</sub>O, rt, 16 h; (ii) <b>D</b>, HATU, DIPEA, DMF, 60 °C, 24 h, 57% (2 steps); (e) <b>D</b>, NaBH<sub>3</sub>CN, MeOH, rt, 16 h, 76%; (f) (i) LiOH, THF/H<sub>2</sub>O, rt, 16 h; (ii) <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, HATU, Et<sub>3</sub>N, DMF, rt, 16 h, 23–48% (2 steps); (g) HCl/dioxane, THF, rt, 16 h, 23–61%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compounds <b>39</b>–<b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>E</b>, NaBH<sub>3</sub>CN, MeOH, rt, 16 h, 71%; (b) (i) LiOH, THF/H<sub>2</sub>O, rt, 16 h; (ii) <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, HATU, Et<sub>3</sub>N, DMF, rt, 16 h, 57% (2 steps); (c) HCl/dioxane, 1,4-dioxane, rt, 16 h, 90%.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0013.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Compound <b>45</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>42</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, overnight; (b) (i) LiOH, THF/H<sub>2</sub>O, 50 °C, 24 h; (ii) <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, HATU, Et<sub>3</sub>N, DMF, rt, overnight; (c) HCl/dioxane, dioxane, rt, overnight.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>24</b> docked into a homology model of the second catalytic domain of HDAC6. Compound <b>24</b> is shown in stick with green carbon and the catalytic zinc in magenta CPK representation. HDAC6 is shown as a turquoise cartoon with selected residues in thin stick with gray carbon (left) and with an electrostatic surface (right). The hydroxamic acid coordinates to the catalytic zinc and forms three additional hydrogen bonds to the side chains of Tyr782, His610, and His611. The pyrrolopyrimidine and pyrazole have hydrophobic interactions with the surface residues His500, Pro501, and Phe620.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>24</b> docked into HDAC1. Compound <b>24</b> is shown in stick with green carbon and the catalytic zinc in magenta CPK representation. HDAC1 is shown as a turquoise cartoon with selected residues in thin stick with gray carbon (left) and with an electrostatic surface (right). The hydroxamic acid coordinates to the catalytic zinc and forms two additional hydrogen bonds to the side chains of Tyr303 and His141.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>24</b> docked into JAK1. Compound <b>24</b> is shown with green carbon in stick representation. JAK1 is shown as a turquoise cartoon with selected residues in thin stick with gray carbon (left) and with an electrostatic surface (right). The pyrrolopyrimidine forms hydrogen bonds to the backbone of the kinase hinge residues Glu957 and Leu959. The methylene chain extends under the glycine-rich loop with the hydroxamic acid extending out of the binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>24</b> docked into JAK2. Compound <b>24</b> is shown with green carbon in stick representation. JAK2 is shown as a turquoise cartoon with selected residues in thin stick with gray carbon (left) and with an electrostatic surface (right). The pyrrolopyrimidine forms hydrogen bonds to the backbone of the kinase hinge residues Glu930 and Leu932. The methylene chain extends under the glycine-rich loop with the hydroxamic acid extending out of the binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0001.jpeg" id="rightTab-GRAPHIC-d129e2426-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Kinase Panel Screening Data of Compound <b>24</b> against 97 Kinases (DiscoveRx) Tested at a Concentraiton of 1 μM<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Chart a</span>The TREE<i>spot</i> map indicates the very high selectivity of compound <b>24</b>. From 90 nonmutated kinases only 7 were hit with <35% of control binding remaining (approximately equates to an IC<sub>50</sub> of around 10 μM). “<i>S</i>” scores are all less than 0.1, indicating a high degree of kinase selectivity.</p></p></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>24</b> effectively blocks dual signaling pathways in MM and AML cell lines. (A) KMS-12-BM and (B) MOLM-14 were treated with <b>24</b> at the respective concentrations for 16 h. After lysis, acetylated tubulin (Ac-tubulin) and acetylated histone 3 (Ac-H3) were detected by immunoblotting. Subsequently, as a loading control the same membranes were reprobed with tubulin and H3, respectively. Compound <b>2</b> was used as a postive control for the inhibtion of HDACs. (C) KMS-12-BM and (D) MOLM-14 were pretreated with <b>24</b> for 3 h and then were treated with 10 ng/mL of IL-6 for 15 min. Compound <b>1</b> was used as a positive control for the inhibition of the JAK2 pathway at 3 μM (sub-IC<sub>50</sub> concentration). After lysis, p-STAT3 was detected by immunoblotting. The same membranes were reprobed with STAT3 to detect total protein levels. (E) KMS-12-BM and (F) MOLM-14 cells were treated with <b>24</b> at the respective concentrations for 24 h and then lysed. Tubastatin and <b>1</b> were utilized as negative and positive controls, respectively. Cleaved PARP was detected by immunoblotting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/medium/jm-2017-006785_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Pharmacokinetics of <b>24</b> in Wistar rats. (A) Semilogarithmic plot of mean plasma concentration versus time following a single iv dose of 1 mg/kg and oral dose of 5 mg/kg. Error bars are ± SEM. (B) Intravenous PK parameters. (C) Oral PK parameters.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00678/20171020/images/large/jm-2017-006785_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00678&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i88">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86850" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86850" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 48 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Stewart, B. W.; Wild, C. P.</span> <span class="citation_source-book">World Cancer Report 2014</span>. <span class="NLM_publisher-name">World Health Organization, International Agency for Research on Cancer</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=B.+W.+Stewart&author=C.+P.+Wild&title=World+Cancer+Report+2014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DB.%2BW.%26btitle%3DWorld%2520Cancer%2520Report%25202014%26pub%3DWorld%2520Health%2520Organization%252C%2520International%2520Agency%2520for%2520Research%2520on%2520Cancer%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Combinatorial drug therapy for cancer in the post-genomic era</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">692</span><span class="refDoi"> DOI: 10.1038/nbt.2284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2Fnbt.2284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=22781697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=679-692&author=B.+Al-Lazikaniauthor=U.+Banerjiauthor=P.+Workman&title=Combinatorial+drug+therapy+for+cancer+in+the+post-genomic+era&doi=10.1038%2Fnbt.2284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial drug therapy for cancer in the post-genomic era</span></div><div class="casAuthors">Al-Lazikani, Bissan; Banerji, Udai; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted.  Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups.  This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach.  However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility.  One soln. to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon5IOOPfsgR7Vg90H21EOLACvtfcHk0lgiw6Jjtdp4pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGmtLg%253D&md5=a61b1b222a7146a92366f57cb0e708ca</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2284%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DCombinatorial%2520drug%2520therapy%2520for%2520cancer%2520in%2520the%2520post-genomic%2520era%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D679%26epage%3D692%26doi%3D10.1038%2Fnbt.2284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7887</span><span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lgk4nGYEhliFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Kiu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, S. E.</span><span> </span><span class="NLM_article-title">Biology and significance of the JAK/STAT signalling pathways</span> <span class="citation_source-journal">Growth Factors</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.3109/08977194.2012.660936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.3109%2F08977194.2012.660936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=22339650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVahtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=88-106&author=H.+Kiuauthor=S.+E.+Nicholson&title=Biology+and+significance+of+the+JAK%2FSTAT+signalling+pathways&doi=10.3109%2F08977194.2012.660936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and significance of the JAK/STAT signalling pathways</span></div><div class="casAuthors">Kiu, Hiu; Nicholson, Sandra E.</div><div class="citationInfo"><span class="NLM_cas:title">Growth Factors</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">88-106</span>CODEN:
                <span class="NLM_cas:coden">GRFAEC</span>;
        ISSN:<span class="NLM_cas:issn">0897-7194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Since its discovery 2 decades ago, the activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway by numerous cytokines and growth factors has resulted in it becoming 1 of the most well-studied intracellular signaling networks.  The field has progressed from the identification of the individual components to high-resoln. crystal structures of both JAK and STAT, and an understanding of the complexities of the mol. activation and deactivation cycle which results in a diverse, yet highly specific and regulated pattern of transcriptional responses.  While there is still more to learn, we now appreciate how disruption and deregulation of this pathway can result in clin. disease and look forward to adoption of the next generation of JAK inhibitors in routine clin. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM2feFVqfQ77Vg90H21EOLACvtfcHk0lgk4nGYEhliFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVahtbo%253D&md5=d81b34c514392de2c2179229633e9a55</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3109%2F08977194.2012.660936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08977194.2012.660936%26sid%3Dliteratum%253Aachs%26aulast%3DKiu%26aufirst%3DH.%26aulast%3DNicholson%26aufirst%3DS.%2BE.%26atitle%3DBiology%2520and%2520significance%2520of%2520the%2520JAK%252FSTAT%2520signalling%2520pathways%26jtitle%3DGrowth%2520Factors%26date%3D2012%26volume%3D30%26spage%3D88%26epage%3D106%26doi%3D10.3109%2F08977194.2012.660936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Harrison, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiladjian, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Ali, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gisslinger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltzman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stalbovskaya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuitty, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoops, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vannucchi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barosi, G.</span><span> </span><span class="NLM_article-title">JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">787</span><span class="NLM_x">–</span> <span class="NLM_lpage">798</span><span class="refDoi"> DOI: 10.1056/NEJMoa1110556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1056%2FNEJMoa1110556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=22375970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2qurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=787-798&author=C.+Harrisonauthor=J.+J.+Kiladjianauthor=H.+K.+Al-Aliauthor=H.+Gisslingerauthor=R.+Waltzmanauthor=V.+Stalbovskayaauthor=M.+McQuittyauthor=D.+S.+Hunterauthor=R.+Levyauthor=L.+Knoopsauthor=F.+Cervantesauthor=A.+M.+Vannucchiauthor=T.+Barbuiauthor=G.+Barosi&title=JAK+inhibition+with+ruxolitinib+versus+best+available+therapy+for+myelofibrosis&doi=10.1056%2FNEJMoa1110556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</span></div><div class="casAuthors">Harrison, Claire; Kiladjian, Jean-Jacques; Al-Ali, Haifa Kathrin; Gisslinger, Heinz; Waltzman, Roger; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah S.; Levy, Richard; Knoops, Laurent; Cervantes, Francisco; Vannucchi, Alessandro M.; Barbui, Tiziano; Barosi, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">787-798</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Treatment options for myelofibrosis are limited.  We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis.  METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy.  The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% redn. in spleen vol. at week 48 and at week 24, resp., as assessed with the use of magnetic resonance imaging or computed tomog.  RESULTS: A total of 28% of the patients in the ruxolitinib group had at least a 35% redn. in spleen vol. at week 48, as compared with 0% in the group receiving the best available therapy (P<0.001); the corresponding percentages at week 24 were 32% and 0% (P<0.001).  At 48 wk, the mean palpable spleen length had decreased by 56% with ruxolitinib but had increased by 4% with the best available therapy.  The median duration of response with ruxolitinib was not reached, with 80% of patients still having a response at a median follow-up of 12 mo.  Patients in the ruxolitinib group had an improvement in overall quality-of-life measures and a redn. in symptoms assocd. with myelofibrosis.  The most common hematol. abnormalities of grade 3 or higher in either group were thrombocytopenia and anemia, which were managed with a dose redn., interruption of treatment, or transfusion.  One patient in each group discontinued treatment owing to thrombocytopenia, and none discontinued owing to anemia.  Nonhematol. adverse events were rare and mostly grade 1 or 2.  Two cases of acute myeloid leukemia were reported with the best available therapy.  CONCLUSIONS: Continuous ruxolitinib therapy, as compared with the best available therapy, was assocd. with marked and durable redns. in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.  An influence on overall survival has not yet been shown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP7WEm5MUTc7Vg90H21EOLACvtfcHk0lgRkddBRCB6LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2qurs%253D&md5=80494b8923fa49536383523066b22b19</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1110556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1110556%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DKiladjian%26aufirst%3DJ.%2BJ.%26aulast%3DAl-Ali%26aufirst%3DH.%2BK.%26aulast%3DGisslinger%26aufirst%3DH.%26aulast%3DWaltzman%26aufirst%3DR.%26aulast%3DStalbovskaya%26aufirst%3DV.%26aulast%3DMcQuitty%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DD.%2BS.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DKnoops%26aufirst%3DL.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DBarbui%26aufirst%3DT.%26aulast%3DBarosi%26aufirst%3DG.%26atitle%3DJAK%2520inhibition%2520with%2520ruxolitinib%2520versus%2520best%2520available%2520therapy%2520for%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D787%26epage%3D798%26doi%3D10.1056%2FNEJMoa1110556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span> </span><span class="NLM_article-title">Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span><span class="refDoi"> DOI: 10.1124/jpet.113.209304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1124%2Fjpet.113.209304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=24218541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=165-173&author=M.+E.+Dowtyauthor=M.+I.+Jessonauthor=S.+Ghoshauthor=J.+Leeauthor=D.+M.+Meyerauthor=S.+Krishnaswamiauthor=N.+Kishore&title=Preclinical+to+clinical+translation+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+in+rheumatoid+arthritis&doi=10.1124%2Fjpet.113.209304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis</span></div><div class="casAuthors">Dowty, Martin E.; Jesson, Michael I.; Ghosh, Sarbani; Lee, Jamie; Meyer, Debra M.; Krishnaswami, Sriram; Kishore, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-173, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A crit. piece in the translation of preclin. studies to clin. trials is the detn. of dosing regimens that allow max. therapeutic benefit with min. toxicity.  The preclin. pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clin. PK/PD data from patients with rheumatoid arthritis (RA).  Preclin. evaluations included target modulation and PK/PD modeling based on continuous s.c. infusion or oral once- or twice-daily (BID) dosing paradigms in mice.  The human PK/PD profile was obtained from pooled data from four phase 2 studies in patients with RA, and maximal effect models were used to evaluate efficacy after 12 wk of tofacitinib treatment (1-15 mg BID).  In mCIA, the main driver of efficacy was inhibition of cytokine receptor signaling mediated by JAK1 heterodimers, but not JAK2 homodimers, and continuous daily inhibition was not required to maintain efficacy.  Projected efficacy could be predicted from total daily exposure irresp. of the oral dosing paradigm, with a total steady-state plasma concn. achieving 50% of the maximal response (Cave50) of ∼100 nM.  Tofacitinib potency (ED50) in clin. studies was ∼3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of ∼40 nM, derived using Disease Activity Scores from patients with RA.  The collective clin. and preclin. data indicated the importance of Cave as a driver of efficacy, rather than max. or min. plasma concn. (Cmax or Cmin), where Cave50 values were within ∼2-fold of each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDs-lnT0HFF7Vg90H21EOLACvtfcHk0lgRkddBRCB6LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D&md5=faed45ef8eabb5e1bde0819702f26ffa</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.209304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.209304%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DKishore%26aufirst%3DN.%26atitle%3DPreclinical%2520to%2520clinical%2520translation%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D165%26epage%3D173%26doi%3D10.1124%2Fjpet.113.209304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Kim, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.-s.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, Y.</span><span> </span><span class="NLM_article-title">Benzimidazole derivatives as potent JAK1-selective inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7596</span><span class="NLM_x">–</span> <span class="NLM_lpage">7602</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7596-7602&author=M.+K.+Kimauthor=H.+Shinauthor=K.-s.+Parkauthor=H.+Kimauthor=J.+Parkauthor=K.+Kimauthor=J.+Namauthor=H.+Chooauthor=Y.+Chong&title=Benzimidazole+derivatives+as+potent+JAK1-selective+inhibitors&doi=10.1021%2Facs.jmedchem.5b01263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01263%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DShin%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DK.-s.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DNam%26aufirst%3DJ.%26aulast%3DChoo%26aufirst%3DH.%26aulast%3DChong%26aufirst%3DY.%26atitle%3DBenzimidazole%2520derivatives%2520as%2520potent%2520JAK1-selective%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7596%26epage%3D7602%26doi%3D10.1021%2Facs.jmedchem.5b01263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu-Farseeva, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span> </span><span class="NLM_article-title">Selective JAK inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1439</span><span class="NLM_x">–</span> <span class="NLM_lpage">1471</span><span class="refDoi"> DOI: 10.4155/fmc.14.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.4155%2Ffmc.14.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=25329199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1439-1471&author=B.+W.+Dymockauthor=E.+G.+Yangauthor=Y.+Chu-Farseevaauthor=L.+Yao&title=Selective+JAK+inhibitors&doi=10.4155%2Ffmc.14.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Selective JAK inhibitors</span></div><div class="casAuthors">Dymock, Brian W.; Yang, Eugene Guorong; Chu-Farseeva, Yuyi; Yao, Lianbin</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1471</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders.  Recent progress in the discovery of selective inhibitors has been significant, with selective compds. now reported for each isoform.  This article summarizes the current state-of-the-art with a discussion of the most recently described selective compds.  X-ray co-crystal structures reveal the mol. reasons for the obsd. biochem. selectivity.  A concluding anal. of JAK inhibitors in the clinic highlights increased clin. trial activity and diversity of indications.  Selective JAK inhibitors, as single agents or in combination regimens, have a very promising future in the treatment of oncol., immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6G9eFT7Ww27Vg90H21EOLACvtfcHk0lgkKZDga6RHkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jI&md5=343aa75228918e6e4e063adb1fed96f1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.92%26sid%3Dliteratum%253Aachs%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DChu-Farseeva%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DL.%26atitle%3DSelective%2520JAK%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1439%26epage%3D1471%26doi%3D10.4155%2Ffmc.14.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gao, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F. J.</span><span> </span><span class="NLM_article-title">Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms</span> <span class="citation_source-journal">Exp. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1016/j.exphem.2012.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.exphem.2012.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=23111066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVKnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=261-270&author=S.+M.+Gaoauthor=C.+Q.+Chenauthor=L.+Y.+Wangauthor=L.+L.+Hongauthor=J.+B.+Wuauthor=P.+H.+Dongauthor=F.+J.+Yu&title=Histone+deacetylases+inhibitor+sodium+butyrate+inhibits+JAK2%2FSTAT+signaling+through+upregulation+of+SOCS1+and+SOCS3+mediated+by+HDAC8+inhibition+in+myeloproliferative+neoplasms&doi=10.1016%2Fj.exphem.2012.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms</span></div><div class="casAuthors">Gao, Shen-meng; Chen, Chi-qi; Wang, Lu-yao; Hong, Li-li; Wu, Jian-bo; Dong, Pei-hong; Yu, Fu-jun</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-270.e4</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Constitutive activation of Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) signaling has an important role in the oncogenesis of myeloproliferative neoplasms (MPNs) and leukemia.  Histone deacetylases (HDACs) inhibitors have been reported to possess anticancer activity through different mechanisms.  However, whether HDACs inhibitors suppress JAK2/STAT signaling in MPNs is still unknown.  In this study, we show that the HDAC inhibitor sodium butyrate (SB) inhibited JAK2/STAT signaling and increased the expression of suppressors of cytokine signaling 1 (SOCS1) and SOCS3, both of which are the potent feedback inhibitors of JAK2/STAT signaling.  SB upregulated the expression of SOCS1 and SOCS3 by triggering the promoter-assocd. histone acetylation of SOCS1 and SOCS3 in K562 and HEL cell lines.  Importantly, we found that upon knockdown of each class I HDACs, only knockdown of HDAC8 resulted in the increased expression of SOCS1 and SOCS3.  Moreover, overexpression of SOCS1 and SOCS3 significantly inhibited cell growth and suppressed JAK2/STAT signaling in K562 and HEL cells.  Furthermore, SB increased the transcript levels of SOCS1 and SOCS3 and inhibited the clonogenic activity of hematopoietic progenitors from patients with MPNs.  Taken together, these data establish a new anticancer mechanism that SB inhibits JAK2/STAT signaling through HDAC8-mediated upregulation of SOCS1 and SOCS3.  Thus, HDACs inhibitors may have therapeutic potential for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUyHeZIFKSQrVg90H21EOLACvtfcHk0lgkKZDga6RHkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVKnsg%253D%253D&md5=b57bcdeb8347c2b49060cacf3014a66f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2012.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2012.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DS.%2BM.%26aulast%3DChen%26aufirst%3DC.%2BQ.%26aulast%3DWang%26aufirst%3DL.%2BY.%26aulast%3DHong%26aufirst%3DL.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BB.%26aulast%3DDong%26aufirst%3DP.%2BH.%26aulast%3DYu%26aufirst%3DF.%2BJ.%26atitle%3DHistone%2520deacetylases%2520inhibitor%2520sodium%2520butyrate%2520inhibits%2520JAK2%252FSTAT%2520signaling%2520through%2520upregulation%2520of%2520SOCS1%2520and%2520SOCS3%2520mediated%2520by%2520HDAC8%2520inhibition%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DExp.%2520Hematol.%26date%3D2013%26volume%3D41%26spage%3D261%26epage%3D270%26doi%3D10.1016%2Fj.exphem.2012.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Quintás-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span><span class="refDoi"> DOI: 10.1016/j.leukres.2012.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.leukres.2012.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=22475363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvF2hsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=1124-1127&author=A.+Quint%C3%A1s-Cardamaauthor=H.+Kantarjianauthor=Z.+Estrovauthor=G.+Borthakurauthor=J.+Cortesauthor=S.+Verstovsek&title=Therapy+with+the+histone+deacetylase+inhibitor+pracinostat+for+patients+with+myelofibrosis&doi=10.1016%2Fj.leukres.2012.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Kantarjian, Hagop; Estrov, Zeev; Borthakur, Gautam; Cortes, Jorge; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1124-1127</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Approx. half of the patients with myelofibrosis (MF) carry mutant JAK2V617F proteins.  JAK2V617F has been recently shown to translocate to the nucleus and modify specific histones, thus regulating transcription.  We report on a phase II study testing the activity and tolerability of the histone deacetylase inhibitor pracinostat given at 60 mg every other day for three weeks per mo in 22 patients with intermediate or high risk MF.  Eight (36%) patients experienced clin. benefit, with 6 (27%) experiencing redns. in splenomegaly (median 3 cm, range 1-4 cm).  According to International Working Group criteria, 2 (9%) patients had clin. improvement (anemia response in both cases).  The most frequent side effect assocd. to pracinostat therapy was fatigue, which occurred in 20 (91%) patients (grade 2 in 3 patients).  Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 13%, 0%, and 21%, resp.  Twenty-one patients permanently discontinued pracinostat, mainly due to lack of efficacy.  In conclusion, pracinostat at the dose tested is reasonably tolerated and has modest activity in patients with MF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWKtgUKtLxerVg90H21EOLACvtfcHk0lh9j2js1029ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvF2hsr4%253D&md5=f91f89904ae5bc95102b7b533f2d598f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2012.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2012.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DTherapy%2520with%2520the%2520histone%2520deacetylase%2520inhibitor%2520pracinostat%2520for%2520patients%2520with%2520myelofibrosis%26jtitle%3DLeuk.%2520Res.%26date%3D2012%26volume%3D36%26spage%3D1124%26epage%3D1127%26doi%3D10.1016%2Fj.leukres.2012.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">New patented histone deacetylase inhibitors</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1727</span><span class="NLM_x">–</span> <span class="NLM_lpage">1757</span><span class="refDoi"> DOI: 10.1517/13543770903393789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1517%2F13543770903393789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=19939190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WhtLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1727-1757&author=H.+Wangauthor=B.+W.+Dymock&title=New+patented+histone+deacetylase+inhibitors&doi=10.1517%2F13543770903393789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">New patented histone deacetylase inhibitors</span></div><div class="casAuthors">Wang, Haishan; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1727-1757</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Following FDA approval of vorinostat in 2006, several novel HDAC inhibitors (HDACis) have entered clin. trials, and there are numerous published patent applications claiming novel HDACis which were optimized as potential drug candidates, designed for regional or systemic release, and created as dual or multifunctional inhibitors.  Given the breadth and depth of recent reporting of novel HDACis, there has emerged a need to review the field from a chemist's perspective in one compact article.  Areas covered in this review: This review provides a summary of published patent applications claiming novel HDACis from 2007 until mid-2009, covering mainly classes I, II and IV anticancer HDACis including those that have recently advanced to the clinic.  What the reader will gain: Readers will rapidly gain an overview of the majority of HDACi scaffolds with representative structure-activity relationships; they will learn how these new compds. were created, how their drug like properties were improved and which companies are the main players in the field.  Take home message: Although competition in this field is intense, the future application of HDACis to treat human disease either as single agents or in combination with existing drugs holds real promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9k6M0WIgm2rVg90H21EOLACvtfcHk0lh9j2js1029ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WhtLfK&md5=673162bef16012b32a8122c8fefd92ee</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F13543770903393789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903393789%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DNew%2520patented%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1727%26epage%3D1757%26doi%3D10.1517%2F13543770903393789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span> </span><span class="NLM_article-title">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.1038/nbt1272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+sulfoxide+to+vorinostat%3A+development+of+this+histone+deacetylase+inhibitor+as+an+anticancer+drug&doi=10.1038%2Fnbt1272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0lh9j2js1029ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520sulfoxide%2520to%2520vorinostat%253A%2520development%2520of%2520this%2520histone%2520deacetylase%2520inhibitor%2520as%2520an%2520anticancer%2520drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90%26doi%3D10.1038%2Fnbt1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Yang, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustafa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanujulu, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chng, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">8233</span><span class="NLM_x">–</span> <span class="NLM_lpage">8262</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+janus+kinase+2+%28JAK2%29+and+histone+deacetlyase+%28HDAC%29+bispecific+inhibitors+based+on+pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0lgPLswun4mX-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetlyase%2520%2528HDAC%2529%2520bispecific%2520inhibitors%2520based%2520on%2520pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Zwergel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stazi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, A.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: updated studies in various epigenetic-related diseases</span> <span class="citation_source-journal">J. Clin. Epigenet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.21767/2472-1158.100015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.21767%2F2472-1158.100015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=1-15&author=C.+Zwergelauthor=G.+Staziauthor=S.+Valenteauthor=A.+Mai&title=Histone+deacetylase+inhibitors%3A+updated+studies+in+various+epigenetic-related+diseases&doi=10.21767%2F2472-1158.100015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.21767%2F2472-1158.100015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21767%252F2472-1158.100015%26sid%3Dliteratum%253Aachs%26aulast%3DZwergel%26aufirst%3DC.%26aulast%3DStazi%26aufirst%3DG.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DMai%26aufirst%3DA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520updated%2520studies%2520in%2520various%2520epigenetic-related%2520diseases%26jtitle%3DJ.%2520Clin.%2520Epigenet.%26date%3D2016%26volume%3D2%26spage%3D1%26epage%3D15%26doi%3D10.21767%2F2472-1158.100015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Guha, M.</span><span> </span><span class="NLM_article-title">HDAC inhibitors still need a home run, despite recent approval</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">226</span><span class="refDoi"> DOI: 10.1038/nrd4583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2Fnrd4583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=25829268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1artLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=225-226&author=M.+Guha&title=HDAC+inhibitors+still+need+a+home+run%2C+despite+recent+approval&doi=10.1038%2Fnrd4583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors still need a home run, despite recent approval</span></div><div class="casAuthors">Guha, Malini</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">225-226</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A beleaguered class of epigenetic modulators continues to struggle for oncol. success, but new insights into their mechanisms in cancer may yet offer hope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotdd1X74wEP7Vg90H21EOLACvtfcHk0lgPLswun4mX-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1artLs%253D&md5=011db36451b31bc7d19e8ffab8281af8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrd4583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4583%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26atitle%3DHDAC%2520inhibitors%2520still%2520need%2520a%2520home%2520run%252C%2520despite%2520recent%2520approval%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D225%26epage%3D226%26doi%3D10.1038%2Fnrd4583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Evrot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andraos, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolemeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dammassa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baffert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radimerski, T.</span><span> </span><span class="NLM_article-title">JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6230</span><span class="NLM_x">–</span> <span class="NLM_lpage">6241</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1158%2F1078-0432.CCR-13-0905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=24081976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyku7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6230-6241&author=E.+Evrotauthor=N.+Ebelauthor=V.+Romanetauthor=C.+Roelliauthor=R.+Andraosauthor=Z.+Qianauthor=A.+Dolemeyerauthor=E.+Dammassaauthor=D.+Sterkerauthor=R.+Cozensauthor=F.+Hofmannauthor=M.+Murakamiauthor=F.+Baffertauthor=T.+Radimerski&title=JAK1%2F2+and+Pan-deacetylase+inhibitor+combination+therapy+yields+improved+efficacy+in+preclinical+mouse+models+of+JAK2V617F-driven+disease&doi=10.1158%2F1078-0432.CCR-13-0905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease</span></div><div class="casAuthors">Evrot, Emeline; Ebel, Nicolas; Romanet, Vincent; Roelli, Claudia; Andraos, Rita; Qian, Zhiyan; Doelemeyer, Arno; Dammassa, Ernesta; Sterker, Dario; Cozens, Robert; Hofmann, Francesco; Murakami, Masato; Baffert, Fabienne; Radimerski, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6230-6241</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The myeloproliferative neoplasm myelofibrosis is characterized by frequent deregulation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling, and JAK inhibitors were shown to reduce splenomegaly and ameliorate disease-related symptoms.  However, the mutant clone and bone marrow fibrosis persist in the majority of patients.  Using preclin. models, we explored whether JAK and pan-deacetylase inhibitor combination yielded addnl. benefits.  Exptl. Design: The combination of the JAK1/2 inhibitor ruxolitinib and panobinostat was investigated using two different mouse models of JAK2V617F-driven disease.  A Ba/F3 JAK2V617F cell-driven leukemic disease model was used to identify tolerated and efficacious doses.  The drugs were then evaluated alone and in combination in a mouse model of myeloproliferative neoplasm-like disease based on transplantation of bone marrow transduced with a retrovirus expressing JAK2V617F.  Exposures were detd. in blood and tissues, and phosphorylated STAT5 and acetylated histone H3 pharmacodynamic readouts were assessed in spleen and bone marrow.  Histol. anal. was conducted on spleen and bone marrow, including staining of reticulin fibers in the latter organ.  Results: The combination of ruxolitinib and panobinostat was found to have a more profound effect on splenomegaly, as well as on bone marrow and spleen histol., compared with either agent alone, and the anal. of pharmacodynamic readouts showed that ruxolitinib and panobinostat have nonoverlapping and complementary effects.  Conclusion: Combining JAK1/2 and pan-deacetylase inhibitors was fairly well tolerated and resulted in improved efficacy in mouse models of JAK2V617F-driven disease compared with the single agents.  Thus, the combination of ruxolitinib and panobinostat may represent a promising novel therapeutic modality for myeloproliferative neoplasms.  Clin Cancer Res; 19(22); 6230-41. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEzgbAtJVQ27Vg90H21EOLACvtfcHk0lhBXaLHZiYUGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyku7jM&md5=ff3662f4ba7be74aa3395046e9516e04</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0905%26sid%3Dliteratum%253Aachs%26aulast%3DEvrot%26aufirst%3DE.%26aulast%3DEbel%26aufirst%3DN.%26aulast%3DRomanet%26aufirst%3DV.%26aulast%3DRoelli%26aufirst%3DC.%26aulast%3DAndraos%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DDolemeyer%26aufirst%3DA.%26aulast%3DDammassa%26aufirst%3DE.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DBaffert%26aufirst%3DF.%26aulast%3DRadimerski%26aufirst%3DT.%26atitle%3DJAK1%252F2%2520and%2520Pan-deacetylase%2520inhibitor%2520combination%2520therapy%2520yields%2520improved%2520efficacy%2520in%2520preclinical%2520mouse%2520models%2520of%2520JAK2V617F-driven%2520disease%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D6230%26epage%3D6241%26doi%3D10.1158%2F1078-0432.CCR-13-0905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">de Lera, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganesan, A.</span><span> </span><span class="NLM_article-title">Epigenetic polypharmacology: from combination therapy to multitargeted drugs</span> <span class="citation_source-journal">Clin. Epigenet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1186/s13148-016-0271-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1186%2Fs13148-016-0271-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=26753011" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=1-21&author=A.+R.+de+Leraauthor=A.+Ganesan&title=Epigenetic+polypharmacology%3A+from+combination+therapy+to+multitargeted+drugs&doi=10.1186%2Fs13148-016-0271-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs13148-016-0271-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13148-016-0271-9%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLera%26aufirst%3DA.%2BR.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DEpigenetic%2520polypharmacology%253A%2520from%2520combination%2520therapy%2520to%2520multitargeted%2520drugs%26jtitle%3DClin.%2520Epigenet.%26date%3D2016%26volume%3D8%26spage%3D1%26epage%3D21%26doi%3D10.1186%2Fs13148-016-0271-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Bieliauskas, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflum, M. K.</span><span> </span><span class="NLM_article-title">Isoform-selective histone deacetylase inhibitors</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1402</span><span class="NLM_x">–</span> <span class="NLM_lpage">1413</span><span class="refDoi"> DOI: 10.1039/b703830p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1039%2Fb703830p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=18568166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFejsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2008&pages=1402-1413&author=A.+V.+Bieliauskasauthor=M.+K.+Pflum&title=Isoform-selective+histone+deacetylase+inhibitors&doi=10.1039%2Fb703830p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-selective histone deacetylase inhibitors</span></div><div class="casAuthors">Bieliauskas, Anton V.; Pflum, Mary Kay H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1402-1413</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer.  As a result, multiple small mol. HDAC inhibitors are in various phases of clin. trials as anti-cancer drugs.  The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes.  This tutorial review focuses on the recent progress toward the identification of class-selective and isoform-selective HDAC inhibitors.  The emerging trends suggest that subtle differences in the active sites of the HDAC isoforms can be exploited to dictate selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXOB_YFWaeZrVg90H21EOLACvtfcHk0lhBXaLHZiYUGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFejsbs%253D&md5=326e20da0623a00114f43e5c459c9920</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1039%2Fb703830p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb703830p%26sid%3Dliteratum%253Aachs%26aulast%3DBieliauskas%26aufirst%3DA.%2BV.%26aulast%3DPflum%26aufirst%3DM.%2BK.%26atitle%3DIsoform-selective%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2008%26volume%3D37%26spage%3D1402%26epage%3D1413%26doi%3D10.1039%2Fb703830p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Russell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tayebi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migone, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span><span class="refDoi"> DOI: 10.1126/science.270.5237.797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1126%2Fscience.270.5237.797" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=797-800&author=S.+M.+Russellauthor=N.+Tayebiauthor=H.+Nakajimaauthor=M.+C.+Riedyauthor=J.+L.+Robertsauthor=M.+J.+Amanauthor=T.+S.+Migoneauthor=M.+Noguchiauthor=M.+L.+Markertauthor=R.+H.+Buckleyauthor=J.+J.+O%E2%80%99Sheaauthor=W.+J.+Leonard&title=Mutation+of+Jak3+in+a+patient+with+SCID%3A+essential+role+of+Jak3+in+lymphoid+development&doi=10.1126%2Fscience.270.5237.797"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5237.797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5237.797%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DS.%2BM.%26aulast%3DTayebi%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DRoberts%26aufirst%3DJ.%2BL.%26aulast%3DAman%26aufirst%3DM.%2BJ.%26aulast%3DMigone%26aufirst%3DT.%2BS.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DMarkert%26aufirst%3DM.%2BL.%26aulast%3DBuckley%26aufirst%3DR.%2BH.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DMutation%2520of%2520Jak3%2520in%2520a%2520patient%2520with%2520SCID%253A%2520essential%2520role%2520of%2520Jak3%2520in%2520lymphoid%2520development%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D797%26epage%3D800%26doi%3D10.1126%2Fscience.270.5237.797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Alicea-Velazquez, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span> </span><span class="NLM_article-title">The use of structural biology in Janus kinase targeted drug discovery</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">546</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span><span class="refDoi"> DOI: 10.2174/138945011794751528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.2174%2F138945011794751528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=21126226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=546-555&author=N.+L.+Alicea-Velazquezauthor=T.+J.+Boggon&title=The+use+of+structural+biology+in+Janus+kinase+targeted+drug+discovery&doi=10.2174%2F138945011794751528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The use of structural biology in Janus kinase targeted drug discovery</span></div><div class="casAuthors">Alicea-Velazquez, Nilda L.; Boggon, Titus J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">546-555</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (or Jak kinases) mediate cytokine and growth factor signal transduction.  Acquired or inherited Jak mutations can result in dysregulation of Jak-mediated signal transduction and can be crit. to disease acquisition in neoplasias including acute myeloid, acute lymphoblastic and acute megakaryoblastic leukemias, and in rare X-linked severe combined immunodeficiency.  The discovery of an acquired Jak2 point mutation, V617F, in significant nos. of patients with classical myeloproliferative disorders has increased the interest in development of Jak2-specific tyrosine kinase inhibitors and consequently there are now over 20 publically available structures of Jak kinase domains that describe all four family members, Jak1, Jak2, Jak3, and Tyk2.  Here we review the recent advances in understanding the druggable structure and function of the Jak family, with a focus on the structural biol. of the Jak kinase domain.  We will discuss how these advances impact the development of Jak-targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJwEtMK-lOu7Vg90H21EOLACvtfcHk0lhBXaLHZiYUGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOkurg%253D&md5=5e76fc7eda3ffe580dc4e28044a88c2c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F138945011794751528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011794751528%26sid%3Dliteratum%253Aachs%26aulast%3DAlicea-Velazquez%26aufirst%3DN.%2BL.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520use%2520of%2520structural%2520biology%2520in%2520Janus%2520kinase%2520targeted%2520drug%2520discovery%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26spage%3D546%26epage%3D555%26doi%3D10.2174%2F138945011794751528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munger, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepicelli, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">3647</span><span class="NLM_x">–</span> <span class="NLM_lpage">3656</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1158%2F0008-5472.CAN-09-3360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=20388807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.+J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.+G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.+X.+Xuauthor=S.+DellaRoccaauthor=H.+X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2%2C+exerts+potent+anticancer+activity&doi=10.1158%2F0008-5472.CAN-09-3360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity</span></div><div class="casAuthors">Lai, Cheng-Jung; Bao, Rudi; Tao, Xu; Wang, Jing; Atoyan, Ruzanna; Qu, Hui; Wang, Da-Gong; Yin, Ling; Samson, Maria; Forrester, Jeffrey; Zifcak, Brian; Xu, Guang-Xin; DellaRocca, Steven; Zhai, Hai-Xiao; Cai, Xiong; Munger, William E.; Keegan, Mitchell; Pepicelli, Carmen V.; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3647-3656</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers.  However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.  To overcome these limitations, we created a novel small mol., CUDC-101, which simultaneously inhibits histone deacetylase and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in cancer cells.  Because of its integrated histone deacetylase inhibition, CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.  CUDC-101 displayed potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.  Our results show that CUDC-101 has the potential to dramatically improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.  Further, they provide a framework to create individual small mols. that simultaneously antagonize multiple biochem. distinct oncogenic targets, suggesting a general paradigm to surpass conventional, single-target cancer therapeutics.  Cancer Res; 70(9); 3647-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscJsyultc3bVg90H21EOLACvtfcHk0liMHLaguhjoiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D&md5=bc30667b0890e3c505c9608de6fa0c68</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3360%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%252C%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656%26doi%3D10.1158%2F0008-5472.CAN-09-3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Williams, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucet, I. S.</span><span> </span><span class="NLM_article-title">Dissecting specificity in the janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span><span class="refDoi"> DOI: 10.1016/j.jmb.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains&doi=10.1016%2Fj.jmb.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0liMHLaguhjoiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232%26doi%3D10.1016%2Fj.jmb.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Butler, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">10842</span><span class="NLM_x">–</span> <span class="NLM_lpage">10846</span><span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+design+and+simple+chemistry+yield+a+superior%2C+neuroprotective+HDAC6+inhibitor%2C+tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0liMHLaguhjoiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520design%2520and%2520simple%2520chemistry%2520yield%2520a%2520superior%252C%2520neuroprotective%2520HDAC6%2520inhibitor%252C%2520tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alex, A.</span><span> </span><span class="NLM_article-title">Ligand efficiency: a useful metric for lead selection</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+a+useful+metric+for+lead+selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eYa7rzlBN2P1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520a%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Tarcsay, A. k.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyíri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keserű, G. r. M.</span><span> </span><span class="NLM_article-title">Impact of lipophilic efficiency on compound quality</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1260</span><span class="refDoi"> DOI: 10.1021/jm201388p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201388p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1252-1260&author=A.+k.+Tarcsayauthor=K.+Ny%C3%ADriauthor=G.+r.+M.+Keser%C5%B1&title=Impact+of+lipophilic+efficiency+on+compound+quality&doi=10.1021%2Fjm201388p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Lipophilic Efficiency on Compound Quality</span></div><div class="casAuthors">Tarcsay, Akos; Nyiri, Kinga; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1252-1260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lipophilic efficiency indexes such as LLE and LELP were suggested to support balanced optimization of potency and ADMET profile.  Here we investigated the performance of LLE and LELP on multiple data sets representing different stages of drug discovery including fragment and HTS hits and leads, development candidates, phase II compds., and launched drugs.  Analyzing their impact on ADME and safety properties and binding thermodn., we found that both LLE and LELP help identifying better quality compds.  LLE is sensible for the development stages but does not prefer fragment-type hits, while LELP has an advantage for this class of compds. and discriminates preferred starting points effectively.  Both LLE and LELP have significant impact on ADME and safety profiles; however, LELP outperforms LLE in risk assessment at least on the present data set.  On the basis of the results reported here, monitoring lipophilic efficiency metrics could contribute significantly to compd. quality and might improve the output of medicinal chem. programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxB8xs6-5DL7Vg90H21EOLACvtfcHk0lhB_qL0A4tmlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D&md5=2536abef781f52806013016971c78bcb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm201388p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201388p%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3DA.%2Bk.%26aulast%3DNy%25C3%25ADri%26aufirst%3DK.%26aulast%3DKeser%25C5%25B1%26aufirst%3DG.%2Br.%2BM.%26atitle%3DImpact%2520of%2520lipophilic%2520efficiency%2520on%2520compound%2520quality%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1252%26epage%3D1260%26doi%3D10.1021%2Fjm201388p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2000</span><span class="NLM_x">–</span> <span class="NLM_lpage">2009</span><span class="refDoi"> DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.+X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.+J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-ethynylphenylamino%29-7-methoxyquinazolin-6-yloxy%29-N-hydroxyheptanamide+%28CUDC-101%29+as+a+potent+multi-acting+HDAC%2C+EGFR%2C+and+HER2+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lhB_qL0A4tmlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2520%2528CUDC-101%2529%2520as%2520a%2520potent%2520multi-acting%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Duong-Thi, M.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meiby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergström, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fex, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaksson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlson, S.</span><span> </span><span class="NLM_article-title">Weak affinity chromatography as a new approach for fragment screening in drug discovery</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">414</span><span class="NLM_x">, </span> <span class="NLM_fpage">138</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span><span class="refDoi"> DOI: 10.1016/j.ab.2011.02.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.ab.2011.02.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2011&pages=138-146&author=M.-D.+Duong-Thiauthor=E.+Meibyauthor=M.+Bergstr%C3%B6mauthor=T.+Fexauthor=R.+Isakssonauthor=S.+Ohlson&title=Weak+affinity+chromatography+as+a+new+approach+for+fragment+screening+in+drug+discovery&doi=10.1016%2Fj.ab.2011.02.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2011.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2011.02.022%26sid%3Dliteratum%253Aachs%26aulast%3DDuong-Thi%26aufirst%3DM.-D.%26aulast%3DMeiby%26aufirst%3DE.%26aulast%3DBergstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DFex%26aufirst%3DT.%26aulast%3DIsaksson%26aufirst%3DR.%26aulast%3DOhlson%26aufirst%3DS.%26atitle%3DWeak%2520affinity%2520chromatography%2520as%2520a%2520new%2520approach%2520for%2520fragment%2520screening%2520in%2520drug%2520discovery%26jtitle%3DAnal.%2520Biochem.%26date%3D2011%26volume%3D414%26spage%3D138%26epage%3D146%26doi%3D10.1016%2Fj.ab.2011.02.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Ohlson, S.; Duong-Thi, M.-D.</span> <span class="citation_source-book">Emerging Technologies for Fragment Screening</span>; <span class="NLM_publisher-name">Wiley-VCH Verlag</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">67</span>, pp  <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1002%2F9783527683604.ch08" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=173-195&author=S.+Ohlson&author=M.-D.+Duong-Thi&title=Emerging+Technologies+for+Fragment+Screening"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2F9783527683604.ch08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527683604.ch08%26sid%3Dliteratum%253Aachs%26aulast%3DOhlson%26aufirst%3DS.%26btitle%3DEmerging%2520Technologies%2520for%2520Fragment%2520Screening%26pub%3DWiley-VCH%2520Verlag%26date%3D2016%26volume%3D67%26spage%3D173%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span> </span><span class="NLM_article-title">A small molecule–kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floyd&title=A+small+molecule%E2%80%93kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lgHsC6a3ZWPvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26atitle%3DA%2520small%2520molecule%25E2%2580%2593kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhfJhgRfX3eog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Vishwakarma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shastry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulathingal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijaykanth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajesh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathinasamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kachhadia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilambi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajgopal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, S.</span><span> </span><span class="NLM_article-title">Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span><span class="refDoi"> DOI: 10.1016/j.intimp.2013.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.intimp.2013.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=23541634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlWjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=72-78&author=S.+Vishwakarmaauthor=L.+R.+Iyerauthor=M.+Muleyauthor=P.+K.+Singhauthor=A.+Shastryauthor=A.+Saxenaauthor=J.+Kulathingalauthor=G.+Vijaykanthauthor=J.+Raghulauthor=N.+Rajeshauthor=S.+Rathinasamyauthor=V.+Kachhadiaauthor=N.+Kilambiauthor=S.+Rajgopalauthor=G.+Balasubramanianauthor=S.+Narayanan&title=Tubastatin%2C+a+selective+histone+deacetylase+6+inhibitor+shows+anti-inflammatory+and+anti-rheumatic+effects&doi=10.1016%2Fj.intimp.2013.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects</span></div><div class="casAuthors">Vishwakarma, Santosh; Iyer, Lakshmi R.; Muley, Milind; Singh, Pankaj Kumar; Shastry, Arun; Saxena, Ambrish; Kulathingal, Jayanarayan; Vijaykanth, G.; Raghul, J.; Rajesh, Navin; Rathinasamy, Suresh; Kachhadia, Virendra; Kilambi, Narasimhan; Rajgopal, Sridharan; Balasubramanian, Gopalan; Narayanan, Shridhar</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-78</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Epigenetic modifications represent a promising new approach to modulate cell functions as obsd. in autoimmune diseases.  Emerging evidence suggests the utility of HDAC inhibitors in the treatment of chronic immune and inflammatory disorders.  However, class and isoform selective inhibition of HDAC is currently favored as it limits the toxicity that was obsd. with pan-HDAC inhibitors.  HDAC6, a member of the HDAC family, whose major substrate is α-tubulin, is being increasingly implicated in the pathogenesis of inflammatory disorders.  The present study was carried out to study the potential anti-inflammatory and anti-rheumatic effects of HDAC6 selective inhibitor Tubastatin.  Tubastatin, a potent human HDAC6 inhibitor with an IC50 of 11 nM showed significant inhibition of TNF-α and IL-6 in LPS stimulated human THP-1 macrophages with an IC50 of 272 nM and 712 nM, resp.  Addnl., Tubastatin inhibited NO secretion in murine Raw 264.7 macrophages dose dependently with an IC50 of 4.2 μM and induced α-tubulin hyperacetylation corresponding to HDAC6 inhibition in THP-1 cells without affecting the cell viability.  Tubastatin showed significant inhibition of paw vol. at 30 mg/kg i.p. in a Freund's complete adjuvant (FCA) induced animal model of inflammation.  The disease modifying activity of Tubastatin was also evident in collagen induced arthritis DBA1 mouse model at 30 mg/kg i.p.  The significant attenuation of clin. scores (∼ 70%) by Tubastatin was confirmed histopathol. and was found comparable to dexamethasone (∼ 90% inhibition of clin. scores).  Tubastatin showed significant inhibition of IL-6 in paw tissues of arthritic mice.  The present work has demonstrated anti-inflammatory and antirheumatic effects of a selective HDAC6 inhibitor Tubastatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVjF7tHATlYbVg90H21EOLACvtfcHk0lhfJhgRfX3eog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlWjsr4%253D&md5=1810b101113330405d3923cbadb628b7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2013.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2013.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DVishwakarma%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DL.%2BR.%26aulast%3DMuley%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DShastry%26aufirst%3DA.%26aulast%3DSaxena%26aufirst%3DA.%26aulast%3DKulathingal%26aufirst%3DJ.%26aulast%3DVijaykanth%26aufirst%3DG.%26aulast%3DRaghul%26aufirst%3DJ.%26aulast%3DRajesh%26aufirst%3DN.%26aulast%3DRathinasamy%26aufirst%3DS.%26aulast%3DKachhadia%26aufirst%3DV.%26aulast%3DKilambi%26aufirst%3DN.%26aulast%3DRajgopal%26aufirst%3DS.%26aulast%3DBalasubramanian%26aufirst%3DG.%26aulast%3DNarayanan%26aufirst%3DS.%26atitle%3DTubastatin%252C%2520a%2520selective%2520histone%2520deacetylase%25206%2520inhibitor%2520shows%2520anti-inflammatory%2520and%2520anti-rheumatic%2520effects%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2013%26volume%3D16%26spage%3D72%26epage%3D78%26doi%3D10.1016%2Fj.intimp.2013.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">–</span> <span class="NLM_lpage">4658</span><span class="refDoi"> DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.+1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0lhfJhgRfX3eog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.%25201%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Coe, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rademacher, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bammler, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farin, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plymate, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fausto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. D.</span><span> </span><span class="NLM_article-title">Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1277</span><span class="NLM_x">–</span> <span class="NLM_lpage">1290</span><span class="refDoi"> DOI: 10.1021/tx7001349</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx7001349" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1277-1290&author=K.+J.+Coeauthor=Y.+Jiaauthor=H.+K.+Hoauthor=P.+Rademacherauthor=T.+K.+Bammlerauthor=R.+P.+Beyerauthor=F.+M.+Farinauthor=L.+Woodkeauthor=S.+R.+Plymateauthor=N.+Faustoauthor=S.+D.+Nelson&title=Comparison+of+the+cytotoxicity+of+the+nitroaromatic+drug+flutamide+to+its+cyano+analogue+in+the+hepatocyte+cell+line+TAMH%3A+evidence+for+complex+I+inhibition+and+mitochondrial+dysfunction+using+toxicogenomic+screening&doi=10.1021%2Ftx7001349"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Ftx7001349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx7001349%26sid%3Dliteratum%253Aachs%26aulast%3DCoe%26aufirst%3DK.%2BJ.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DHo%26aufirst%3DH.%2BK.%26aulast%3DRademacher%26aufirst%3DP.%26aulast%3DBammler%26aufirst%3DT.%2BK.%26aulast%3DBeyer%26aufirst%3DR.%2BP.%26aulast%3DFarin%26aufirst%3DF.%2BM.%26aulast%3DWoodke%26aufirst%3DL.%26aulast%3DPlymate%26aufirst%3DS.%2BR.%26aulast%3DFausto%26aufirst%3DN.%26aulast%3DNelson%26aufirst%3DS.%2BD.%26atitle%3DComparison%2520of%2520the%2520cytotoxicity%2520of%2520the%2520nitroaromatic%2520drug%2520flutamide%2520to%2520its%2520cyano%2520analogue%2520in%2520the%2520hepatocyte%2520cell%2520line%2520TAMH%253A%2520evidence%2520for%2520complex%2520I%2520inhibition%2520and%2520mitochondrial%2520dysfunction%2520using%2520toxicogenomic%2520screening%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1277%26epage%3D1290%26doi%3D10.1021%2Ftx7001349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Davidson, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palenzuela, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaac, N. D.</span><span> </span><span class="NLM_article-title">Novel cell lines derived from adult human ventricular cardiomyocytes</span> <span class="citation_source-journal">J. Mol. Cell. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span><span class="refDoi"> DOI: 10.1016/j.yjmcc.2005.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.yjmcc.2005.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=15913645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGgtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2005&pages=133-147&author=M.+M.+Davidsonauthor=C.+Nestiauthor=L.+Palenzuelaauthor=W.+F.+Walkerauthor=E.+Hernandezauthor=L.+Protasauthor=M.+Hiranoauthor=N.+D.+Isaac&title=Novel+cell+lines+derived+from+adult+human+ventricular+cardiomyocytes&doi=10.1016%2Fj.yjmcc.2005.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Novel cell lines derived from adult human ventricular cardiomyocytes</span></div><div class="casAuthors">Davidson, Mercy M.; Nesti, Claudia; Palenzuela, Lluis; Walker, Winsome F.; Hernandez, Evelyn; Protas, Lev; Hirano, Michio; Isaac, Nithila D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">133-147</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background. - We have established proliferating human cardiomyocyte cell lines derived from non-proliferating primary cultures of adult ventricular heart tissue, using a novel method that may be applicable to many post-mitotic primary cultures.  Methods and results. - Primary cells from human ventricular tissue, were fused with SV40 transformed, uridine auxotroph human fibroblasts, devoid of mitochondrial DNA.  This was followed by selection in uridine-free medium to eliminate unfused fibroblasts.  The fused cells were subcloned and screened for cell type-specific markers.  Four clones (AC1, AC10, AC12, AC16) that express markers characteristic of cardiomyocytes were studied.  Clones were homogeneous morphol., and expressed transcription factors (GATA4, MYCD, NFATc4), contractile proteins such as α- and β-myosin heavy chain, α-cardiac actin, troponin I, desmoplakin, α actinin, the muscle-specific intermediate filament protein, desmin, the cardiomyocyte-specific peptide hormones, BNP, the L-type calcium channel α1C subunit and gap junction proteins, connexin-43 and connexin-40.  Furthermore, dye-coupling studies confirmed the presence of functional gap junctions.  EM ultra structural anal. revealed the presence of myofibrils in the subsarcolemmal region, indicating a precontractile developmental stage.  When grown in mitogen-depleted medium, the AC cells stopped proliferating and formed a multinucleated syncytium.  When the SV40 oncogene was silenced using the RNAi technique, AC16 cells switched from a proliferating to a more differentiated quiescent state, with the formation of multinucleated syncyntium.  Concurrently, the cells expressed BMP2, an important signaling mol. for induction of cardiac-specific markers, that was not expressed by the proliferating cells.  The presence of the combination of transcription factors in addn. to muscle-specific markers is a good indication for the presence of a cardiac transcription program in these cells.  Conclusions. - Based on the expression of myogenic markers and a fully functional respiratory chain, the AC cells have retained the nuclear DNA and the mitochondrial DNA of the primary cardiomyocytes.  They can be frozen and thawed repeatedly and can differentiate when grown in mitogen-free medium.  These cell lines are potentially useful in vitro models to study developmental regulation of cardiomyocytes in normal and pathol. states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCsbmml_wFm7Vg90H21EOLACvtfcHk0lgHha37KNR8sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGgtLY%253D&md5=41e9f3a6924a93e8b2d46ea6365b0e7d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2005.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2005.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DM.%2BM.%26aulast%3DNesti%26aufirst%3DC.%26aulast%3DPalenzuela%26aufirst%3DL.%26aulast%3DWalker%26aufirst%3DW.%2BF.%26aulast%3DHernandez%26aufirst%3DE.%26aulast%3DProtas%26aufirst%3DL.%26aulast%3DHirano%26aufirst%3DM.%26aulast%3DIsaac%26aufirst%3DN.%2BD.%26atitle%3DNovel%2520cell%2520lines%2520derived%2520from%2520adult%2520human%2520ventricular%2520cardiomyocytes%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2005%26volume%3D39%26spage%3D133%26epage%3D147%26doi%3D10.1016%2Fj.yjmcc.2005.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">West, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span> </span><span class="NLM_article-title">New and emerging HDAC inhibitors for cancer treatment</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1172/JCI69738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1172%2FJCI69738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=24382387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=30-39&author=A.+C.+Westauthor=R.+W.+Johnstone&title=New+and+emerging+HDAC+inhibitors+for+cancer+treatment&doi=10.1172%2FJCI69738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">New and emerging HDAC inhibitors for cancer treatment</span></div><div class="casAuthors">West, Alison C.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci.  The identification of these enzymes and their partner proteins has driven the rapid development of small-mol. inhibitors that target the cancer epigenome.  Herein, the authors discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis.  The authors examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpELUU7P0B_grVg90H21EOLACvtfcHk0lgHha37KNR8sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D&md5=ab59960223b33e89725f6539b031f531</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1172%2FJCI69738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69738%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DA.%2BC.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DNew%2520and%2520emerging%2520HDAC%2520inhibitors%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D30%26epage%3D39%26doi%3D10.1172%2FJCI69738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Hubbert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardiola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nixon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, T.-P.</span><span> </span><span class="NLM_article-title">HDAC6 is a microtubule-associated deacetylase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">458</span><span class="refDoi"> DOI: 10.1038/417455a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2F417455a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=12024216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=455-458&author=C.+Hubbertauthor=A.+Guardiolaauthor=R.+Shaoauthor=Y.+Kawaguchiauthor=A.+Itoauthor=A.+Nixonauthor=M.+Yoshidaauthor=X.-F.+Wangauthor=T.-P.+Yao&title=HDAC6+is+a+microtubule-associated+deacetylase&doi=10.1038%2F417455a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is a microtubule-associated deacetylase</span></div><div class="casAuthors">Hubbert, Charlotte; Guardiola, Amaris; Shao, Rong; Kawaguchi, Yoshiharu; Ito, Akihiro; Nixon, Andrew; Yoshida, Minoru; Wang, Xiao-Fan; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6887</span>),
    <span class="NLM_cas:pages">455-458</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reversible acetylation of α-tubulin has been implicated in regulating microtubule stability and function.  The distribution of acetylated α-tubulin is tightly controlled and stereotypic.  Acetylated α-tubulin is most abundant in stable microtubules but is absent from dynamic cellular structures such as neuronal growth cones and the leading edges of fibroblasts.  However, the enzymes responsible for regulating tubulin acetylation and deacetylation are not known.  Here we report that a member of the histone deacetylase family, HDAC6, functions as a tubulin deacetylase.  HDAC6 is localized exclusively in the cytoplasm, where it assocs. with microtubules and localizes with the microtubule motor complex contg. p150glued.  In vivo, the overexpression of HDAC6 leads to a global deacetylation of α-tubulin, whereas a decrease in HDAC6 increases α-tubulin acetylation.  In vitro, purified HDAC6 potently deacetylates α-tubulin in assembled microtubules.  Furthermore, overexpression of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-mediated deacetylation regulates microtubule-dependent cell motility.  Our results show that HDAC6 is the tubulin deacetylase, and provide evidence that reversible acetylation regulates important biol. processes beyond histone metab. and gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp76Er3MrWtO7Vg90H21EOLACvtfcHk0lhwUBXGiNeXVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D&md5=f18cbb0af388925c606e822358ba3da6</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2F417455a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F417455a%26sid%3Dliteratum%253Aachs%26aulast%3DHubbert%26aufirst%3DC.%26aulast%3DGuardiola%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DR.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DNixon%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.-F.%26aulast%3DYao%26aufirst%3DT.-P.%26atitle%3DHDAC6%2520is%2520a%2520microtubule-associated%2520deacetylase%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D455%26epage%3D458%26doi%3D10.1038%2F417455a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J. B.</span><span> </span><span class="NLM_article-title">Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5023</span><span class="NLM_x">–</span> <span class="NLM_lpage">5038</span><span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.+B.+Telliez&title=Discovery+and+development+of+janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lhwUBXGiNeXVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">D’Amours, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sallmann, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixit, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span> </span><span class="NLM_article-title">Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">3771</span><span class="NLM_x">–</span> <span class="NLM_lpage">3778</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=11707529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD3MXot12nsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2001&pages=3771-3778&author=D.+D%E2%80%99Amoursauthor=F.+R.+Sallmannauthor=V.+M.+Dixitauthor=G.+G.+Poirier&title=Gain-of-function+of+poly%28ADP-ribose%29+polymerase-1+upon+cleavage+by+apoptotic+proteases%3A+implications+for+apoptosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis</span></div><div class="casAuthors">D'Amours, Damien; Sallmann, Frederic R.; Dixit, Vishva M.; Poirier, Guy G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3771-3778</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Poly(ADP-ribosyl)ation is an important mechanism for the maintenance of genomic integrity in response to DNA damage.  The enzyme responsible for poly(ADP-ribose) synthesis, poly(ADP-ribose) polymerase 1 (PARP-1), has been implicated in two distinct modes of cell death induced by DNA damage, namely apoptosis and necrosis.  During the execution phase of apoptosis, PARP-1 is specifically proteolyzed by caspases to produce an N-terminal DNA-binding domain (DBD) and a C-terminal catalytic fragment.  The functional consequence of this proteolytic event is not known.  However, it has recently been shown that overactivation of full-length PARP-1 can result in energy depletion and necrosis in dying cells.  Here, the authors investigate the mol. basis for the differential involvement of PARP-1 in these two types of cellular demise.  The authors show that the C-terminal apoptotic fragment of PARP-1 loses its DNA-dependent catalytic activity upon cleavage with caspase 3.  However, the N-terminal apoptotic fragment, retains a strong DNA-binding activity and totally inhibits the catalytic activity of uncleaved PARP-1.  This dominant-neg. behavior was confirmed and extended in cellular exts. where DNA repair was completely inhibited by nanomolar concns. of the N-terminal fragment.  Furthermore, overexpression of the apoptotic DBD in mouse fibroblast inhibits endogenous PARP-1 activity very efficiently in vivo, thereby confirming the authors' biochem. observations.  Taken together, these expts. indicate that the apoptotic DBD of PARP-1 acts cooperatively with the proteolytic inactivation of the enzyme to trans-inhibit NAD hydrolysis and to maintain the energy levels of the cell.  These results are consistent with a model in which cleavage of PARP-1 promotes apoptosis by preventing DNA repair-induced survival and by blocking energy depletion-induced necrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouW9f4pYihjrVg90H21EOLACvtfcHk0lhwUBXGiNeXVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXot12nsrk%253D&md5=18622ce2e1abc4ca30c3d3e92d471b6f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Amours%26aufirst%3DD.%26aulast%3DSallmann%26aufirst%3DF.%2BR.%26aulast%3DDixit%26aufirst%3DV.%2BM.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26atitle%3DGain-of-function%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520upon%2520cleavage%2520by%2520apoptotic%2520proteases%253A%2520implications%2520for%2520apoptosis%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2001%26volume%3D114%26spage%3D3771%26epage%3D3778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Danial, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korsmeyer, S. J.</span><span> </span><span class="NLM_article-title">Cell death: critical control points</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1016/S0092-8674(04)00046-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2FS0092-8674%2804%2900046-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=14744432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtValsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=205-219&author=N.+N.+Danialauthor=S.+J.+Korsmeyer&title=Cell+death%3A+critical+control+points&doi=10.1016%2FS0092-8674%2804%2900046-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cell death: Critical control points</span></div><div class="casAuthors">Danial, Nika N.; Korsmeyer, Stanley J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-219</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review and discussion.  Programmed cell death (apoptosis) is a distinct genetic and biochem. pathway essential to metazoans.  An intact death pathway is required for successful embryonic development and the maintenance of normal tissue homeostasis.  Apoptosis has proven to be tightly interwoven with other essential cell pathways.  The identification of crit. control points in the cell death pathway has yielded fundamental insights for basic biol., as well as provided rational targets for new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfuRt2EjV6WLVg90H21EOLACvtfcHk0ljKnKIIK0n1og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtValsrY%253D&md5=de853177ac091305b7f237e58108f579</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900046-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900046-7%26sid%3Dliteratum%253Aachs%26aulast%3DDanial%26aufirst%3DN.%2BN.%26aulast%3DKorsmeyer%26aufirst%3DS.%2BJ.%26atitle%3DCell%2520death%253A%2520critical%2520control%2520points%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D205%26epage%3D219%26doi%3D10.1016%2FS0092-8674%2804%2900046-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crackett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaines, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avitabile-Woo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span> </span><span class="NLM_article-title">Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">–</span> <span class="NLM_lpage">4785</span><span class="refDoi"> DOI: 10.1021/jm4004895</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+Koehlerauthor=P.+Bir+Kohliauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+van+Abbemaauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+hydroxyethyl+imidazopyrrolopyridines+as+potent+JAK1+inhibitors+with+favorable+physicochemical+properties+and+high+selectivity+over+JAK2&doi=10.1021%2Fjm4004895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2</span></div><div class="casAuthors">Zak, Mark; Hurley, Christopher A.; Ward, Stuart I.; Bergeron, Philippe; Barrett, Kathy; Balazs, Mercedesz; Blair, Wade S.; Bull, Richard; Chakravarty, Paroma; Chang, Christine; Crackett, Peter; Deshmukh, Gauri; DeVoss, Jason; Dragovich, Peter S.; Eigenbrot, Charles; Ellwood, Charles; Gaines, Simon; Ghilardi, Nico; Gibbons, Paul; Gradl, Stefan; Gribling, Peter; Hamman, Chris; Harstad, Eric; Hewitt, Peter; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Koehler, Michael F. T.; Bir Kohli, Pawan; Labadie, Sharada; Lee, Wyne P.; Liao, Jiangpeng; Liimatta, Marya; Mendonca, Rohan; Narukulla, Raman; Pulk, Rebecca; Reeve, Austin; Savage, Scott; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; van Abbema, Anne; Aliagas, Ignacio; Avitabile-Woo, Barbara; Xiao, Yisong; Yang, Jing; Kulagowski, Janusz J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4764-4785</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors.  X-ray structures of a C-2 hydroxyethyl analog in complex with both JAK1 and JAK2 revealed differential ligand/protein interactions between the two isoforms and offered an explanation for the obsd. selectivity.  Anal. of historical data from related mols. was used to develop a set of physicochem. compd. design parameters to impart desirable properties such as acceptable membrane permeability, potent whole blood activity, and a high degree of metabolic stability.  This work culminated in the identification of a highly JAK1 selective compd. (31) exhibiting favorable oral bioavailability across a range of preclin. species and robust efficacy in a rat CIA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP0DlLtJCYq7Vg90H21EOLACvtfcHk0ljKnKIIK0n1og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVWit74%253D&md5=0b0d1950adebf325cc434344f57ca139</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520hydroxyethyl%2520imidazopyrrolopyridines%2520as%2520potent%2520JAK1%2520inhibitors%2520with%2520favorable%2520physicochemical%2520properties%2520and%2520high%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785%26doi%3D10.1021%2Fjm4004895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Millard, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celardo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordiyenko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowley, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwabe, J. W.</span><span> </span><span class="NLM_article-title">Class I HDACs share a common mechanism of regulation by inositol phosphates</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1016/j.molcel.2013.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2Fj.molcel.2013.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=23791785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVygu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2013&pages=57-67&author=C.+J.+Millardauthor=P.+J.+Watsonauthor=I.+Celardoauthor=Y.+Gordiyenkoauthor=S.+M.+Cowleyauthor=C.+V.+Robinsonauthor=L.+Fairallauthor=J.+W.+Schwabe&title=Class+I+HDACs+share+a+common+mechanism+of+regulation+by+inositol+phosphates&doi=10.1016%2Fj.molcel.2013.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates</span></div><div class="casAuthors">Millard, Christopher J.; Watson, Peter J.; Celardo, Ivana; Gordiyenko, Yuliya; Cowley, Shaun M.; Robinson, Carol V.; Fairall, Louise; Schwabe, John W. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-67</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Class I histone deacetylases (HDAC1, HDAC2, and HDAC3) are recruited by cognate corepressor proteins into specific transcriptional repression complexes that target HDAC activity to chromatin resulting in chromatin condensation and transcriptional silencing.  The authors previously reported the structure of HDAC3 in complex with the SMRT corepressor.  This structure revealed inositol-tetraphosphate [Ins(1,4,5,6)P4] at the interface of the two proteins.  It was previously unclear whether the role of Ins(1,4,5,6)P4 is to act as a structural cofactor or a regulator of HDAC3 activity.  Here the authors report the structure of HDAC1 in complex with MTA1 from the NuRD complex.  The ELM2-SANT domains from MTA1 wrap completely around HDAC1 occupying both sides of the active site such that the adjacent BAH domain is ideally positioned to recruit nucleosomes to the active site of the enzyme.  Functional assays of both the HDAC1 and HDAC3 complexes reveal that Ins(1,4,5,6)P4 is a bona fide conserved regulator of class I HDAC complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYPhL0103LkLVg90H21EOLACvtfcHk0lhSBzpk4HcfkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVygu74%253D&md5=05a4267bf965b5a6217873217044ef2a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2013.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2013.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DMillard%26aufirst%3DC.%2BJ.%26aulast%3DWatson%26aufirst%3DP.%2BJ.%26aulast%3DCelardo%26aufirst%3DI.%26aulast%3DGordiyenko%26aufirst%3DY.%26aulast%3DCowley%26aufirst%3DS.%2BM.%26aulast%3DRobinson%26aufirst%3DC.%2BV.%26aulast%3DFairall%26aufirst%3DL.%26aulast%3DSchwabe%26aufirst%3DJ.%2BW.%26atitle%3DClass%2520I%2520HDACs%2520share%2520a%2520common%2520mechanism%2520of%2520regulation%2520by%2520inositol%2520phosphates%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D51%26spage%3D57%26epage%3D67%26doi%3D10.1016%2Fj.molcel.2013.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Lauffer, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mintzer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zilberleyb, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flicke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritscher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorowicz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modrusan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koth, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupardus, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminker, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, P.</span><span> </span><span class="NLM_article-title">Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">26926</span><span class="NLM_x">–</span> <span class="NLM_lpage">26943</span><span class="refDoi"> DOI: 10.1074/jbc.M113.490706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1074%2Fjbc.M113.490706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=23897821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=26926-26943&author=B.+E.+Laufferauthor=R.+Mintzerauthor=R.+Fongauthor=S.+Mukundauthor=C.+Tamauthor=I.+Zilberleybauthor=B.+Flickeauthor=A.+Ritscherauthor=G.+Fedorowiczauthor=R.+Valleroauthor=D.+F.+Ortwineauthor=J.+Gunznerauthor=Z.+Modrusanauthor=L.+Neumannauthor=C.+M.+Kothauthor=P.+J.+Lupardusauthor=J.+S.+Kaminkerauthor=C.+E.+Heiseauthor=P.+Steiner&title=Histone+deacetylase+%28HDAC%29+inhibitor+kinetic+rate+constants+correlate+with+cellular+histone+acetylation+but+not+transcription+and+cell+viability&doi=10.1074%2Fjbc.M113.490706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span></div><div class="casAuthors">Lauffer, Benjamin E. L.; Mintzer, Robert; Fong, Rina; Mukund, Susmith; Tam, Christine; Zilberleyb, Inna; Flicke, Birgit; Ritscher, Allegra; Fedorowicz, Grazyna; Vallero, Roxanne; Ortwine, Daniel F.; Gunzner, Janet; Modrusan, Zora; Neumann, Lars; Koth, Christopher M.; Lupardus, Patrick J.; Kaminker, Joshua S.; Heise, Christopher E.; Steiner, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">26926-26943</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crit. in the control of gene expression, and dysregulation of their activity has been implicated in a broad range of diseases, including cancer, cardiovascular, and neurol. diseases.  HDAC inhibitors (HDACi) employing different zinc chelating functionalities such as hydroxamic acids and benzamides have shown promising results in cancer therapy.  Although it has also been suggested that HDACi with increased isoenzyme selectivity and potency may broaden their clin. utility and minimize side effects, the translation of this idea to the clinic remains to be investigated.  Moreover, a detailed understanding of how HDACi with different pharmacol. properties affect biol. functions in vitro and in vivo is still missing.  Here, we show that a panel of benzamide-contg. HDACi are slow tight-binding inhibitors with long residence times unlike the hydroxamate-contg. HDACi vorinostat and trichostatin-A.  Characterization of changes in H2BK5 and H4K14 acetylation following HDACi treatment in the neuroblastoma cell line SH-SY5Y revealed that the timing and magnitude of histone acetylation mirrored both the assocn. and dissocn. kinetic rates of the inhibitors.  In contrast, cell viability and microarray gene expression anal. indicated that cell death induction and changes in transcriptional regulation do not correlate with the dissocn. kinetic rates of the HDACi.  Therefore, our study suggests that detg. how the selective and kinetic inhibition properties of HDACi affect cell function will help to evaluate their therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2goaOx8CDGbVg90H21EOLACvtfcHk0lhSBzpk4HcfkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM&md5=af1074c79e8abd932313f4ae13333a98</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.490706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.490706%26sid%3Dliteratum%253Aachs%26aulast%3DLauffer%26aufirst%3DB.%2BE.%26aulast%3DMintzer%26aufirst%3DR.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DFlicke%26aufirst%3DB.%26aulast%3DRitscher%26aufirst%3DA.%26aulast%3DFedorowicz%26aufirst%3DG.%26aulast%3DVallero%26aufirst%3DR.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNeumann%26aufirst%3DL.%26aulast%3DKoth%26aufirst%3DC.%2BM.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DKaminker%26aufirst%3DJ.%2BS.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DSteiner%26aufirst%3DP.%26atitle%3DHistone%2520deacetylase%2520%2528HDAC%2529%2520inhibitor%2520kinetic%2520rate%2520constants%2520correlate%2520with%2520cellular%2520histone%2520acetylation%2520but%2520not%2520transcription%2520and%2520cell%2520viability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D26926%26epage%3D26943%26doi%3D10.1074%2Fjbc.M113.490706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Hai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christianson, D. W.</span><span> </span><span class="NLM_article-title">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1038/nchembio.2134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1038%2Fnchembio.2134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=27454933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=741-747&author=Y.+Haiauthor=D.+W.+Christianson&title=Histone+deacetylase+6+structure+and+molecular+basis+of+catalysis+and+inhibition&doi=10.1038%2Fnchembio.2134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span></div><div class="casAuthors">Hai, Yang; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">741-747</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a crit. target for drug design because of its role in oncogenic transformation and cancer metastasis, and is unique among all histone deacetylases in that it contains tandem catalytic domains designated CD1 and CD2.  We now report the crystal structures of CD2 from Homo sapiens HDAC6 and of CD1 and CD2 from Danio rerio HDAC6.  We correlated these structures with activity measurements using 13 different substrates.  The catalytic activity of CD2 from both species exhibited broad substrate specificity, whereas that of CD1 was highly specific for substrates bearing C-terminal acetyllysine residues.  Crystal structures of substrate complexes yielded unprecedented snapshots of the catalytic mechanism.  Addnl., crystal structures of complexes with eight different inhibitors, including belinostat and panobinostat (currently used in cancer chemotherapy), the macrocyclic tetrapeptide HC toxin, and the HDAC6-specific inhibitor N-hydroxy-4-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl)benzamide, revealed surprising new insight regarding changes in Zn2+ coordination and isoenzyme-specific inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqCfziGBHBRLVg90H21EOLACvtfcHk0ljrUFVWs71ZQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ&md5=e167bc6f66e00923da4f2bced2b306b9</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2134%26sid%3Dliteratum%253Aachs%26aulast%3DHai%26aufirst%3DY.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520deacetylase%25206%2520structure%2520and%2520molecular%2520basis%2520of%2520catalysis%2520and%2520inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D741%26epage%3D747%26doi%3D10.1038%2Fnchembio.2134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span>Schrödinger, L L.C., 2014. New York, NY, U.S.<a href="http://www.schrodinger.com" class="extLink">http://www.schrodinger.com</a> (accessed April 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Schr%C3%B6dinger%2C+L+L.C.%2C+2014.+New+York%2C+NY%2C+U.S.http%3A%2F%2Fwww.schrodinger.com+%28accessed+April+10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Harder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damm, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maple, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reboul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupyan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlgren, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaus, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerutti, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krilov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span> </span><span class="NLM_article-title">OPLS3: a force field providing broad coverage of drug-like small molecules and proteins</span> <span class="citation_source-journal">J. Chem. Theory Comput.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">–</span> <span class="NLM_lpage">296</span><span class="refDoi"> DOI: 10.1021/acs.jctc.5b00864</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.5b00864" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=281-296&author=E.+Harderauthor=W.+Dammauthor=J.+Mapleauthor=C.+Wuauthor=M.+Reboulauthor=J.+Y.+Xiangauthor=L.+Wangauthor=D.+Lupyanauthor=M.+K.+Dahlgrenauthor=J.+L.+Knightauthor=J.+W.+Kausauthor=D.+S.+Ceruttiauthor=G.+Krilovauthor=W.+L.+Jorgensenauthor=R.+Abelauthor=R.+A.+Friesner&title=OPLS3%3A+a+force+field+providing+broad+coverage+of+drug-like+small+molecules+and+proteins&doi=10.1021%2Facs.jctc.5b00864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins</span></div><div class="casAuthors">Harder, Edward; Damm, Wolfgang; Maple, Jon; Wu, Chuanjie; Reboul, Mark; Xiang, Jin Yu; Wang, Lingle; Lupyan, Dmitry; Dahlgren, Markus K.; Knight, Jennifer L.; Kaus, Joseph W.; Cerutti, David S.; Krilov, Goran; Jorgensen, William L.; Abel, Robert; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-296</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The parametrization and validation of the OPLS3 force field for small mols. and proteins are reported.  Enhancements with respect to the previous version (OPLS2.1) include the addn. of off-atom charge sites to represent halogen bonding and aryl nitrogen lone pairs as well as a complete refit of peptide dihedral parameters to better model the native structure of proteins.  To adequately cover medicinal chem. space, OPLS3 employs over an order of magnitude more ref. data and assocd. parameter types relative to other commonly used small mol. force fields (e.g., MMFF and OPLS_2005).  As a consequence, OPLS3 achieves a high level of accuracy across performance benchmarks that assess small mol. conformational propensities and solvation.  The newly fitted peptide dihedrals lead to significant improvements in the representation of secondary structure elements in simulated peptides and native structure stability over a no. of proteins.  Together, the improvements made to both the small mol. and protein force field lead to a high level of accuracy in predicting protein-ligand binding measured over a wide range of targets and ligands (less than 1 kcal/mol RMS error) representing a 30% improvement over earlier variants of the OPLS force field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY_jrOhcBRgrVg90H21EOLACvtfcHk0ljrUFVWs71ZQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE&md5=42663f8cfa84b80a67132bbb13b9b7ce</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.5b00864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.5b00864%26sid%3Dliteratum%253Aachs%26aulast%3DHarder%26aufirst%3DE.%26aulast%3DDamm%26aufirst%3DW.%26aulast%3DMaple%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DReboul%26aufirst%3DM.%26aulast%3DXiang%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLupyan%26aufirst%3DD.%26aulast%3DDahlgren%26aufirst%3DM.%2BK.%26aulast%3DKnight%26aufirst%3DJ.%2BL.%26aulast%3DKaus%26aufirst%3DJ.%2BW.%26aulast%3DCerutti%26aufirst%3DD.%2BS.%26aulast%3DKrilov%26aufirst%3DG.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DOPLS3%253A%2520a%2520force%2520field%2520providing%2520broad%2520coverage%2520of%2520drug-like%2520small%2520molecules%2520and%2520proteins%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2016%26volume%3D12%26spage%3D281%26epage%3D296%26doi%3D10.1021%2Facs.jctc.5b00864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Polak, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribiere, G.</span><span> </span><span class="NLM_article-title">Note sur la convergence de méthodes de directions conjuguées</span> <span class="citation_source-journal">Rev. Fr. Info Res. Op.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1969</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1051/m2an/196903R100351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1051%2Fm2an%2F196903R100351" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1969&pages=35-43&author=E.+Polakauthor=G.+Ribiere&title=Note+sur+la+convergence+de+m%C3%A9thodes+de+directions+conjugu%C3%A9es&doi=10.1051%2Fm2an%2F196903R100351"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1051%2Fm2an%2F196903R100351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1051%252Fm2an%252F196903R100351%26sid%3Dliteratum%253Aachs%26aulast%3DPolak%26aufirst%3DE.%26aulast%3DRibiere%26aufirst%3DG.%26atitle%3DNote%2520sur%2520la%2520convergence%2520de%2520m%25C3%25A9thodes%2520de%2520directions%2520conjugu%25C3%25A9es%26jtitle%3DRev.%2520Fr.%2520Info%2520Res.%2520Op.%26date%3D1969%26volume%3D3%26spage%3D35%26epage%3D43%26doi%3D10.1051%2Fm2an%2F196903R100351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Hasel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Still, W. C.</span><span> </span><span class="NLM_article-title">A rapid approximation to the solvent accessible surface areas of atoms</span> <span class="citation_source-journal">Tetrahedron Comput. Methodol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1016/0898-5529(88)90015-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1016%2F0898-5529%2888%2990015-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1988&pages=103-116&author=W.+Haselauthor=T.+F.+Hendricksonauthor=W.+C.+Still&title=A+rapid+approximation+to+the+solvent+accessible+surface+areas+of+atoms&doi=10.1016%2F0898-5529%2888%2990015-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid approximation to the solvent-accessible surface areas of atoms</span></div><div class="casAuthors">Hasel, Winnfried; Hendrickson, Thomas F.; Still, W. Clark</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Computer Methodology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-16</span>CODEN:
                <span class="NLM_cas:coden">TCMTE6</span>;
        ISSN:<span class="NLM_cas:issn">0898-5529</span>.
    </div><div class="casAbstract">An anal. expression for approx. at. and mol. van der Waals and solvent accessible surface areas is described.  The treatment is based on the probabilistic method of Wodak and Janin (1980) but with modifications which allow it to be applied to the calcn. of at. surface areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEtlzGPkwT_7Vg90H21EOLACvtfcHk0lgFzunhgQF9dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D&md5=98b3e7fab9432dccb1ff22f726d54fbf</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0898-5529%2888%2990015-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0898-5529%252888%252990015-2%26sid%3Dliteratum%253Aachs%26aulast%3DHasel%26aufirst%3DW.%26aulast%3DHendrickson%26aufirst%3DT.%2BF.%26aulast%3DStill%26aufirst%3DW.%2BC.%26atitle%3DA%2520rapid%2520approximation%2520to%2520the%2520solvent%2520accessible%2520surface%2520areas%2520of%2520atoms%26jtitle%3DTetrahedron%2520Comput.%2520Methodol.%26date%3D1988%26volume%3D1%26spage%3D103%26epage%3D116%26doi%3D10.1016%2F0898-5529%2888%2990015-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Bergström, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiick, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlson, S.</span><span> </span><span class="NLM_article-title">Cholera toxin inhibitors studied with high–performance liquid affinity chromatography: a robust method to evaluate receptor–ligand interactions</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2008.00758.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=10.1111%2Fj.1747-0285.2008.00758.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=19152642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FotFyguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2009&pages=132-141&author=M.+Bergstr%C3%B6mauthor=S.+Liuauthor=K.+L.+Kiickauthor=S.+Ohlson&title=Cholera+toxin+inhibitors+studied+with+high%E2%80%93performance+liquid+affinity+chromatography%3A+a+robust+method+to+evaluate+receptor%E2%80%93ligand+interactions&doi=10.1111%2Fj.1747-0285.2008.00758.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Cholera toxin inhibitors studied with high-performance liquid affinity chromatography: a robust method to evaluate receptor-ligand interactions</span></div><div class="casAuthors">Bergstrom Maria; Liu Shuang; Kiick Kristi L; Ohlson Sten</div><div class="citationInfo"><span class="NLM_cas:title">Chemical biology & drug design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">132-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Anti-adhesion drugs may be an alternative to antibiotics to control infection of micro-organisms.  The well-characterized interaction between cholera toxin and the cellular glycolipid GM1 makes it an attractive model for inhibition studies in general.  In this report, we demonstrate a high-performance liquid affinity chromatography approach called weak affinity chromatography to evaluate cholera toxin inhibitors.  The cholera toxin B-subunit was covalently coupled to porous silica and a (weak) affinity column was produced.  The K(D) values of galactose and meta-nitrophenyl alpha-D-galactoside were determined with weak affinity chromatography to be 52 and 1 mM, respectively, which agree well with IC(50) values previously reported.  To increase inhibition potency multivalent inhibitors have been developed and the interaction with multivalent glycopolypeptides was also evaluated.  The affinity of these compounds was found to correlate with the galactoside content but K(D) values were not obtained because of the inhomogeneous response and slow off-rate from multivalent interactions.  Despite the limitations in obtaining direct K(D) values of the multivalent galactopolypeptides, weak affinity chromatography represents an additional and valuable tool in the evaluation of monovalent as well as multivalent cholera toxin inhibitors.  It offers multiple advantages, such as a low sample consumption, high reproducibility and short analysis time, which are often not observed in other methods of analysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-AB2cNMO0u75XHngOXiV_fW6udTcc2eZjIViZ5odeV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FotFyguw%253D%253D&md5=366eb8b8017308e715cc8be80c3661c3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2008.00758.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2008.00758.x%26sid%3Dliteratum%253Aachs%26aulast%3DBergstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DKiick%26aufirst%3DK.%2BL.%26aulast%3DOhlson%26aufirst%3DS.%26atitle%3DCholera%2520toxin%2520inhibitors%2520studied%2520with%2520high%25E2%2580%2593performance%2520liquid%2520affinity%2520chromatography%253A%2520a%2520robust%2520method%2520to%2520evaluate%2520receptor%25E2%2580%2593ligand%2520interactions%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2009%26volume%3D73%26spage%3D132%26epage%3D141%26doi%3D10.1111%2Fj.1747-0285.2008.00758.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IVB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IVB','PDB','4IVB'); return false;">PDB: 4IVB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP','PDB','3FUP'); return false;">PDB: 3FUP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX','PDB','4BKX'); return false;">PDB: 4BKX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ','PDB','4LXZ'); return false;">PDB: 4LXZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI','PDB','5EEI'); return false;">PDB: 5EEI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0G" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0G','PDB','5G0G'); return false;">PDB: 5G0G</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00678">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_15774"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00678">10.1021/acs.jmedchem.7b00678</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional synthesis of compounds, NMR and HPLC spectra for final compounds, additional immunoblotting data, selected IC<sub>50</sub> curves, RLM and oral PK data for <b>24</b>, docking of <b>45</b> to HDAC1/6 and JAK1/2, and PK of <b>45</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_002.csv">CSV</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_006.pdb">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_007.pdb">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_008.pdb">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_009.pdb">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_010.pdb">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_011.pdb">PDB</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_012.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_001.pdf">jm7b00678_si_001.pdf (15.56 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_002.csv">jm7b00678_si_002.csv (1.94 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_003.pdb">jm7b00678_si_003.pdb (390.22 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_004.pdb">jm7b00678_si_004.pdb (236.91 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_005.pdb">jm7b00678_si_005.pdb (414.79 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_006.pdb">jm7b00678_si_006.pdb (273.0 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_007.pdb">jm7b00678_si_007.pdb (268.3 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_008.pdb">jm7b00678_si_008.pdb (390.52 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_009.pdb">jm7b00678_si_009.pdb (237.21 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_010.pdb">jm7b00678_si_010.pdb (415.07 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_011.pdb">jm7b00678_si_011.pdb (273.3 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00678/suppl_file/jm7b00678_si_012.pdb">jm7b00678_si_012.pdb (268.6 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-20%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00678" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00678" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0c23a88772254","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
